Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed

Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

IND Number: 115561
EudraCT Number: 2016-003632-20

Indication: Chronic Hepatitis B


Gilead Sciences Study Director:
Name: PPD
Telephone: PPD
Fax: PPD
Mobile: PPD
Email: PPD

Gilead Sciences Medical Monitor:
Name: PPD
Telephone: PPD
Fax: PPD
Mobile: PPD
Email: PPD

Protocol Version/Date: Original: 30 September 2016

CONFIDENTIALITY STATEMENT
The information contained in this document, particularly unpublished data, is the property or under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies of the investigational drug described in the protocol. You will not disclose any of the information to others without written authorization from Gilead Sciences, Inc., except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered.
TABLE OF CONTENTS

TABLE OF CONTENTS .................................................................................................................................... 2
LIST OF IN-TEXT TABLES .................................................................................................................................. 5
PROTOCOL SYNSOPSIS .................................................................................................................................... 6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ................................................................. 18

1. INTRODUCTION .............................................................................................................................................. 22
  1.1. Background ............................................................................................................................................... 22
  1.2. Tenofovir Alafenamide (TAF, GS-7340) .................................................................................................... 24
     1.2.1. General Information .......................................................................................................................... 24
     1.2.2. Preclinical Pharmacology and Toxicology ..................................................................................... 25
     1.2.3. Clinical Trials of Tenofovir Alafenamide (TAF, GS-7340) .............................................................. 27
     1.3. Information about Tenofovir Disoproxil Fumarate (TDF) ................................................................. 45
  1.4. Rationale for This Study .......................................................................................................................... 45
  1.5. Risk/Benefit Assessment for the Study .................................................................................................... 45
  1.6. Compliance ............................................................................................................................................. 46

2. OBJECTIVES ..................................................................................................................................................... 47

3. STUDY DESIGN ................................................................................................................................................ 49
  3.1. Study Treatment Plan and Regimen ........................................................................................................ 49
  3.2. Biomarker Testing .................................................................................................................................... 50
     3.2.1. Biomarker Samples to Address the Study Objectives ................................................................... 50
     3.2.2. Biomarker Samples for Optional Future Research ....................................................................... 51
     3.2.3. PPDO ............................................................................................................................................ 51
  3.3. End of Study .......................................................................................................................................... 51
  3.4. Post Study Care ...................................................................................................................................... 51

4. SUBJECT POPULATION ..................................................................................................................................... 52
  4.1. Number of Subjects and Subject Selection ............................................................................................ 52
  4.2. Inclusion Criteria .................................................................................................................................... 52
  4.3. Exclusion Criteria .................................................................................................................................. 53

5. INVESTIGATIONAL MEDICINAL PRODUCTS ............................................................................................... 55
  5.1. Randomization, Blinding and Treatment Codes .................................................................................... 55
     5.1.1. Procedures for Breaking Treatment Codes .................................................................................... 55
  5.2. Description and Handling of Tenofovir Alafenamide (TAF) and TDF ................................................ 56
     5.2.1. Formulation .................................................................................................................................. 56
     5.2.2. Packaging and Labeling ................................................................................................................ 56
     5.2.3. Storage and Handling .................................................................................................................... 57
  5.3. Dosage and Administration of Tenofovir Alafenamide (TAF) and TDF .............................................. 57
  5.4. Prior and Concomitant Medications ....................................................................................................... 58
  5.5. Accountability for Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF) and Matched Placebos .......................................................................................................................... 59
     5.5.1. Investigational Medicinal Product Return or Disposal .................................................................. 59

6. STUDY PROCEDURES ..................................................................................................................................... 60
  6.1. Subject Enrollment and Treatment Assignment ...................................................................................... 60
  6.2. Pretreatment Assessments ...................................................................................................................... 60
     6.2.1. Screening Visit ................................................................................................................................ 60
     6.2.2. Baseline Assessments ..................................................................................................................... 61
8. STATISTICAL CONSIDERATIONS ................................................................................................................ 84
  8.1. Analysis Objectives and Endpoints ........................................................................................................ 84
    8.1.1. Analysis Objectives .................................................................................................................. 84
    8.1.2. Primary Endpoint ..................................................................................................................... 85
    8.1.3. Secondary Endpoint ................................................................................................................ 85
    8.1.4. Other Endpoints of Interest .................................................................................................. 86
  8.2. Analysis Conventions .......................................................................................................................... 86
    8.2.1. Analysis Sets ........................................................................................................................ 86
  8.3. Data Handling Conventions ................................................................................................................ 87
  8.4. Multiplicity Adjustments ...................................................................................................................... 87
  8.5. Demographic Data and Baseline Characteristics ................................................................................ 89
  8.6. Efficacy Analysis ................................................................................................................................... 89
    8.6.1. Primary Analysis ...................................................................................................................... 89
    8.6.2. Analyses of Secondary Endpoints ........................................................................................ 90
  8.7. Safety Analysis ..................................................................................................................................... 90
    8.7.1. Key Secondary Safety Analyses ............................................................................................ 90
  8.8. Resistance Surveillance and Virologic Rebound Management ............................................................. 91

7. ADVERSE EVENTS AND TOXICITY MANAGEMENT .................................................................................. 73
  7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events .................................... 73
    7.1.1. Adverse Events ...................................................................................................................... 73
    7.1.2. Serious Adverse Events ........................................................................................................ 73
    7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious Adverse Events ................................................................................................................ 74
  7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................ 74
    7.2.1. Assessment of Causality for Study Drugs and Procedures ...................................................... 74
    7.2.2. Assessment of Severity ......................................................................................................... 75
  7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious Adverse Events to Gilead .................................................................................................................. 75
  7.4. Gilead Reporting Requirements .......................................................................................................... 77
  7.5. Toxicity Management .......................................................................................................................... 77
    7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event ...................................................... 78
    7.5.2. Grade 3 Laboratory Abnormality or Clinical Event ................................................................ 78
    7.5.3. Grade 4 Laboratory Abnormality or Clinical Event ................................................................ 78
    7.5.4. Management of Bone Evaluation ........................................................................................... 78
    7.5.5. On-Treatment ALT Flare and Post-Treatment Exacerbation of Hepatitis Management ........... 79
    7.5.6. Management of Ocular Safety ................................................................................................. 80
    7.5.7. Management of Potential Nephrotoxicity ................................................................................. 81
  7.6. Special Situations Reports .................................................................................................................... 82
    7.6.1. Definitions of Special Situations ............................................................................................ 82
    7.6.2. Instructions for Reporting Special Situations .......................................................................... 82

6.7. Other Evaluations ................................................................................................................................... 62
  6.7.1. Bone and Renal Markers ............................................................................................................. 71
  6.8. Resistance Surveillance and Virologic Rebound Management ............................................................. 72

6.6. Criteria for Discontinuation of Study Treatment ..................................................................................... 70
  6.7. Other Evaluations ................................................................................................................................... 71
  6.8. Resistance Surveillance and Virologic Rebound Management ............................................................. 72

6.5. Assessments for Premature Discontinuation from Study .......................................................................... 69
  6.6. Criteria for Discontinuation of Study Treatment ..................................................................................... 70
  6.7. Other Evaluations ................................................................................................................................... 71
  6.8. Resistance Surveillance and Virologic Rebound Management ............................................................. 72

6.4. Post-Treatment Assessments .................................................................................................................. 69
  6.4.1. HBsAg Loss and Seroconversion Subjects .................................................................................... 69
  6.4.2. All Other Subjects Who Discontinue Study Drug ........................................................................ 69
  6.4.3. Treatment-Free Follow Up Visit Assessments (All Subjects) ..................................................... 69

6.3. Treatment Assessments .......................................................................................................................... 62
  6.3.1. Double Blind Visits (Visit Window ± 3 days) .............................................................................. 62
  6.3.2. Open Label Visits (Visit Window ± 7 days) .................................................................................. 67

6.2. Assessment of Causality for Study Drugs and Procedures ........................................................................ 74
  6.3.1. Double Blind Visits (Visit Window ± 3 days) .............................................................................. 62
  6.3.2. Open Label Visits (Visit Window ± 7 days) .................................................................................. 67

6.1. Adverse Events ....................................................................................................................................... 62
  6.2. Assessment of Causality for Study Drugs and Procedures ........................................................................ 74
  6.3.1. Double Blind Visits (Visit Window ± 3 days) .............................................................................. 62
  6.3.2. Open Label Visits (Visit Window ± 7 days) .................................................................................. 67
8.7.2. Extent of Exposure ............................................................................................................... 91
8.7.3. Adverse Events ..................................................................................................................... 91
8.7.4. Laboratory Evaluations ........................................................................................................ 91
8.8. Biomarker Analysis .................................................................................................................. 92
8.9. Sample Size .......................................................................................................................... 92
8.10. Data Monitoring Committee ................................................................................................. 93
9. RESPONSIBILITIES .................................................................................................................. 94
9.1. Investigator Responsibilities .................................................................................................. 94
9.1.1. Good Clinical Practice ......................................................................................................... 94
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee
      (IEC)/Ethics Committee (EC) Review and Approval .......................................................... 94
9.1.3. Informed Consent .............................................................................................................. 94
9.1.4. Confidentiality .................................................................................................................... 95
9.1.5. Study Files and Retention of Records ............................................................................... 95
9.1.6. Case Report Forms ........................................................................................................... 96
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 97
9.1.8. Inspections ......................................................................................................................... 97
9.1.9. Protocol Compliance ......................................................................................................... 97
9.2. Sponsor Responsibilities ........................................................................................................ 97
9.2.1. Protocol Modifications ....................................................................................................... 97
9.2.2. Study Report and Publications ......................................................................................... 98
9.3. Joint Investigator/Sponsor Responsibilities ............................................................................. 98
9.3.1. Payment Reporting ............................................................................................................ 98
9.3.2. Access to Information for Monitoring .............................................................................. 98
9.3.3. Access to Information for Auditing or Inspections ............................................................. 99
9.3.4. Study Discontinuation ....................................................................................................... 99
10. REFERENCES .......................................................................................................................... 100
11. APPENDICES .......................................................................................................................... 103

Appendix 1. Investigator Signature Page ..................................................................................... 104
Appendix 2. Study Procedures Table ............................................................................................ 105
Appendix 3. Management of Clinical and Laboratory Adverse Events ..................................... 107
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ... 108
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and
    Contraceptive Requirements ................................................................................................. 130
LIST OF IN-TEXT TABLES

Table 1-1. Clinical Studies to Support Efficacy for the TAF Marketing Applications ............................. 30
Table 1-2. GS US 320-0108 and GS US 320-0110: HBV DNA Outcome at Week 48 Using HBV DNA of < 29 IU/mL, Missing = Failure (Full Analysis Set) ........................................ 31
Table 1-3. GS-US-320-0108 and GS-US-320-0110: Proportion of Subjects with ALT Normalization at Week 48, Missing = Failure (Full Analysis Set with Baseline ALT > ULN) ................................................................................................................................... 32
Table 1-4. GS-US-320-0110: Proportion of Subjects with HBeAg Loss or Seroconversion at Week 48, Missing = Failure (Serologically Evaluable Full Analysis Set) ......................... 33
Table 1-5. GS-US-320-0108 and GS-US-320-0110: Subjects Exposed to Study Drug for the TAF Phase 3 Safety Population (Safety Analysis Set) ........................................................... 35
Table 1-7. GS-US-320-0108 and GS-US-320-0110: Adverse Events Reported for ≥ 5% of Subjects in Either Treatment Group in the TAF Phase 3 Safety Population (Safety Analysis Set) ........................................................................................................................... 37
Table 1-8. GS-US-320-0108 and GS-US-320-0110: Serious Adverse Events by Treatment Regimen in > 1 Subject in the TAF Phase 3 Safety Population (Safety Analysis Set) .......... 38
Table 1-10. GS-US-320-0108 and GS-US-320-0110: Renal Biomarkers to Urine Creatinine Ratios at Week 48 in the TAF Phase 3 Safety Population (Safety Analysis Set) .................. 41
Table 1-11. GS-US-320-0108 and GS-US-320-0110: Treatment-Emergent Grade 3 or 4 Laboratory Abnormalities Reported for at Least 1% of Subjects in Either Treatment Group in the Overall TAF Phase 3 Safety Population (Safety Analysis Set) .......................................................................................................................... 43
Table 5-1. Disallowed Concomitant Medications .................................................................................... 58
PROTOCOL SYNOPSIS

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed

IND Number: 115561
EudraCT Number: 2016-003632-20

Study Centers Planned: Approximately 50 centers in North America, Europe, and Asia Pacific regions

Objectives: The primary objectives of this study are as follows:

• To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus continued tenofovir disoproxil fumarate (TDF) 300 mg QD in virologically suppressed subjects with chronic HBV as determined by the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at Week 24

• To compare the safety and tolerability of switching to TAF 25 mg QD versus continuing TDF 300 mg QD in virologically suppressed subjects with chronic HBV at Week 24

The key secondary objectives of this study are as follows:

• To compare the safety of switching TAF 25 mg QD versus continued TDF 300 mg QD as determined by the percent change from baseline in hip and spine bone mineral density (BMD) at Week 24

• To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the change from baseline in estimated creatinine clearance by Cockcroft-Gault method (eGFR\textsubscript{CG}) at Week 24
Other secondary objectives of this study are as follows:

- To compare the safety of switching TAF 25 mg QD versus continued TDF 300 mg QD as determined by the percent change from baseline in hip and spine bone mineral density (BMD) at Weeks 48 and 96.

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the change from baseline in estimated creatinine clearance by Cockcroft-Gault method (eGFR<sub>CG</sub>) at Weeks 48 and 96.

- To compare the safety and tolerability of switching to TAF 25 mg QD versus continued TDF 300 mg QD in virologically suppressed subjects with chronic hepatitis B at Week 48.

- To evaluate the efficacy of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at Weeks 48 and 96.

- To compare the serological response (loss of HBsAg and seroconversion to anti-HBs, and loss of HBeAg and seroconversion to anti-HBe in HBeAg-positive subjects) of switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96.

- To compare biochemical response (normal ALT and normalized ALT) of switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96.

- To compare the change in fibrosis as assessed by FibroTest<sup>®</sup> after switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 48 and 96.

- To evaluate the comparative open-label efficacy and safety of switching to TAF 25 mg QD from Week 48 through Week 96 in subjects initially randomized to TAF 25 mg QD and in subjects sequentially treated with continued TDF 300 mg QD for 48 weeks and then switched to open-label TAF 25 mg QD.

- To evaluate the proportion of subjects with HBV DNA < 20 IU/mL and target detected/not detected (i.e. < LLOD) at Weeks 24, 48 and 96.
The exploratory objectives of this study are as follows:

**Study Design:**

This is a randomized, double-blind, multicenter, active-controlled study to evaluate the safety and efficacy of TAF 25 mg QD in virologically suppressed subjects who switch from TDF to TAF compared to continued TDF treatment.

Approximately 300 subjects (with approximately 50% of subjects being ≥ 50 years old) who are virologically suppressed and actively taking TDF 300 mg QD, will be randomized in a 1:1 ratio (A:B) to receive either TAF 25 mg QD and matched placebo of TDF 300 mg QD, or Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD. At randomization, subjects will be stratified by screening HBeAg status (HBeAg-negative vs. HBeAg-positive) and age (≥ 50 or < 50 years).

- **Treatment Arm A:** approximately 150 subjects administered TAF 25 mg QD and matched placebo of TDF 300 mg QD
- **Treatment Arm B:** approximately 150 subjects administered Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD

The duration of double blind treatment is 48 weeks. All subjects who complete 48 weeks of treatment are eligible for participation in the open label TAF 25 mg extension period for an additional 48 weeks (through Week 96). During the double-blind period only, subjects with a confirmed creatinine clearance by Cockcroft Gault Method (eGFR$_{CG}$) < 50 ml/min, and > 20% decline in estimated glomerular filtration rate (eGFR$_{CysC}$) by CKD-EPI (cystatin C) compared to baseline during the study, will be required to undergo dose modification to every other day dosing of study drug. Subjects with confirmed creatinine clearance < 30 mL/min during the double-blind period of the study will have the study drug discontinued.
Subjects who permanently discontinue study drug (either prematurely or at the end of study [Week 96]) for reasons other than HBsAg loss with confirmed seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or until initiation of appropriate alternative, HBV therapy, whichever occurs first. Use of appropriate, alternative HBV therapy is strongly encouraged.

Subjects with HBsAg loss with confirmed seroconversion to anti-HBs should discontinue study drug within 3-6 months following confirmation of seroconversion to anti-HBs. Subjects with HBsAg loss with confirmed seroconversion prior to Week 24 are not permitted to discontinue study drug prior to the Week 24 visit. Subjects with HBsAg loss with confirmed seroconversion will be followed off treatment every 4 weeks for 12 weeks and then per the study visit schedule (Appendix 2) through Week 96/ED.

Discontinuation of study drug for subjects experiencing HBsAg loss with confirmed seroconversion, who have known bridging fibrosis or cirrhosis, should be considered on a case by case basis.

The primary analysis will occur at Week 24 with the primary efficacy endpoint being the proportion of subjects with HBV DNA ≥ 20 IU/mL, as determined by the modified US FDA-defined snapshot algorithm.

An external, independent, multidisciplinary Data Monitoring Committee (DMC) will convene and review the progress and safety of this study after the last subject enrolled completes 24 weeks of the study. However, Gilead will defer to the DMC for any decision to convene earlier or more frequently. At each meeting, the DMC will review routine safety and dual energy X-ray absorptiometry (DXA) data and will make recommendations regarding modification of the study treatment.

Number of Subjects Planned: Approximately 300 subjects (approximately 150 subjects will receive TAF 25 mg QD and matched placebo of TDF 300 mg QD, and 150 subjects will receive Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD)

Target Population: Adult subjects with CHB who are currently (≥12 weeks) virologically suppressed (HBV DNA < LLOQ) while receiving therapy with TDF 300 mg QD for ≥ 48 weeks, and as monotherapy for ≥ 24 weeks prior to Screening.

Duration of Treatment: The duration of the double-blind treatment is 48 weeks. After completing the double-blind period, all subjects will be eligible to receive open label TAF 25 mg QD for an additional 48 weeks until Week 96.
<table>
<thead>
<tr>
<th>Diagnosis and Main Eligibility Criteria:</th>
<th>Inclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Subjects must meet <strong>all</strong> of the following inclusion criteria to be eligible to participate in the study:</td>
</tr>
<tr>
<td></td>
<td>1) Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures</td>
</tr>
<tr>
<td></td>
<td>2) Adult male and non-pregnant, non-lactating female subjects, ≥18 years of age based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (as defined in Appendix 5).</td>
</tr>
<tr>
<td></td>
<td>3) Documented evidence of chronic HBV infection previously (e.g., documented HBsAg positive for more than 6 months)</td>
</tr>
<tr>
<td></td>
<td>4) Maintained on TDF 300 mg QD for at least 48 weeks, and as monotherapy for CHB for at least 24 weeks prior to screening and with viral suppression (HBV DNA &lt; LLOQ) for a minimum of 12 weeks prior to Screening, and including a Screening HBV DNA value of &lt; 20 IU/mL (by central laboratory)</td>
</tr>
<tr>
<td></td>
<td>5) Estimated creatinine clearance ≥ 50 ml/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at the Screening evaluation, as follows:</td>
</tr>
</tbody>
</table>
|                                        | \[
|                                        | \frac{(140 – \text{age in years}) \times \text{body weight [kg]}}{(72) \times \text{serum creatinine [mg/dL]}} |
|                                        | (Note: multiply estimated rate by 0.85 for women) |
|                                        | 6) Normal ECG (or if abnormal, determined by the Investigator not to be clinically significant) |
|                                        | 7) Must be willing and able to comply with all study requirements |
|                                        | Exclusion Criteria |
|                                        | Subjects who meet **any** of the following exclusion criteria are not to be enrolled in this study: |
|                                        | 1) Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study |
|                                        | 2) Males and females of reproductive potential who are unwilling to use an “effective”, protocol-specified method(s) of contraception during the study. For a list of protocol-specified Contraceptive methods, refer to Appendix 5. |
3) Co-infection with HCV, HDV, HIV

4) Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging)

5) Current evidence of, or recent (≤ 5 year) history of clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage)

6) Abnormal hematological and biochemical parameters, including:
   a) Hemoglobin < 10 g/dL
   b) Absolute neutrophil count < 750/mm³
   c) Platelets ≤ 50,000/mm³
   d) AST or ALT > 5 × ULN
   e) Albumin < 3.0 mg/dL
   f) INR > 1.5 × ULN (unless stable on anticoagulant regimen)
   g) Total bilirubin > 2.5 × ULN

7) Received solid organ or bone marrow transplant

8) Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the investigator

9) Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g. basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are not eligible.

10) Currently receiving therapy with immunomodulators (e.g. corticosteroids), nephrotoxic agents, or agents capable of modifying renal excretion

11) Known hypersensitivity to study drugs, metabolites, or formulation excipients

12) Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance

13) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.

14) Use of investigational agents within 3 months of Screening, unless allowed by the Sponsor

15) Use of any prohibited medications as described in Section 5.4. Subjects on prohibited medications, who are otherwise eligible, will need a wash out period of at least 30 days prior to the Baseline visit.
Study Procedures/ Frequency:

- Screening Visit
- Treatment Period Visits: Baseline/Day 1, Weeks 4, 8, 12, 24, 36 and 48, and open label Weeks 60, 72, and 96/Early Discontinuation (ED)

- Subjects who permanently discontinue study drug (either prematurely or at the end of study [Week 96]) for reasons other than HBsAg loss with confirmed seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or until initiation of appropriate, alternative, HBV therapy, whichever occurs first. Use of appropriate, alternative HBV therapy is strongly encouraged.

- Review of concomitant medications and assessment for adverse events and vital signs, and weight measurement will be conducted at all study visits.

- Laboratory analyses (serum chemistry, hematology, eGFR_<sub>CG</sub>, urinalysis, plasma HBV DNA levels, pregnancy testing [for females of childbearing potential]) will be conducted at all study visits.

**Screening Visit assessments include:**

- Complete physical examination with height, body weight, and vital signs and medical history (including HBV disease and treatment history)
- INR and Alpha-fetoprotein (AFP); an AFP > 50 ng/mL at Screening must have an appropriate evaluation (i.e., CT scan) in order to rule out HCC prior to being permitted to enter the study.
- Plasma HBV DNA levels (must be < 20 IU/mL at time of Screening to be eligible)
- HBV serology (qualitative HBsAg, and qualitative HBeAg; HBeAb and HBsAb reflex testing will be performed as needed) and quantitative HBsAg
- HCV, HDV and HIV testing
- Urinalysis and urine drug screen
- Baseline DXA scans of the hip and spine can be conducted anytime during the Screening period, but should be conducted at least 14 days prior to the Baseline visit to ensure results are received prior to the first dose of study drug
- ECG
Baseline and On-treatment assessments include:

- Complete physical examinations with body weight and vital signs will be performed at Baseline, Weeks 24, 48, 72, and 96/ED. A symptom driven physical exam will be performed at all other visits.

- HBV serology (qualitative HBsAg and HBeAg) and quantitative HBsAg will be performed at Baseline and Weeks 12, 24, 36, 48, 60, 72, and 96/ED. HBeAb and HBsAb reflex testing will be performed as needed.

- Fasting blood sample for metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides] at Baseline and Weeks 12, 24, 36, 48, 60, 72, and 96/ED.

- FibroTest® at Baseline and at Weeks 24, 48, and 96/ED.

- Serum Cystatin C (CysC) will be assessed at baseline and repeated if eGFRCG is confirmed to be < 50 ml/min during the double blind period of the study (to estimate eGFR by CKD-EPI\text{CysC})

- Fasting blood and urine for bone and renal biomarker testing will be collected at Baseline and Weeks 4, 12, 24, 48, 72, and 96/ED

- Vitamin D assessment

- Fracture Risk Assessment will be evaluated at Baseline

- DXA scans of the hip and spine will be conducted at Weeks 24, 48, 72, and 96/ED visit. The ED visit DXA should be done if not done within the last 12 weeks of this visit.

- ECG will be performed at Weeks 48 and 96/ED.
• Sequence analysis of the HBV polymerase/reverse transcriptase (pol/RT) for resistance surveillance may be performed at Baseline for subjects with HBV DNA ≥69 IU/mL and may be attempted for viremic subjects (HBV DNA ≥ 69 IU/mL) at Weeks 24, 48, and 96/ED. As it may not be known at the time of the visit whether a subject is viremic or if it will be their last study visit, a separate virology sample for potential resistance surveillance will be collected at each study visit. In the event of unconfirmed virologic rebound (HBV DNA ≥ 20 IU/mL), subjects will be asked to return to the clinic for a scheduled or unscheduled blood draw. For virologic rebound occurring within the first 12 weeks of the study, the next scheduled visit will be used for follow up. For virologic rebound occurring after Week 12, the subject will return for an unscheduled visit 2-3 weeks after the date of the original test that resulted with HBV DNA virologic rebound for confirmation of virologic rebound. At this follow up visit, a serum blood sample for resistance testing will be obtained. For unscheduled visits, the subject will be required to bring their supply of study drug with them and be assessed for adherence by pill count, and if necessary, the subject will be re-counseled on adherence to study medication.

• Health Related Quality of Life (HRQoL) Surveys (SF-36, WPAI and CLDQ) at Baseline, Weeks 24, 48, and 96/ED. The ED visit HRQoLs should be done if not done within the last 24 weeks of this visit.

See Section 6 (Study Procedures) for further information.

<table>
<thead>
<tr>
<th>Test Product, Dose, and Mode of Administration:</th>
<th>Double-Blind Treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Tenofovir alafenamide (TAF) 25 mg QD, oral administration and matched placebo of Tenofovir DF (TDF) 300 mg QD, oral administration</td>
<td></td>
</tr>
<tr>
<td>Open-Label Treatment:</td>
<td></td>
</tr>
<tr>
<td>• Tenofovir alafenamide (TAF) 25 mg QD, oral administration</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference Therapy, Dose, and Mode of Administration:</th>
<th>Double-blind Treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Tenofovir DF (TDF) 300 mg QD, oral administration and matched placebo of Tenofovir alafenamide (TAF) 25 mg QD, oral administration</td>
<td></td>
</tr>
<tr>
<td>Open-label Treatment:</td>
<td>NA</td>
</tr>
</tbody>
</table>
Criteria for Evaluation:

Safety: Key secondary safety endpoints include the percent change from baseline at Week 24 in hip and spine BMD, and the change from baseline at Week 24 in eGFR_{CG}. During the double-blind period of the study if a subject has a confirmed creatinine clearance (eGFR_{CG}) < 50 ml/min with a > 20% decline from baseline in eGFR by CKD-EPI_CysC, the subject will be required to undergo dose modification to every other day dosing of study drug. During the double-blind period, subjects with confirmed eGFR_{CG} < 30 mL/min will have the study drug discontinued.

The proportion of subjects in each treatment arm with tolerability failure (defined as an adverse event [AE] leading to permanent discontinuation of study drug) at Weeks 24 and 48 will be summarized. Percent change from baseline in BMD by DXA of the hip and spine hip will be assessed at Weeks 24 and 48. Change from eGFR_{CG} will be assessed at every visit and summarized through Week 48. Adverse events and clinical laboratory tests will be collected at every visit and summarized through Week 48. Additionally, summaries of AEs, discontinuations due to AEs, and laboratory data including BMD measurements (via DXA scans and eGFR_{CG}) by original treatment arms (TAF versus TDF) will continue on an annual basis through Week 96.

Efficacy: The primary efficacy endpoint is:

- Proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at Week 24

The secondary efficacy endpoints are:

- Proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at Weeks 48 and 96
- Proportion of subjects with serological response (loss of HBsAg and seroconversion to anti-HBs, and loss of HBeAg and seroconversion to anti-HBe in HBeAg-positive subjects) at Weeks 24, 48, and 96
- Proportion of subjects with biochemical response (normal ALT and normalized ALT) at Weeks 24, 48, and 96
- Change from baseline in fibrosis as assessed by FibroTest® at Weeks 48 and 96
- Proportion of subjects with HBV DNA < 20 IU/mL and target detected/not detected (i.e. < LLOD) at Weeks 24, 48 and 96
**Statistical Methods:** The primary analysis will be performed when the last subject has completed Week 24 assessments or discontinued prematurely. The analysis will compare the TAF arm to the TDF arm.

**Analysis Methods:** The primary analysis will consist of a non-inferiority evaluation of efficacy of TAF versus TDF, with respect to the proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at Week 24. It will be concluded that TAF is not inferior to the TDF if the upper bound of the two-sided 95% confidence interval of the difference between treatment arms (TAF arm – TDF arm) in the response rate is less than 6% (ie, a margin of 6% is applied to non-inferiority assessment). The 95% confidence interval will be constructed using the normal approximation method based on stratified Mantel-Haenszel proportions, where stratification factors are screening HBeAg status and age (≥ 50 or < 50 years).

The percent change from baseline in hip and spine BMD at Weeks 24 and 48 will be summarized and compared between the two treatment groups using an ANOVA model with treatment as a fixed effect.

The change from baseline in eGFR$_{CG}$ at Weeks 24 and 48 will be summarized and compared between the two treatment groups using the Wilcoxon Rank-Sum test.

All secondary continuous endpoints will be summarized using an 8-number summary (n, mean, standard deviation, median, Q1, Q3, minimum, and maximum). All categorical secondary endpoints will be summarized by number and percentage of subjects who meet the endpoint.

**Sample Size:** With respect to the primary efficacy endpoint of proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at Week 24, when the sample sizes are 150 (TAF 25 mg arm) and 150 (TDF 300 mg arm), a two-group, large-sample normal approximation test of proportions with a one-sided 0.025 significance level will have 97% power to establish non-inferiority. It is assumed that both treatment arms will have subjects who have HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at a rate of 1.8% at Week 24 based on combined data of suppressed subjects from studies GS-US-174-0102 and GS-US-174-0103 with HBeAg-negative:HBeAg-positive = 2:1), with a non-inferiority margin of 6%.
This sample size also provides > 99% power to detect a 1.21% difference in the percentage change from baseline in hip BMD at Week 24 (assuming a 0.99% [SD 2.09%] change from baseline in TAF 25 mg arm and −0.22% [SD 1.89%] change from baseline in the TDF 300 mg arm, with a two-sided α = 0.05); and > 99% power to detect a 1.69% difference in the percentage change from baseline in spine BMD at Week 24 (assuming a 1.50% [SD 2.80%] change from baseline in the TAF 25 mg arm and −0.19% [SD 3.00%] change in the TDF 300 mg arm, with a two-sided α = 0.05); and 68% power to detect a 3.6 mL/min difference in the change from baseline in eGFRCG at Week 24 (assuming a 1.6 mL/min [SD 13.0] change from baseline in the TAF 25 mg arm and −2.0 mL/min [SD 12.4] change from baseline in the TDF 300 mg arm, with a two-sided α = 0.05). These assumptions were derived from an HIV switch study, GS-US-292-0109, due to the unavailability of switch data from TAF HBV studies.

This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) including archiving of essential documents.
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS

°C Degrees Celsius
°F Degrees Fahrenheit
AASLD American Association for the Study of Liver Diseases
ADV Adefovir dipivoxil
AE Adverse event
AhR Aryl hydrocarbon receptor
ALT Alanine aminotransferase (SGPT)
ANC Absolute neutrophil counts
ANCOVA Analysis of covariance
ANOVA Analysis of variance
Anti-HBe Anti-Hepatitis B e-antigen
AR Adverse reaction
ARV Antiretroviral
AST Aspartate aminotransferase (SGOT)
AUC$_{\text{inf}}$ Area under the concentration versus time curve extrapolated to infinite time, calculated as $\text{AUC}_{0-\text{last}} + \frac{C_{\text{last}}}{\lambda_z}$
AUC$_{\text{tau}}$ Area under the plasma concentration versus time curve over the dosing interval (tau)
BMD Bone mineral density
CatA Cathepsin A
Ces1 Caboxylesterase-1
CHB Chronic hepatitis B
CI confidence interval
CKD Chronic kidney disease
CKD-EPI Chronic kidney disease epidemiology collaboration
CL$_{\text{Cr}}$ Creatinine clearance
CLDQ Chronic Liver Disease Questionarie
C$_{\text{max}}$ The maximum observed serum/plasma/peripheral blood mononuclear (PBMC) concentration of drug
CRF/eCRF case report form(s)/electronic case report form(s)
CRO Contract (or clinical) research organization
CTX C-type collagen sequence
CYP3A4 Cytochrome P450 3A4
DMC Data Monitoring Committee
DNA Deoxyribonucleic acid
DSPH Drug Safety and Public Health
DXA Dual energy x-ray absorptiometry
EC Ethics committee
EC$_{50}$ 50% Effective Concentration
EudraCT European clinical trials database
E/C/F  Elvitegravir/cobicistat/emtricitabine

eGFR  Estimated glomerular filtration rate

eGFR_{CG}  Estimated glomerular filtration rate by the Cockcroft-Gault formula

EKG / ECG  Electrocardiogram

ETV  Entecavir

EU  European Union

EVG  Elvitegravir

FAS  Full analysis set

FDA  (United States) Food and Drug Administration

FDC  Fixed-dose combination

FSH  Follicle stimulating hormone

FTC  Emtricitabine

GCP  Good Clinical Practice (Guidelines)

GFR  Glomerular filtration rate

GSI  Gilead Sciences, Inc.

GGT  Gamma glutamyl transferase

HBeAg  Hepatitis B e antigen

HBsAg  Hepatitis B s antigen

HBV  Hepatitis B virus

HCC  Hepatocellular carcinoma

HCV  Hepatitis C virus

HDL  High-density lipoprotein

HDV  Hepatitis D virus

HDPE  High-density polyethylene

hERG  Human ether-à-go-go-Related Gene

HIV  Human Immunodeficiency Virus

HRQoL  Health Related Quality of Life

IC_{20}  20% inhibitory concentration

IC_{50}  50% inhibitory concentration

ICF  Informed Consent Form

ICH  International Conference on Harmonisation

IEC  Independent ethics committee

IMP  Investigational Medicinal Product

IRB  Institutional review board

IVRS  Interactive voice response system

IWRS  Interactive web response system

IUD  Intrauterine device

LDL  Low-density lipoprotein

LdT  Telbivudine

LAM  Lamivudine
LLOD = Lower Limit of Detection
LLOQ = Lower Limit of Quantitation
LOCF = Last observation carried forward
MedDRA = Medical Dictionary for Regulatory Activities
MT-2 = Human T-lymphotrophic virus-1 transformed cells
M = F = Missing = Failure
NDA = New Drug Application
NOAEL = No observed adverse effect level
NRTI = Nucleoside reverse transcriptase inhibitor
OAV = Oral antivirals
OL = Open-label
PD = Pharmacodynamic
P1NP = Procollagen type 1 amino-terminal propeptide
RBP = Retinol binding protein
pol = Polymerase
PK = Pharmacokinetic
PXR = Pregnane X receptor
PT/INR = Prothrombin time/International normalized ratio
QD = Once daily (use only in tables)
RPV = Rilpivirine
RT = Reverse transcriptase
SAE = Serious adverse event
SAP = Statistical Analysis Plan
SAS = Statistical Analysis Set
sCr = Serum creatinine
SD = Standard deviation
SF-36 = Short Form (36)
SOP = Standard Operating Procedure
STR = Single tablet regimen
SUSAR = Suspected Unexpected Serious Adverse Reaction
TAF = Tenofovir Alafenamide, GS-7340
TAF Fumarate = Tenofovir Alafenamide Fumarate, GS-7340-03
TDF = Tenofovir Disoproxil Fumarate
TFV = Tenofovir
TFV-DP = Tenofovir diphosphate
T_{\text{max}} = The time (observed time point) of C_{\text{max}}
\text{t}_{1/2} = An estimate of the terminal elimination half-life of the drug in serum/plasma/PBMC, calculated by dividing the natural log of 2 by the terminal elimination rate constant (\lambda_z)
T_{3} = Triiodothyronine
UACR = Urine albumin-to-creatinine ratio
UGT1A1  Uridine glucuronosyltransferase 1 family, polypeptide A1
ULN    Upper limit of the normal range
UPCR   Urine protein-to-creatinine ratio
US     United States
WHO    World Health Organization
WPAI   Work Productivity and Activity Impairment
1. INTRODUCTION

1.1. Background

Chronic hepatitis B (CHB) is a major public health care issue worldwide and one of the principal causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). The hepatitis B virus (HBV) is easily transmissible through perinatal, percutaneous, and sexual exposure {Lok et al 2009}. Following acute HBV infection, 5% to 10% of adults and up to 90% of children fail to produce an immune response adequate to clear the infection; these individuals become chronic carriers of the virus {Zuckerman 1996}. Individuals who develop CHB are at substantial risk of cirrhosis, hepatic decompensation, and HCC, which will afflict 15% to 40% of subjects with CHB in the absence of effective treatment {World Health Organization (WHO) 2015a, Wright 2006}. Liver cancer is the third leading cause of cancer deaths globally, with the highest burden of disease found in regions where HBV is endemic {Global Burden of Disease Cancer Collaboration et al 2015}. Recent reports estimated that 250 to 350 million individuals were living with HBV (i.e., are hepatitis B surface antigen [HBsAg] positive) in 2010, representing a worldwide prevalence of 3.6%, with considerable geographic variability {Schweitzer et al 2015, World Health Organization (WHO) 2015b}. For example, HBV prevalence rates of 0.01%, 0.76%, 4.0%, 5.5%, and 22.4% have been reported for the United Kingdom, Canada, Turkey, China, and South Sudan, respectively. In 2013, an estimated 686,000 deaths were due to HBV infection, placing it among the top 20 causes of mortality worldwide {G. B. D. Mortality Causes of Death Collaborators 2015, Ott et al 2012}.

Worldwide universal vaccination remains the goal for eliminating HBV infection and its complications, yet despite the availability of HBV vaccine programs in many countries, new HBV infections are still common even in areas of low prevalence. The World Health Organization estimates that each year there are over 4 million acute clinical cases of HBV infection globally {World Health Organization (WHO) 2015b}. In the United States (US), approximately 20,000 people become acutely infected each year according to an estimate from the Centers for Disease Control and Prevention {Centers for Disease Control (CDC) et al 2013}.

The natural history of chronic hepatitis B virus infection and disease is complex and highly variable. Following acute hepatitis B infection, up to 90% of newborns who are vertically infected, and 25-50% of children who acquire HBV within the first 6 years of life, will become chronic carriers of the virus when the immune system is thought to be immature, compared to immunocompetent individuals who become infected during adulthood (< 1%) {Fattovich et al 2008, Sarin et al 2015}. CHB has traditionally been characterized by four distinct phases of variable duration that reflect the dynamics of viral replication and the evolving host immune response {Fattovich et al 2008, Sokal et al 2013}. In the first, or the immune tolerant phase, individuals have high plasma levels of HBV DNA, detectable hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), with normal or slightly elevated serum alanine transaminase (ALT) levels reflective of minimal inflammation and fibrosis. This phase typically extends into late childhood or adolescence, and is followed by an HBeAg-positive, immune-active phase wherein ALT levels are persistently elevated along with
fluctuating levels of HBV DNA, reflective of moderate to severe inflammation or fibrosis. This phase may be followed by loss of HBeAg with seroconversion to anti-HBe. In the inactive CHB phase, subjects have undetectable or low levels of HBV DNA (<2000 IU/mL), the presence of anti-HBe antibody, and normal or minimal elevation in serum ALT, which reflects minimal inflammation but with variable fibrosis. This third phase can evolve in a subgroup of individuals to an HBeAg-negative, immune reactivation phase, in which ALT levels and HBV DNA levels are increased. Subjects develop HBeAg-negative CHB as a result of variants that arise in the precore or core promoter region of the virus {Sarin et al 2015}. The goal of anti-HBV therapy is to improve long-term survival and quality of life by reducing disease progression to cirrhosis, decompensated liver disease, and HCC {Sarin et al 2015, Terrault et al 2015}. As seroclearance of HBsAg is a rare spontaneous occurrence in patients with CHB, durable anti-HBe seroconversion in HBeAg-positive subjects is sometimes considered a reasonable endpoint, associated with improved prognosis, including a reduced risk of HCC. However, in many subjects who discontinue treatment following anti-HBe seroconversion, disease relapse with increased levels of viremia can occur {Sarin et al 2015}. Successful reduction of viremia to levels below assay detection leads to reduced inflammation and slowing or reversal of fibrosis {Marcellin et al 2013}.

Currently, there are 2 approved options for treatment of CHB: injectable interferons and oral antiviral (OAV) agents. Of these, treatment with OAV agents has been more successful in achieving and maintaining a high degree of viral suppression in subjects with CHB. The development of nucleos(t)ide reverse transcriptase inhibitors (N[t]RTIs) was a major breakthrough for the treatment of CHB, providing effective suppression of viral replication and reducing the risk of long-term complications {Marcellin et al 2013, World Health Organization (WHO) 2015a}. However, several N[t]RTIs possess a low barrier for viral resistance development, including lamivudine (LAM), telbivudine, (TBV) and adefovir dipivoxil (ADV) {European Association for the Study of the Liver (EASL) 2012, Liaw et al 2012}. Additionally, while development of resistance to entecavir (ETV) is low in treatment-naïve subjects, the cumulative probability of ETV resistance increases substantially with long-term use in subjects, particularly in subjects who are refractory to lamivudine, and those with lamivudine resistance (up to 57% through 6 years of treatment) {Tenney et al 2009}. In contrast, resistance to tenofovir disoproxil fumarate (TDF; Viread®) has not been documented through 6 years of use {Kitrinos et al 2014}.

Tenofovir (TFV) is a nucleotide analog with limited oral bioavailability that inhibits reverse transcription in HIV-1 and HBV. TDF, an oral prodrug of TFV, was first approved for the treatment of HIV infection in 2001 to be given in combination with other antiretroviral (ARV) agents and was approved for treatment of CHB as monotherapy in 2008. TDF is currently approved in over 165 countries, including the US, Canada, Europe, Japan, Taiwan, South Korea, and China, with more than 3,393,649 patient-years of use worldwide for both HIV and HBV infections since first marketing approval. TDF is a first-line treatment for CHB in all major treatment guidelines {European Association for the Study of the Liver (EASL) 2012, Sarin et al 2015, Terrault et al 2015}. Although highly effective, use of TDF is associated with nephrotoxicity and bone-related toxicity in some subjects.
Tenofovir alafenamide (TAF) is a phosphonamide prodrug of TFV that is more stable in plasma than TDF, and provides higher intracellular levels of the active phosphorylated metabolite TFV-DP to target cells (eg, HBV-infected hepatocytes and HIV-infected lymphoid cells) with approximately 90% lower circulating levels of TFV relative to TDF at therapeutically active doses \{Agarwal et al 2015, Babusis et al 2013, Murakami et al 2015, Ruane et al 2013\}. The distinct metabolism of TAF offers the potential for an improved safety profile when compared with TDF. In support of this concept are recent results from a large dataset of 1733 HIV-infected, treatment naive subjects randomized to receive treatment with the fixed-dose combination [FDC] of elvitegravir (E), cobicistat (C), emtricitabine (F), TAF [E/C/F/TAF; Genvoya®] or E/C/F/TDF [STB; Stribild®]. Renal and bone parameters were significantly less affected in subjects who received E/C/F/TAF compared with E/C/F/TDF \{Sax et al 2015\}. In a recent open-label Phase 3 study, HIV-1-infected patients were switched from a TDF-based regimen to a TAF-based regimen with data supporting the efficacy and safety of switching regimens. In adult subjects with CHB, a global Phase 3 program for TAF consisting of 2 prospective, randomized, active-controlled studies with 1 each in HBeAg-negative (Study GS-US-320-0108) and HBeAg-positive (Study GS-US-320-0110) subjects is currently ongoing as described below. Efficacy and safety results at Week 48 from Studies GS-US-320-0108 and GS-US-320-0110 are summarized below in Section 1.2.3. Marketing Applications for TAF 25 mg tablets for the treatment of CHB in adults have been filed in the US, EU, Japan, Taiwan and other territories worldwide.

1.2. Tenofovir Alafenamide (TAF, GS-7340)

1.2.1. General Information

Tenofovir alafenamide (GS-7340, TAF, or L-Alanine, N-[(S)-[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy] methyl]phenoxyphosphinyl]-, 1-methylethyl ester, (2E)-2-butenedioate (2:1) is a next generation oral prodrug of TFV, a nucleotide analog that inhibits HIV-1 reverse transcription. Tenofovir is metabolized intracellularly to the active metabolite, TFV-DP, a competitive inhibitor of HIV-1 reverse transcriptase (RT) and HBV reverse transcriptase (HBV RT) that terminates the elongation of the viral DNA chain. In the development of TAF, three forms of the drug substance have been used in various studies: GS-7340, synonym for GS-7340 as the free base; GS-7340-02, synonym for TAF monofumarate (1:1); and GS-7340-03 as the hemifumarate (2:1). GS-7340-03, also known as TAF fumarate, which is being used in the Phase 3 studies GS-US-320-0108 and GS-US-320-0110, is considered comparable based on physical/chemical properties to GS-7340-02 that has been used in previous studies and a number of ongoing studies. GS-7340-03 was also used in the Phase 1b study GS-US-320-0101. GS-7340-03 and GS-7340-02 exist as the free base, TAF (GS-7340), in blood and biological fluids.

For further information on TAF (GS-7340), please refer to the current Investigator’s Brochure for TAF.
1.2.2. Preclinical Pharmacology and Toxicology

Virology

Following its release from the prodrug TAF, TFV is metabolized intracellularly to the active metabolite, TFV-DP, a competitive inhibitor of HBV polymerase/reverse transcriptase (pol/RT) and HIV-1 RT that terminates the elongation of the viral DNA chain during the process of HBV and retroviral replication.

Compared to TDF, TAF is relatively stable in plasma, but rapidly converts to TFV inside cells. The cellular enzymes responsible for conversion of TAF to TFV are cathepsin A (CatA), which is broadly expressed in cells, and carboxylesterase 1 (CES1), which is highly expressed in liver. In HBV target cells, primary human hepatocytes, TAF is primarily hydrolyzed by CES1 with CatA making a minor contribution \{Murakami et al 2015\}. In HIV-1 target cells, primary human lymphoid cells, CatA is the major enzyme hydrolyzing TAF to TFV. In vitro studies have shown no significant variation for conversion to TFV and antiviral activity of TAF within PBMCs and macrophages from multiple donors. The covalent anti-hepatitis C virus (HCV) protease inhibitors (PIs) telaprevir and boceprevir were identified as the only potent inhibitors of CatA mediated hydrolysis of TAF in a biochemical assay (PC-120-2001).

TAF is a potent inhibitor of HBV replication, exhibiting in vitro activity comparable to that of TDF with an effective concentration (EC$_{50}$) value of 18 nM. Additionally, TAF is similarly active in vitro against wild-type genotype A-H HBV clinical isolates (PC-320-2003). TAF also exhibits potent anti-HIV activity in lymphoid T-cells, primary human PBMCs, and macrophages with EC$_{50}$ values ranging from 3 to 14 nM. The in vitro activity of TAF against HIV-1 is 100- to 600-fold greater than TFV and 4- to 6-fold greater than TDF \{Robbins et al 1998\}. In MT-2 cells, TAF shows low cytotoxicity with a selectivity index of > 10,000. Based on data generated with the parent nucleotide TFV, TAF is active against a wide range of HIV-1 subtypes and also against HIV-2.

For further information on the virology of TAF, (GS-7340), refer to the current investigator’s brochure for TAF.

Safety Pharmacology

The IC$_{20}$ and the IC$_{50}$ for the inhibitory effect of TAF fumarate on human ether-a-go-go-related gene (hERG) potassium current was estimated to be greater than 30 μM (PC-120-2005). TAF in the monofumarate form has been evaluated to determine potential functional effects on the central nervous system (R990188), renal system (R990186), cardiovascular (D2000006), and gastrointestinal systems (R990187). Single doses did not induce pharmacologic effects on the central nervous system of the rat (1000 mg/kg), the renal system of the rat (1000 mg/kg), or the cardiovascular system of the dog (100 mg/kg). TAF at 1000 mg/kg reduced distal transit and increased stomach weights starting 2 hours postdosing, with reversibility beginning by 6 hours after dosing. The no observed effect level (NOEL) for gastrointestinal motility was 100 mg/kg.
Nonclinical Pharmacokinetics

All nonclinical pharmacokinetic experiments were performed using TAF monofumarate (GS-7340-02), and all study data described reflect the dosage of the monofumarate. For reference, 100 mg of TAF monofumarate is equivalent to 80 mg of the GS-7340 free base (TAF).

Plasma pharmacokinetics of the intact prodrug, TAF, following oral administration of GS-7340-02 in dogs and monkeys demonstrated rapid absorption with peak plasma concentrations between 0.25 and 0.5 hours.

Peak TFV plasma concentrations occurred following TAF absorption, with TFV $T_{\text{max}}$ values between 0.25 to 1.7 hours in rats, dogs, and monkeys. TFV plasma concentrations declined with a terminal half-life of 11.2 to 16.4 hours in rats (fasted), > 24 hours in dogs (fasted) and 8.1 to 2.5 hours in rhesus monkeys.

The tissue distribution and recovery of $[^{14}\text{C}]$ radiolabeled GS-7340-02 was examined in beagle dogs. Radioactivity was detected in all tissues except brain, with the majority present in the contents of the gastrointestinal tract, liver, kidney, and large intestine. Tissue concentrations were the highest in kidney, PBMCs, liver, large intestine, and bile. Significant concentrations of TFV-related radioactive material were observed in lymph nodes from all 4 sites, suggesting that TAF may be selectively cleaved to tenofovir in the cells of the lymphoreticular system. The primary route of elimination of tenofovir is renal excretion of unchanged drug based on intravenous studies of TFV. Following oral administration of GS-7340-02, approximately 15% of a radiolabeled dose is recovered in dog urine in 24 hours. Tenofovir was the major species present in the urine (90%), with about 3.4% of TAF also present. Biliary excretion of tenofovir in dogs and fecal elimination of tenofovir in rats and dogs are negligible.

Tenofovir was the only species found in the intestinal contents and feces. In human systems, TAF is metabolized by hydrolytic cleavage and, to a lesser extent, by CYP3A4 catalyzed oxidation (AD-120-2004). As a result of the limited metabolism of TAF by CYP3A4 inhibition or induction of this enzyme should have little consequence on TAF exposure in vivo. TAF has limited potential to alter CYP enzyme activity through inhibition and does not inhibit UGT1A1 function. In addition, TAF is not an activator of either the aryl hydrocarbon receptor (AhR) or human pregnane-X-receptor (PXR). These features combined with the relatively low plasma exposures of TAF in humans suggest that the potential of TAF to cause or be affected by clinically relevant drug-drug interactions is very low.

Nonclinical Toxicology

Because of lack of exposure to the prodrug TAF in mice and rats and achievable TFV exposures being less than previously tested in studies with TDF, Gilead and regulatory agencies have agreed that neither carcinogenicity studies nor a peri/postnatal study with TAF were warranted as they would not add to the overall risk evaluation or risk management of TAF.
The oral toxicity of TAF was evaluated in mice, rats, dogs, and monkeys for treatment periods up to 9 months. Based on recommendations that renal karyomegaly is not a dose-limiting effect {Foran 1997} and observations in the rat that renal karyomegaly is not sufficient to induce renal toxicity or predict oncogenicity (M990205) (M990204), its toxicological significance is questionable and, therefore, it was not considered an adverse effect in determining the NOAEL.

The data from the 6-month rat study determined a NOAEL of 25 mg/kg/day; the 9-month dog study defined a No observed adverse effect level (NOAEL) of 2 mg/kg/day, and the 28-day nonhuman primate study defined a NOAEL of ≥ 30 mg/kg/day. While no NOAEL was determined in the 13-week mouse study, the relevance of the nasal findings to humans is unclear.

TAF had no discernible electrocardiograph effect at the low dose of 2 mg/kg/day. There was some evidence at 6 and 18/12 mg/kg/day for an effect to slightly prolong PR intervals. Additionally, at Week 39, TAF appeared to reversibly reduce heart rate with an associated mild QT prolongation. At Week 39, significant decreases in serum tri-iodothyronine (T3) were noted for animals receiving 18/12 mg/kg/day when compared to controls, which may have been associated with the slight prolongation of PR intervals. After the 3-month recovery period, serum T3 values returned to levels similar to the control group animals at the end of the study.

TAF was not genotoxic in either in vitro or in vivo assays. TAF fumarate had no adverse effects on male or female fertility parameters in rats. There was no effect on fetal viability or fetal development in pregnant rats administered doses of TAF monofumarate up to 200 mg/kg/day or in pregnant rabbits administered TAF monofumarate up to 100 mg/kg/day the highest doses tested. In the rat, a minor (7.7%) decrease in mean fetal body weight compared to the control group was observed at 200 mg/kg/day, which was a maternally toxic dose. At the NOAEL for embryo-fetal development of 200 mg/kg/day in rats, AUC\text{tau} values for TAF and TFV on Day 17 were 0.65 and 35.7 μg•h/kg, respectively. At the NOEL for embryo-fetal development of 100 mg/kg/day in rabbits, AUC\text{tau} values for TAF and TFV on Day 20 were 10.7 and 23.5 μg•h/kg, respectively. The TFV exposures in both species were > 30-fold higher than the TFV AUC\text{inf} after a 25-mg dose of TAF monofumarate in humans.

For further information on TAF, (GS-7340), refer to the current investigator’s brochure for TAF.

1.2.3. **Clinical Trials of Tenofovir Alafenamide (TAF, GS-7340)**

As of December 2015, a total of 1286 subjects have received at least 1 dose of TAF 25 mg in the TAF clinical program, including 866 subjects in the TAF Phase 3 studies in subjects with CHB and 420 subjects in TAF single-agent Phase 1 studies. The TAF clinical development program for CHB includes 2 ongoing Phase 3 studies in HBeAg-negative and HBeAg-positive subjects with CHB, a completed Phase 1b antiviral activity and safety/tolerability study in subjects with CHB, as well as several completed Phase 1 safety, pharmacokinetics (PK)/pharmacodynamics (PD), and drug interaction studies in healthy subjects (including Chinese and Japanese subjects) and in subjects with impaired renal or hepatic function.

In some studies, TAF was administered as a single agent or as part of the F/TAF, FTC/RPV/TAF, or E/C/F/TAF FDC tablets.
TAF clinical studies are listed below:

- **GS-US-320-0101**, a Phase 1b study to evaluate the pharmacokinetics, safety, viral kinetics, and anti-HBV activity of TAF in treatment-naive adults with CHB (completed) [Agarwal et al 2015] (completed)

- **GS-US-320-1228**, a Phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of TAF in healthy Japanese and non-Japanese subjects (completed)

- **GS-US-320-1229**, a Phase 1 study to evaluate the pharmacokinetics of a single dose and repeat doses of TAF 25 mg in healthy Chinese subjects (completed; data analysis is ongoing)

- **GS-US-320-1382**, a Phase 1 study to evaluate the effect of food on a single dose of TAF 25 mg in healthy subjects (completed)

- **GS-US-320-1615**, a Phase 1 study to evaluate the pharmacokinetics of a single dose of TAF 25 mg in subjects with severe hepatic impairment and subjects with normal liver function (completed)

- **GS-US-320-0108**, a Phase 3 study to evaluate the safety and efficacy of TAF 25 mg once daily versus TDF 300 mg once daily for the treatment of HBeAg-negative subjects with CHB (ongoing)

- **GS-US-320-0110**, a Phase 3 study to evaluate the safety and efficacy of TAF 25 mg once daily versus TDF 300 mg once daily for the treatment of HBeAg-positive subjects with CHB (ongoing)

- **GS-US-320-1092**, a Phase 2/3 study to evaluate the pharmacokinetics, safety, and antiviral Efficacy of TAF in Adolescents with Chronic Hepatitis B Virus Infection (ongoing)

- **GS-US-320-3912**, a Phase 2 study to evaluate the efficacy and safety of TAF versus TDF 300 in subjects with CHB and Stage 2 or greater chronic kidney disease who have received a liver transplant

- **GS-US-120-0107**, a Phase 1, Partially-Blinded, Randomized, Placebo- and Positive-Controlled Study to Evaluate the Effect of GS-7340 on the QT/QTc Interval in Healthy Subjects (completed)

- **GS-US-120-0108**, a Phase 1, open-label, parallel-design study to evaluate the pharmacokinetics of TAF in subjects with severe renal impairment (completed)

- **GS-US-120-0109**, a Phase 1 mass balance study to evaluate the pharmacokinetics, metabolism and excretion of TAF in healthy subjects (completed)

- **GS-US-120-0114**, a Phase 1 study to evaluate the pharmacokinetics of TAF in subjects with normal, mild, and moderately impaired hepatic function (completed)
• **GS-US-120-1538**, a Phase 1 pharmacokinetic study that evaluated the drug interaction potential between TAF and MDZ (oral and intravenous) in healthy subjects (completed)

• **GS-US-120-1554**, a Phase 1 pharmacokinetic study that evaluated the drug interaction potential between TAF and RPV in healthy subjects (completed)

• **GS-US-311-1386**, a Phase 1 study that evaluated the effect of food on the PK of TAF and FTC when administered as an F/TAF fixed-dose combination tablet in healthy subjects (completed)

• **GS-US-311-1387**, a Phase 1 study that evaluated the drug-drug interaction (DDI) potential between CBZ and TAF administered as F/TAF in healthy subjects (completed)

• **GS-US-311-1790**, a Phase 1 study that evaluated the DDI potential between F/TAF or GS-9883 and norgestimate/ethinyl estradiol in healthy female subjects (completed)

Please refer to the latest version of the investigator’s brochure for information on the clinical program.

An overview of the 2 Phase 3 studies evaluating the efficacy and safety of TAF in Marketing Applications is provided in Table 1-1. The Phase 3 studies are described below as follows:

• **GS-US-320-0108**: This ongoing Phase 3, randomized, double-blind, noninferiority, international, multicenter study is comparing the efficacy, safety, and tolerability of TAF 25 mg once daily versus TDF 300 mg once daily for 48 weeks for the treatment of CHB infection in treatment-naive and treatment-experienced HBeAg-negative subjects.

• **GS-US-320-0110**: This ongoing Phase 3, randomized, double-blind, noninferiority, international, multicenter study is comparing the efficacy, safety, and tolerability of TAF 25 mg once daily versus TDF 300 mg once daily for 48 weeks for the treatment of CHB infection in treatment-naive and treatment-experienced HBeAg-positive subjects.

In both of these similarly designed noninferiority studies, subjects were randomized in a 2:1 ratio to receive either TAF 25 mg or TDF 300 mg once daily for 96 weeks. Randomization was stratified by plasma HBV DNA level (< 7, ≥ 7 to < 8, and ≥ 8 log10 IU/mL for Study GS-US-320-0108; < 8 and ≥ 8 log10 IU/mL for Study GS-US-320-0110) and OAV treatment status (treatment naive vs treatment experienced) at screening. In both studies, all subjects completing 96 weeks of double-blind therapy are eligible to continue open-label treatment with TAF 25 mg for an additional 48 weeks. Both protocols were amended in February 2016 (Amendment 3 of GS-US-320-0108 and GS-US-320-0110) to extend the double-blind period to 144 weeks (3 years) and the open-label phase from Week 144 to Week 384 (8 year total study period).
Table 1-1. Clinical Studies to Support Efficacy for the TAF Marketing Applications

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Treatment Regimen (Number of Subjects)</th>
<th>Data Presented</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS-US-320-0108</td>
<td>Phase 3, randomized, double-blind study to evaluate the safety and efficacy of TAF vs TDF in HBeAg-negative subjects with CHB</td>
<td>TAF 25 mg once daily (N = 285) TDF 300 mg once daily (N = 140)</td>
<td>Week 48 efficacy, PK, and safety</td>
</tr>
<tr>
<td>GS-US-320-0110</td>
<td>Phase 3, randomized, double-blind study to evaluate the safety and efficacy of TAF vs TDF in HBeAg-positive subjects with CHB</td>
<td>TAF 25 mg once daily (N = 581) TDF 300 mg once daily (N = 292)</td>
<td>Week 48 efficacy, PK, and safety</td>
</tr>
</tbody>
</table>

Demographic and disease characteristics were generally similar between the TAF and TDF groups in both studies and are representative of patient population of HBeAg-negative subjects in Study GS-US-320-0108 and HBeAg-positive subjects in Study GS-US-320-0110. In both studies the majority of subjects were male (> 60%) and Asian (> 70%). As would be expected based on the 2 distinct study populations, subjects in Study GS-US-320-0108 were older (median age: 47 years; range: 19-80 years) than subjects in Study GS-US-320-0110 (median age: 36 years; range: 18-69 years). Differences in baseline characteristics between the 2 studies included HBV DNA levels (median levels were 5.7 and 7.9 log_{10} IU/mL for GS-US-320-0108 and GS-US-320-0110, respectively), serum ALT levels (median values were 67 and 85 U/L for GS-US-320-0108 and GS-US-320-0110, respectively), and number of years positive for HBV (6.0 and 4.0 years [median values] for GS-US-320-0108 and GS-US-320-0110, respectively). The distribution of HBV genotypes was similar between treatment groups in both studies with the most common genotypes being C (46.1%), D (24.3%), and B (20.4%).

Efficacy of TAF in Subjects with CHB

Primary Endpoint Analysis

For both studies, the primary efficacy endpoint was the proportion of subjects with plasma HBV DNA < 29 IU/mL at Week 48. Table 1-2 presents HBV DNA outcomes for Studies GS-US-320-0108 {Buti et al 2016} and GS-US-320-0110 {Chan et al 2016} for subjects at Week 48. In both studies, similar rates of HBV DNA suppression were achieved in the 2 treatment groups when assessed using the M = F method at Week 48 for the Full Analysis Set (FAS). The percentages of subjects with HBV DNA levels < 29 IU/mL at Week 48 were as follows:

- **Study GS-US-320-0108**: TAF 94.0%, TDF 92.9%; difference in proportions (baseline stratum-adjusted): 1.8%, 95% CI: −3.6% to 7.2%
- **Study GS-US-320-0110**: TAF 63.9%, TDF 66.8%; difference in proportions (baseline stratum-adjusted): −3.6%, 95% CI: −9.8% to 2.6%
In both studies, because the lower bound of the 2-sided 95% CI of the difference (TAF − TDF) in the response rate was greater than the prespecified −10% margin, the TAF group met the primary endpoint of noninferiority to the TDF group.

**Table 1-2. GS US 320 0108 and GS US 320 0110: HBV DNA Outcome at Week 48 Using HBV DNA of < 29 IU/mL, Missing = Failure (Full Analysis Set)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV DNA &lt; 29 IU/mL</td>
<td>268 (94.0%)</td>
<td>195 (66.8%)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.47</td>
<td>0.25</td>
</tr>
<tr>
<td>Difference in Proportions (95% CI)</td>
<td>1.8% (−3.6% to 7.2%)</td>
<td>−3.6% (−9.8% to 2.6%)</td>
</tr>
<tr>
<td>HBV DNA ≥ 29 IU/mL</td>
<td>7 (2.5%)</td>
<td>183 (31.5%)</td>
</tr>
<tr>
<td>No Virologic Data at Week 48</td>
<td>10 (3.5%)</td>
<td>27 (4.6%)</td>
</tr>
<tr>
<td>Discontinued Study Drug Due to Lack of Efficacy</td>
<td>0</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Discontinued Study Drug Due to AE/Death</td>
<td>3 (1.1%)</td>
<td>6 (1.0%)</td>
</tr>
<tr>
<td>Discontinued Study Drug Due to Other Reasons</td>
<td>6 (2.1%)</td>
<td>19 (3.3%)</td>
</tr>
<tr>
<td>Missing Data During Window but on Study Drug</td>
<td>1 (0.4%)</td>
<td>1 (0.2%)</td>
</tr>
</tbody>
</table>

a P-value for the superiority test comparing the percentages of HBV DNA < 29 IU/mL was from the CMH test stratified by baseline HBV DNA categories and oral antiviral treatment status strata.

b Difference in the proportion between treatment groups and its 95% CI were calculated based on the MH proportions adjusted by baseline HBV DNA categories and oral antiviral treatment status strata.

c Discontinuation due to other reasons included subjects who prematurely discontinued study drug due to investigator’s discretion, withdrew consent, lost to follow-up, noncompliance with study drug, protocol violation, pregnancy, and study termination by sponsor.

Source: GS-US-320-0108 Week 48 CSR, Section 15.1, Table 12; GS-US-320-0110 Week 48 CSR, Section 15.1, Table 12.

**Biochemical Analyses**

**Table 1-3** presents the proportion of subjects with ALT normalization at Week 48 for both studies (GS-US-320-0108) and (GS-US-320-0110) when determined by central laboratory criteria and by AASLD criteria (upper limit of normal range: ≤ 30 U/L for males and ≤ 19 U/L for females {Lok et al 2009, Terrault et al 2015}), respectively.

For Study GS-US-320-0108, the percentage of subjects with normalized ALT (i.e., ALT > ULN at baseline but within the normal range at Week 48) using the central laboratory criteria was numerically higher for the TAF group compared with the TDF group for all time points from Weeks 4 through 48. When assessed at Week 48, rates of ALT normalization were not significantly different between the 2 treatment groups by the Missing = Failure (M = F) method for the Full Analysis Set (FAS). Using the AASLD criteria, the percentage of subjects with normalized ALT was significantly higher in the TAF group than in the TDF group at for all time points from Week 8 onward using the M = F method.
For Study GS-US-320-0110, the percentage of subjects with normalized ALT using the central laboratory criteria was numerically higher for the TAF group compared with the TDF group for all time points from Weeks 8 through 48. When assessed at Week 48, rates of normalization were not significantly different between the 2 treatment groups by the M = F method for the FAS. Using the AASLD criteria, the percentage of subjects with normalized ALT was significantly higher in the TAF group than in the TDF group for all time points from Weeks 8 through 48 using the M = F method.

Overall, the percentage of subjects with normalized ALT at Week 48 was higher in Study GS-US-320-0108 compared with Study GS-US-320-0110 using the central laboratory criteria and similar across the 2 studies using the AASLD criteria.

### Table 1-3. GS-US-320-0108 and GS-US-320-0110: Proportion of Subjects with ALT Normalization at Week 48, Missing = Failure (Full Analysis Set with Baseline ALT > ULN)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TAF 25 mg</td>
<td>TDF 300 mg</td>
</tr>
<tr>
<td>Central Laboratory&lt;sup&gt;a&lt;/sup&gt;</td>
<td>(N = 236)</td>
<td>(N = 121)</td>
</tr>
<tr>
<td>Week 48</td>
<td>196/236 (83.1%)</td>
<td>91/121 (75.2%)</td>
</tr>
<tr>
<td>Proportion Difference (95% CI)</td>
<td>8.0% (−1.3% to 17.2%)</td>
<td>4.6% (−2.3% to 11.4%)</td>
</tr>
<tr>
<td>p-value</td>
<td>0.076</td>
<td></td>
</tr>
<tr>
<td>AASLD&lt;sup&gt;b&lt;/sup&gt;</td>
<td>(N = 276)</td>
<td>(N = 138)</td>
</tr>
<tr>
<td>Week 48</td>
<td>137/276 (49.6%)</td>
<td>44/138 (31.9%)</td>
</tr>
<tr>
<td>Proportion Difference (95% CI)</td>
<td>17.9% (8.0% to 27.7%)</td>
<td>8.7% (1.8% to 15.6%)</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt; 0.001</td>
<td>0.014</td>
</tr>
</tbody>
</table>

<sup>a</sup> Central laboratory ULN for ALT are as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males ≥ 69 years; ≤ 34 U/L for females 18 to < 69 years and ≤ 32 U/L for females ≥ 69 years.

<sup>b</sup> AASLD ULN for ALT criteria are as follows: ≤ 30 U/L for males and ≤ 19 U/L for females.

P-value was from the Cochran-Mantel-Haenszel tests stratified by baseline HBV DNA categories and oral antiviral treatment status strata.

Difference in the proportion between treatment groups and its 95% CI were calculated based on the Mantel-Haenszel proportions adjusted by baseline HBV DNA categories and oral antiviral treatment status strata.

Source: GS-US-320-0108 Week 48 CSR, Section 15.1, Tables 23.1.1 and 23.2.1; GS-US-320-0110 Week 48 CSR, Section 15.1, Tables 23.1.1 and 23.2.1

### Serological Analyses

In Study GS-US-320-0108, no subject in either treatment group experienced HBsAg loss by Week 48. In Study GS-US-320-0110, 4 subjects (0.7%) in the TAF group and 1 subject (0.3%) in the TDF group experienced HBsAg loss at Week 48. Three of the 4 subjects in the TAF group and none in the TDF group also experienced HBsAg seroconversion at Week 48.
In Study GS-US-320-0110, the proportion of subjects with HBeAg loss or seroconversion to anti-HBe at Week 48 was also evaluated; these data are presented on Table 1-4. A total of 78 (13.8%) and 34 (11.9%) subjects in the TAF and TDF groups, respectively, had HBeAg loss at Week 48. A total of 58 (10.3%) and 23 (8.1%) subjects in the TAF and TDF groups, respectively, experienced HBeAg seroconversion at Week 48.

Table 1-4. GS-US-320-0110: Proportion of Subjects with HBeAg Loss or Seroconversion at Week 48, Missing = Failure (Serologically Evaluable Full Analysis Set)

<table>
<thead>
<tr>
<th></th>
<th>GS-US-320-0110</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TAF 25 mg (N = 565)</td>
</tr>
<tr>
<td></td>
<td>p-value</td>
</tr>
<tr>
<td>HBeAg Loss, n (%)</td>
<td>78/565 (13.8%)</td>
</tr>
<tr>
<td>HBeAg Seroconversion, n (%)</td>
<td>58/565 (10.3%)</td>
</tr>
</tbody>
</table>

P-values were from the Cochran-Mantel-Haenszel test stratified by baseline HBV DNA categories and oral antiviral treatment status. Differences in the proportion between treatment groups and its 95% CI were calculated based on the Mantel-Haenszel proportions adjusted by baseline HBV DNA categories and oral antiviral treatment status strata. Serologically Evaluable Full Analysis Set for HBeAg loss/seroconversion included subjects who were HBeAg positive and HBeAb negative/missing at baseline. HBeAg loss was defined as changes from HBeAg-positive at baseline to HBeAg-negative at a post-baseline visit with baseline anti-HBe negative/missing. HBeAg seroconversion was defined as HBeAg loss and anti-HBe change from negative/missing at baseline to positive at a post-baseline visit.

Source: GS-US-320-0110 Week 48 CSR, Section 15.1, Table 19.1

Virologic Resistance Analysis

In an integrated analysis of Studies GS-US-320-0108 and GS-US-320-0110, 24 subjects (2.8%) in the TAF group and 14 subjects (3.2%) in the TDF group qualified for population-based sequence analysis after up to 48 weeks of treatment. Among the 24 subjects in the TAF group who qualified for population-based sequence analysis, 15 had no changes detected in the pol/RT sequence from baseline, 4 were unable to be sequenced, and 5 had polymorphic site substitutions. Among the 14 subjects in the TDF treatment group who qualified for population-based sequence analysis, 6 had no changes detected in the pol/RT sequence from baseline, 4 were unable to be sequenced, 2 had polymorphic site substitutions, and 2 had a conserved site substitution. Overall, no HBV pol/RT amino acid substitutions associated with resistance to TFV were detected by sequencing and phenotypic analysis through 48 weeks of the study in either treatment group.

Safety of TAF in CHB Subjects

The principal sources of safety data for TAF are presented above in Table 1-1 and consist of 2 Phase 3 studies in subjects with CHB, Study GS-US-320-0108 and GS-US-320-0110. Subjects included in the Safety Analysis Set received at least 1 dose of study drug.
Overall Extent of Exposure

Of the 2387 subjects screened in Studies GS-US-320-0108 and GS-US-320-0110 combined, 1301 were randomized (TAF 867 subjects; TDF 434 subjects), and 1298 received at least 1 dose of study drugs (TAF 866 subjects; TDF 432 subjects); 3 subjects (TAF 1 subject; TDF 2 subjects) did not receive study drug due to withdrawal of consent. As of the Week 48 data cutoff date for each Phase 3 study, a total of 1208 subjects (TAF 93.1%, 806 subjects; TDF 93.1%, 402 subjects) were continuing double-blind study drugs, and 27 subjects (TAF 2.1%, 18 subjects; TDF 2.1%, 9 subjects) had entered the open-label phase as of the Week 48 data cutoff date. Of the 1298 subjects randomized and treated, 63 subjects (4.9%) discontinued blinded study drugs (TAF 4.8%, 42 subjects; TDF 4.9%, 21 subjects), and 61 subjects (TAF 40 subjects; TDF 21 subjects) discontinued from the study prior to the Week 48 data cutoff date. Similar rates of discontinuation and reasons for treatment discontinuation were observed for TAF compared with TDF. The most common reasons for premature discontinuation of blinded study treatment were withdrew consent (TAF 1.6%, 14 subjects; TDF 1.6%, 7 subjects); adverse event (AE; TAF 1.0%, 9 subjects; TDF 1.2%, 5 subjects); and lost to follow-up (TAF 0.7%, 6 subjects; TDF 0.7%, 3 subjects). The most common reasons for discontinuation from the study were: subjects withdrew consent (TAF 2.0%, 17 subjects; TDF 2.1%, 9 subjects), lost to follow-up (TAF 0.8%, 7 subjects; TDF 0.7%, 3 subjects), and AEs (TAF 0.3%, 3 subjects; TDF 0.9%, 4 subjects).

Table 1-5 summarizes the duration of exposure to blinded study drug in the TAF Phase 3 Safety Population. Median (first quartile [Q1], third quartile [Q3]) exposures were nearly identical between the 2 treatment groups (TAF 56.1 [48.1, 64.4] weeks; TDF 56.1 [48.1, 64.7] weeks). More than half of the subjects in each treatment group had received blinded study drug for \( \geq 56 \) weeks at the time of the Week 48 data cutoff date for each Phase 3 study (TAF 60.5%, 524 subjects; TDF 62.0%, 268 subjects). There was no statistically significant difference between groups in the overall Kaplan-Meier estimate of time to premature discontinuation of blinded study drug.
Table 1-5. GS-US-320-0108 and GS-US-320-0110: Subjects Exposed to Study Drug for the TAF Phase 3 Safety Population (Safety Analysis Set)

<table>
<thead>
<tr>
<th>Duration of Exposure to Study Regimen (Weeks)</th>
<th>GS-US-320-0108 and GS-US-320-0110</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TAF 25 mg</td>
</tr>
<tr>
<td></td>
<td>(N = 866)</td>
</tr>
<tr>
<td></td>
<td>TDF 300 mg</td>
</tr>
<tr>
<td></td>
<td>(N = 432)</td>
</tr>
<tr>
<td>N</td>
<td>866</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>58.9 (14.71)</td>
</tr>
<tr>
<td>Median</td>
<td>56.1</td>
</tr>
<tr>
<td>Q1, Q3</td>
<td>48.1, 64.4</td>
</tr>
<tr>
<td>Min, Max</td>
<td>0.1, 96.3</td>
</tr>
</tbody>
</table>

**Total Exposure to Study Drug n(%)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 4 Weeks [28 days]</td>
<td>860 (99.3%)</td>
<td>426 (98.6%)</td>
</tr>
<tr>
<td>≥ 8 weeks [56 days]</td>
<td>858 (99.1%)</td>
<td>426 (98.6%)</td>
</tr>
<tr>
<td>≥ 12 weeks [84 days]</td>
<td>854 (98.6%)</td>
<td>423 (97.9%)</td>
</tr>
<tr>
<td>≥ 16 Weeks [112 days]</td>
<td>851 (98.3%)</td>
<td>422 (97.7%)</td>
</tr>
<tr>
<td>≥ 20 Weeks [140 days]</td>
<td>851 (98.3%)</td>
<td>422 (97.7%)</td>
</tr>
<tr>
<td>≥ 24 Weeks [168 days]</td>
<td>851 (98.3%)</td>
<td>419 (97.0%)</td>
</tr>
<tr>
<td>≥ 28 Weeks [196 days]</td>
<td>849 (98.0%)</td>
<td>418 (96.8%)</td>
</tr>
<tr>
<td>≥ 32 Weeks [224 days]</td>
<td>843 (97.3%)</td>
<td>418 (96.8%)</td>
</tr>
<tr>
<td>≥ 36 Weeks [252 days]</td>
<td>838 (96.8%)</td>
<td>418 (96.8%)</td>
</tr>
<tr>
<td>≥ 40 Weeks [280 days]</td>
<td>835 (96.4%)</td>
<td>418 (96.8%)</td>
</tr>
<tr>
<td>≥ 44 Weeks [308 days]</td>
<td>832 (96.1%)</td>
<td>418 (96.8%)</td>
</tr>
<tr>
<td>≥ 48 Weeks [336 days]</td>
<td>669 (77.3%)</td>
<td>346 (80.1%)</td>
</tr>
<tr>
<td>≥ 56 Weeks [392 days]</td>
<td>524 (60.5%)</td>
<td>268 (62.0%)</td>
</tr>
<tr>
<td>≥ 64 Weeks [448 days]</td>
<td>356 (41.1%)</td>
<td>174 (40.3%)</td>
</tr>
<tr>
<td>≥ 72 Weeks [504 days]</td>
<td>190 (21.9%)</td>
<td>92 (21.3%)</td>
</tr>
<tr>
<td>≥ 80 Weeks [560 days]</td>
<td>89 (10.3%)</td>
<td>46 (10.6%)</td>
</tr>
<tr>
<td>≥ 88 Weeks [616 days]</td>
<td>36 (4.2%)</td>
<td>24 (5.6%)</td>
</tr>
</tbody>
</table>

Duration of exposure to blinded study drug was the number of weeks between the first dose and the last dose of blinded study drug. If the last dose date of blinded study drug is missing for subjects prematurely discontinued blinded study drug, or for subjects still on blinded study drug, the latest of nonmissing blinded study drug start and end dates or clinic and laboratory visit dates (excluding open-label and treatment-free follow-up visits) was used to impute the last dose date of blinded study drug. 

Source: TAF Week 48 ISS, Table 4
Adverse Events for the TAF Phase 3 Safety Population

Summary of Adverse Events

Table 1-6 presents an overall summary of AEs by treatment group for the TAF Phase 3 Safety Population. Similar percentages of subjects in each treatment group had experienced at least 1 AE (TAF 70.2%, 608 subjects; TDF 67.4%, 291 subjects) and had experienced at least 1 Grade 3 or 4 AE (TAF 4.5%, 39 subjects; TDF 3.9%, 17 subjects). In addition, 57 subjects (TAF 4.2%, 36 subjects; TDF 4.9%, 21 subjects) had at least 1 SAE, with no subjects experiencing a treatment-related SAE. A similar percentage of subjects in each treatment group experienced an AE leading to discontinuation of study drugs (TAF 1.0%, 9 subjects; TDF 1.2%, 5 subjects). No deaths occurred in any subject on treatment. There were 2 deaths which occurred after treatment was discontinued and were considered non-treatment emergent (1 subject in each treatment group).


<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>TAF 25 mg (N = 866)</th>
<th>TDF 300 mg (N = 432)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects Experiencing Any AE</td>
<td>608 (70.2%)</td>
<td>291 (67.4%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any Grade 2, 3, or 4 AE</td>
<td>221 (25.5%)</td>
<td>120 (27.8%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any Grade 3 or 4 AE</td>
<td>39 (4.5%)</td>
<td>17 (3.9%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any Study Drug-Related AE</td>
<td>123 (14.2%)</td>
<td>68 (15.7%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any Grade 2, 3, or 4 Study Drug-Related AE</td>
<td>33 (3.8%)</td>
<td>21 (4.9%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any Grade 3 or 4 Study Drug-Related AE</td>
<td>6 (0.7%)</td>
<td>2 (0.5%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any SAE</td>
<td>36 (4.2%)</td>
<td>21 (4.9%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any Study Drug-Related SAE</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Subjects Experiencing Any AE Leading to Premature Study Drug Discontinuation</td>
<td>9 (1.0%)</td>
<td>5 (1.2%)</td>
</tr>
<tr>
<td>Subjects Experiencing Any AE Leading to Dose Modification or Study Drug Interruption</td>
<td>17 (2.0%)</td>
<td>7 (1.6%)</td>
</tr>
<tr>
<td>Deatha</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

a Treatment-emergent death refers to the death occurred between the first dose date and the last dose date (inclusive). Adverse events were mapped according to MedDRA Version 18. Treatment-emergent AEs was defined as follows:
1) Any AEs with onset date of on or after the study drug start date and no later than the study drug stop date for those who discontinued study drug permanently, or
2) Any AE with an onset date on or after the study drugs start date for those who had not discontinued study drug permanently, or
3) Any AEs leading to study drug discontinuation

Source: TAF Week 48 ISS, Table 6
Common Adverse Events

Table 1-7 presents AEs reported for ≥ 5% of subjects for any treatment group by system organ class (SOC) and preferred term (PT) in the TAF Phase 3 Safety Population. The rate and types of AEs were similar in the 2 treatment groups. Overall, the 3 most frequently reported AEs by treatment group were as follows:

- **TAF group** — upper respiratory tract infection (9.9%, 86 subjects), nasopharyngitis (9.9%, 86 subjects), and headache (9.5%, 82 subjects)

- **TDF group** — headache (8.3%, 36 subjects), upper respiratory tract infection (7.4%, 32 subjects), and nasopharyngitis (7.2%, 31 subjects)

### Table 1-7. GS-US-320-0108 and GS-US-320-0110: Adverse Events Reported for ≥ 5% of Subjects in Either Treatment Group in the TAF Phase 3 Safety Population (Safety Analysis Set)

<table>
<thead>
<tr>
<th>Adverse Events by System Organ Class and Preferred Term&lt;sup&gt;a,b,c&lt;/sup&gt;</th>
<th>TAF 25 mg (N = 866)</th>
<th>TDF 300 mg (N = 432)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Subjects Experiencing Any Adverse Event</td>
<td>608 (70.2%)</td>
<td>291 (67.4%)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>227 (26.2%)</td>
<td>108 (25.0%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>43 (5.0%)</td>
<td>22 (5.1%)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>125 (14.4%)</td>
<td>62 (14.4%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>49 (5.7%)</td>
<td>23 (5.3%)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>259 (29.9%)</td>
<td>121 (28.0%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>86 (9.9%)</td>
<td>32 (7.4%)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>86 (9.9%)</td>
<td>31 (7.2%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>149 (17.2%)</td>
<td>60 (13.9%)</td>
</tr>
<tr>
<td>Headache</td>
<td>82 (9.5%)</td>
<td>36 (8.3%)</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>106 (12.2%)</td>
<td>44 (10.2%)</td>
</tr>
<tr>
<td>Cough</td>
<td>55 (6.4%)</td>
<td>27 (6.3%)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Adverse events were mapped according to MedDRA Version 18.

<sup>b</sup> SOC were presented alphabetically, and PT was presented by decreasing order of the total frequencies.

<sup>c</sup> Multiple AEs were counted only once per subject for each SOC and PT, respectively.

Source: TAF Week 48 ISS, Table 7

Adverse Events by Severity

The majority of AEs reported in the TAF Phase 3 Safety Population were Grade 1 or 2. A similar percentage of subjects in each treatment group experienced at least 1 Grade 3 AE (TAF 4.5%, 39 subjects; TDF 3.9%, 17 subjects). No subjects in either group had a Grade 4 AE. The only Grade 3 AE that occurred in more than 2 subjects in either treatment group were increased ALT (TAF 0.6%, 5 subjects; TDF 0.7%, 3 subjects) and hepatocellular carcinoma (HCC) (TAF 0 subjects; TDF 0.7%, 3 subjects). Four Grade 3 ALT increases (TAF 3 subjects; TDF 1 subject) were assessed as related to study drug.
Serious Adverse Events

Table 1-8 presents SAEs reported for > 1 subjects for any treatment group in the TAF Phase 3 Safety Population. A similar percentage of subjects experienced SAEs in each treatment group (TAF 4.2%, 36 subjects; TDF 4.9%, 21 subjects). None of the SAEs were considered related to study drugs by the investigators. Hepatocellular carcinoma was reported for 6 subjects (TAF 0.1%, 1 of 866 subjects; TDF 1.2%, 5 of 432 subjects). Other SAEs reported in > 1 subject in either treatment group were cellulitis, hand fracture, dizziness, and calculus ureteric.

Table 1-8.


<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>TAF 25 mg (N = 866)</th>
<th>TDF 300 mg (N = 432)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Subjects (%) Experiencing Any SAE</td>
<td>36 (4.2%)</td>
<td>21 (4.9%)</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>1 (0.1%)</td>
<td>5 (1.2%)</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>0</td>
<td>3 (0.7%)</td>
</tr>
<tr>
<td>Hand fracture</td>
<td>2 (0.2%)</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2 (0.2%)</td>
<td>0</td>
</tr>
<tr>
<td>Calculus ureteric</td>
<td>2 (0.2%)</td>
<td>0</td>
</tr>
</tbody>
</table>

a Adverse events were mapped according to MedDRA Version 18.
b Multiple AEs were counted only once per subject for each SOC and PT, respectively.

Source: TAF Week 48 ISS, Table 14

Summary of Bone Safety

Bone safety was assessed in the TAF Phase 3 Safety Population due to decreases in bone mineral density (BMD) and mineralization defects that have been seen in subjects treated with TDF.

Summary of Fractures

In the TAF Phase 3 Safety Population, the incidence of fracture events was uncommon (TAF 0.7%, 6 of 866 subjects; TDF 0.2%, 1 of 432 subjects; p = 0.44). Six of the 7 reported fractures were associated with trauma and 1 subject, in the TAF group, had a spinal compression fracture identified incidentally on a computed tomography (CT) scan. In the TAF group, 4 fractures were reported as SAEs (hand fracture [3 subjects] and 1 spinal compression fracture). In the TDF group, 1 fracture (lower limb fracture) was reported as an SAE. Of the 7 subjects who had fractures, 4 subjects in the TAF group (tibia fracture, spinal compression identified incidentally, hand fracture [2 subjects]) had normal hip and spine BMD T-scores at all timepoints, 2 subjects in the TAF group (hand fracture and traumatic spinal compression fracture) had hip and/or spine baseline BMD T-scores consistent with osteoporosis at baseline, 1 subject in the TDF group (lower limb fracture) had normal hip and spine BMD at baseline which worsened while on treatment. All fractures were considered unrelated to the study drugs by the investigators and, none resulted in discontinuation of study drugs.
Summary of Bone Mineral Density

Percentage change from baseline in hip BMD and spine BMD were the first and second key alpha-controlled safety endpoints, respectively, for both studies. Subjects receiving TAF experienced significantly less BMD reduction than those receiving TDF. At Week 48, the mean (SD) percentage decreases from baseline were as follows:

- **Hip:** TAF −0.163% (2.2437 %); TDF −1.860 % (2.4525 %)
- **Spine:** TAF −0.570 % (2.9147 %); TDF −2.366 % (3.2051 %)

Table 1-9 presents measure of BMD at Week 48. Percentage changes from baseline in hip and spine BMD were the first and second key alpha-controlled safety endpoints in Studies GS-US-320-0108 and GS-US-320-0110. Mean percentage decreases from baseline in BMD at the hip or spine were smaller in the TAF group compared with the TDF group (p < 0.001). A lower percentage of subjects in the TAF group had a > 3% decrease in hip BMD compared with subjects in the TDF group (8.4% TAF; 26.7% TDF). Similarly, a lower percentage of subjects in the TAF group had a > 3% decrease in spine BMD compared with subjects in the TDF group (TAF 19.5%; TDF 38.1%). At Week 48, fewer subjects had ≥ 7% decrease in hip BMD (TAF 0.4%; TDF 2.0%) and ≥ 5% decrease in spine BMD (TAF 6.3%; TDF 20.4%) in the TAF group compared with the TDF group.

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>TAF 25 mg</th>
<th>N</th>
<th>TDF 300 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hip DXA Analysis Set</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) Percent Change in Hip BMD</td>
<td>807</td>
<td>−0.163 (2.2437)</td>
<td>404</td>
<td>−1.860 (2.4525)</td>
</tr>
<tr>
<td>P-Value&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference in LSM</td>
<td></td>
<td>1.697 (1.420, 1.974)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with &gt; 3% Decrease in Hip BMD, n (%)</td>
<td>807</td>
<td>68 (8.4%)</td>
<td>404</td>
<td>108 (26.7%)</td>
</tr>
<tr>
<td>P-Value&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with &gt; 3% Increase in Hip BMD, n (%)</td>
<td>807</td>
<td>55 (6.8%)</td>
<td>404</td>
<td>8 (2.0%)</td>
</tr>
<tr>
<td>P-Value&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with no Decrease (≥ Zero %Change) in Hip BMD, n (%)</td>
<td>807</td>
<td>383 (47.5%)</td>
<td>404</td>
<td>83 (20.5%)</td>
</tr>
<tr>
<td><strong>Spine DXA Analysis Set</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) Percent Change in Spine BMD</td>
<td>814</td>
<td>−0.570 (2.9147)</td>
<td>407</td>
<td>−2.366 (3.2051)</td>
</tr>
<tr>
<td>P-Value&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference in LSM</td>
<td></td>
<td>1.796 (1.437, 2.155)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with &gt; 3% Decrease in Spine BMD, n (%)</td>
<td>814</td>
<td>159 (19.5%)</td>
<td>407</td>
<td>155 (38.1%)</td>
</tr>
<tr>
<td>P-Value&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with &gt; 3% Increase in Spine BMD, n (%)</td>
<td>814</td>
<td>89 (10.9%)</td>
<td>407</td>
<td>11 (2.7%)</td>
</tr>
<tr>
<td>P-Value&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with no Decrease (≥ Zero %Change) in Spine BMD, n (%)</td>
<td>814</td>
<td>331 (40.7%)</td>
<td>407</td>
<td>89 (21.9%)</td>
</tr>
</tbody>
</table>

DXA = dual-energy x-ray absorptiometry; LSM = least-squares mean
a P-values, difference in least squares means, and its 95% CI were from the ANOVA model including treatment as a fixed effect.
b P-values were calculated from the Cochran-Mantel-Haenszel test for ordinal data (row mean scores differ statistic was used).

Source: TAF Week 48 ISS, Tables 23.1.2, 23.2.2, 25.1, and 25.2 and Request 7633 Tables 2.1 and 2.2

Renal Safety

In the TAF Phase 3 Safety Population in Studies GS-US-320-0108 and GS-US-320-0110 (TAF 25 mg N = 866, TDF 300 mg N = 432; Total N = 1301), no cases of proximal renal tubulopathy (including Fanconi syndrome) or renal failure were reported in either treatment group. No subject in the TAF Phase 3 Safety population experienced a renal SAE or AE resulting in discontinuation of study drugs while on study.

Summary of Renal Laboratory Parameters

Change from baseline in serum creatinine was the third key alpha-controlled safety endpoint. Overall, increases from baseline in mean values for serum creatinine were smaller in the TAF group compared with the TDF group. Mean (SD) changes from baseline at Week 48 were 0.010 (0.1140) mg/dL for the TAF group and 0.024 (0.0974) mg/dL for the TDF group (p = 0.012). Graded serum creatinine abnormalities were reported for 6 subjects (0.7%) in the TAF group; all of which were Grade 1 or 2. Of the 6 subjects, 5 subjects had isolated serum
relevant medical history of hypertension and diabetes, had multiple instances of graded creatinine elevations and eGFR ≤ 50 mL/min. No subjects in the TDF group had graded serum creatinine elevations.

In the TAF group, decreases from baseline in median eGFR values were significantly smaller compared with the TDF group. Median (Q1, Q3) changes from baseline at Week 48 were −1.2 (−8.4, 7.5) mL/min in the TAF group and −5.4 (−12.0, 3.0) mL/min in the TDF group (p < 0.001). The overall number of subjects who had any confirmed renal laboratory abnormality (ie, confirmed increases from baseline in creatinine of at least 0.5 mg/dL, or eGFR below 50 mL/min, or confirmed phosphorus < 2 mg/dL, was small (TAF 0.6%, 5 subjects; TDF 1.6%, 7 subjects). Most instances were isolated, transient, and resolved without treatment.

**Summary of Proteinuria by Urinalysis (Dipstick) and by Quantitative Assessment**

A similar percentage of subjects in each treatment group had at least 1 recorded, graded proteinuria by dipstick while on study; most of which were Grade 1. Table 1-10 presents a summary of the quantitative markers of proteinuria, urine protein to creatinine ratio (UPCR) and urine albumin to creatinine ratio (UACR). There was a significant difference between the 2 treatment groups in median percentage changes from baseline in 1 of the quantitative markers of proteinuria UPCR at Week 48. The median (Q1, Q3) percentage change in UPCR was 6.0 (−31.0, 57.6) mg/g in the TAF group and 16.5 (−21.6, 72.4) mg/g in the TDF group (p = 0.010). Although not statistically significant, the median percentage change from baseline in UACR was lower in the TAF group compared with the TDF group. Median percentage changes from baseline in the markers of proximal tubular dysfunction, urine retinol binding protein (RBP) to creatinine ratio and urine beta-2-microglobulin to creatinine ratio were smaller in the TAF group compared with the TDF group (p < 0.001 for the differences between the 2 groups at Weeks 24 and 48).

**Table 1-10.** GS-US-320-0108 and GS-US-320-0110: Renal Biomarkers to Urine Creatinine Ratios at Week 48 in the TAF Phase 3 Safety Population (Safety Analysis Set)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Median Percentage Change (%) (Q1, Q3)</th>
<th>P-Valuea</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TAF 25 mg (N = 866)</td>
<td>TDF 300 mg (N = 432)</td>
</tr>
<tr>
<td>UPCR (mg/g)</td>
<td>6.0 (−31.0, 57.6)</td>
<td>16.5 (−21.6, 72.4)</td>
</tr>
<tr>
<td>UACR (mg/g)</td>
<td>6.9 (−25.8, 46.7)</td>
<td>12.2 (−21.0, 63.5)</td>
</tr>
<tr>
<td>Urine RBP to Urine Creatinine Ratio (μg/g)</td>
<td>−0.3 (−23.2, 33.3)</td>
<td>25.1 (−7.9, 73.2)</td>
</tr>
<tr>
<td>Urine Beta-2-Microglobulin to Creatinine Ratio (μg/g)</td>
<td>−3.5 (−34.3, 32.0)</td>
<td>37.9 (−4.6, 152.4)</td>
</tr>
</tbody>
</table>

UACR = urine albumin to creatinine ratio; UPCR = urine protein to creatinine ratio
% Change = Change from baseline at a postbaseline visit/baseline × 100%.

a P-values were from the 2-sided Wilcoxon rank sum test to compare the 2 treatment groups.
Source: TAF Week 48 ISS, Tables 34.1, 34.2, 34.3, and 34.4
Graded Laboratory Abnormalities

Most subjects participating in Studies GS-US-320-0108 and GS-US-320-0110 experienced at least 1 laboratory abnormality of Grade 1 or higher (TAF 94.8%, 814 of 859 subjects; TDF 91.1%, 390 of 428 subjects). The majority of subjects had abnormalities that were Grade 1 or 2 at worst severity (TAF 63.4%, 545 subjects; TDF 61.7%, 264 subjects). Grade 3 laboratory abnormalities occurred in 26.2% (225 subjects) in the TAF group and 22.4% (96 subjects) in the TDF group; Grade 4 laboratory abnormalities were less common, occurring in 5.1% (44 subjects) in the TAF group and 7.0% (30 subjects) in the TDF group. In total, a similar percentage of subjects in each group had at least 1 Grade 3 or 4 laboratory abnormality (TAF 31.3%, 269 subjects; TDF 29.4%, 126 subjects).

Table 1-11 presents a summary of the subject incidence of Grade 3 or 4 serum chemistry or urinalysis abnormalities reported for ≥1% in either treatment group for the overall TAF Phase 3 Safety Population. The only Grade 3 or 4 serum chemistry laboratory abnormality that occurred in >5% of subjects overall in each of the treatment groups individually was ALT elevation (TAF 8.1%, 70 subjects; TDF 9.3%, 40 subjects). In the TDF group, Grade 3 or 4 elevations of AST also occurred in >5% of subjects overall (TAF 3.3%, 28 subjects; TDF 5.4%, 23 subjects). Grade 3 urinalysis abnormalities included occult blood (TAF 7.7%, 66 subjects; TDF 7.0%, 30 subjects), urine erythrocytes (TAF 7.7%, 59 subjects; TDF 9.1%, 35 subjects), and urine glucose (TAF 4.8%, 41 subjects; TDF 1.2%, 5 subjects). The majority of subjects (88.6%; 124 of 140 subjects) who had Grade 3 urine occult blood or urine erythrocytes were women of child bearing potential (defined as age ≤ 54 years). The abnormalities were generally asymptomatic and not associated with AEs; none of the events were considered related to study drugs. Among the 41 subjects in the TAF group with Grade 3 urine glucose on treatment, 18 subjects (43.9%) had Grade 3 urine glucose at either screening or baseline, while the majority of the remaining 23 subjects had a medical history relevant for diabetes mellitus and/or had a graded elevation in blood glucose, or experienced an isolated and transient occurrence of Grade 3 urine glucose.
### Table 1-11. GS-US-320-0108 and GS-US-320-0110: Treatment-Emergent Grade 3 or 4 Laboratory Abnormalities Reported for at Least 1% of Subjects in Either Treatment Group in the Overall TAF Phase 3 Safety Population (Safety Analysis Set)

<table>
<thead>
<tr>
<th></th>
<th>TAF 25 mg (N = 866)</th>
<th>TDF 300 mg (N = 432)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum Postbaseline Toxicity Grade (N)</td>
<td>859</td>
<td>428</td>
</tr>
<tr>
<td>Grade 3</td>
<td>225 (26.2%)</td>
<td>96 (22.4%)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>44 (5.1%)</td>
<td>30 (7.0%)</td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine Aminotransferase (N)</td>
<td>859</td>
<td>428</td>
</tr>
<tr>
<td>Grade 3</td>
<td>52 (6.1%)</td>
<td>27 (6.3%)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>18 (2.1%)</td>
<td>13 (3.0%)</td>
</tr>
<tr>
<td>Amylase (N)</td>
<td>859</td>
<td>427</td>
</tr>
<tr>
<td>Grade 3</td>
<td>22 (2.6%)</td>
<td>9 (2.1%)</td>
</tr>
<tr>
<td>Aspartate Aminotransferase (N)</td>
<td>859</td>
<td>428</td>
</tr>
<tr>
<td>Grade 3</td>
<td>25 (2.9%)</td>
<td>18 (4.2%)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>3 (0.3%)</td>
<td>5 (1.2%)</td>
</tr>
<tr>
<td>Creatine Kinase (N)</td>
<td>859</td>
<td>428</td>
</tr>
<tr>
<td>Grade 3</td>
<td>16 (1.9%)</td>
<td>7 (1.6%)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>9 (1.0%)</td>
<td>6 (1.4%)</td>
</tr>
<tr>
<td>Fasting Glucose (Hyperglycemia) (N)</td>
<td>857</td>
<td>425</td>
</tr>
<tr>
<td>Grade 3</td>
<td>9 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td>Fasting LDL Cholesterol (N)</td>
<td>837</td>
<td>417</td>
</tr>
<tr>
<td>Grade 3</td>
<td>37 (4.4%)</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Nonfasting Glucose (Hyperglycemia) (N)</td>
<td>856</td>
<td>426</td>
</tr>
<tr>
<td>Grade 3</td>
<td>25 (2.9%)</td>
<td>7 (1.6%)</td>
</tr>
<tr>
<td>Urinalysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occult Blood (N)</td>
<td>859</td>
<td>426</td>
</tr>
<tr>
<td>Grade 3</td>
<td>66 (7.7%)</td>
<td>30 (7.0%)</td>
</tr>
<tr>
<td>Urine Erythrocytes (N)</td>
<td>768</td>
<td>386</td>
</tr>
<tr>
<td>Grade 3</td>
<td>59 (7.7%)</td>
<td>35 (9.1%)</td>
</tr>
<tr>
<td>Urine Glucose (N)</td>
<td>859</td>
<td>426</td>
</tr>
<tr>
<td>Grade 3</td>
<td>41 (4.8%)</td>
<td>5 (1.2%)</td>
</tr>
</tbody>
</table>

Denominator for percentage (N) is the number of subjects in the safety analysis set with at least 1 postbaseline laboratory value for the test.

Subjects were counted once for the maximum postbaseline severity for each laboratory test. For urinalysis (ie, urine glucose, urine protein, and urine RBC), the highest grade is Grade 3.

For nonfasting glucose, the maximum postbaseline toxicity grades, instead of treatment-emergent abnormalities, were summarized, because nonfasting glucose test was not done at baseline.

‘Hyper’ means high and ‘Hypo’ means low.

Source: TAF Week 48 ISS, Table 20

### Hepatic Laboratory Abnormalities

In Studies GS-US-320-0108 and GS-US-320-0110 the incidence of graded hepatic laboratory abnormalities through the Week 48 data cutoff date was generally lower for subjects in the TAF group compared with subjects in the TDF group, and included ALT increased...
Hepatic laboratory abnormalities in both treatment groups were generally Grade 1 or 2 at maximum severity; Grade 3 or 4 ALT abnormalities and Grade 3 or 4 AST abnormalities were observed in lower percentages of subjects in the TAF group compared with the TDF group (ALT: TAF 8.1%, 70 subjects; TDF 9.3%, 40 subjects; AST: TAF 3.3%, 28 subjects; TDF 5.4%, 23 subjects), while Grade 3 or 4 bilirubin elevations were observed in comparable percentages of subjects in the TAF group (0.3%, 3 subjects) compared with the TDF group (0.2%, 1 subject). Hepatic laboratory abnormalities were generally not associated with hepatic AEs.

**Hepatic Flares**

An ALT elevation was defined as treatment-emergent serum ALT > 2 × baseline value and > 10 × ULN, with or without associated symptoms. Through Week 48, ALT elevations were observed for 16 subjects (1.8%) in the TAF group and 9 subjects (2.1%) of subjects in the TDF group. Most of the events were at isolated time points within the first 8 weeks of dosing and resolved without recurrence while the subject remained on study drug. An ALT elevation that was confirmed at 2 consecutive postbaseline visits was considered an ALT flare. The incidence of these events was balanced between the treatment groups. Five subjects (0.6%) in the TAF group and 4 subjects (0.9%) in the TDF group had a treatment-emergent ALT flare. With the exception of 2 events, ALT flares occurred early in the dosing period; for 7 of the 9 subjects, the ALT flares resolved without recurrence while the subject remained on study drug.

**Metabolic Laboratory Parameters**

Administration of TDF has been associated with lower fasting low-density lipoprotein (LDL) and high-density lipoprotein (HDL) as compared with other antiviral agents. As plasma TFV exposures are approximately 90% lower with TAF administration than with TDF, fasting lipid concentrations remained relatively stable through Week 48 in the TAF treatment group, while TDF administration resulted in the expected lipid-lowering TFV effect, with decreases from baseline in fasting lipid parameters observed in the TDF group. Median decreases from baseline in total cholesterol, LDL, HDL, and triglycerides were greater in the TDF group than the TAF group, with TDF subjects demonstrating reductions in all parameters at Week 48. The difference between groups in median change from baseline was statistically significant a Week 48 for total cholesterol, direct LDL, HDL, and triglycerides (p < 0.001). Median (Q1, Q3) changes from baseline at Week 48 for fasting lipid parameters were as follows:

- **Total cholesterol:** TAF −2 (−17, 17) mg/dL; TDF −24 (−42, −6) mg/dL
- **LDL:** TAF 4 (−9, 20) mg/dL; TDF −9 (−25, 5) mg/dL
- **HDL:** TAF −3 (−10, 2) mg/dL; TDF −9 (−17, −3) mg/dL
- **Triglycerides:** TAF 6 (−13, 26) mg/dL; TDF −7 (−27, 10) mg/dL
The median (Q1, Q3) change from baseline at Week 48 in total cholesterol to HDL ratio was 0.2 (−0.1, 0.5) in the TAF group and 0.2 (−0.2, 0.5) in the TDF group (p = 0.16 for the difference between treatment groups).

Eight subjects (0.9%) in the TAF group had Grade 3 elevated fasting cholesterol; 7 of the 8 subjects had a history of hyperlipidemia and/or elevated fasting cholesterol at baseline. There were no subjects with Grade 4 elevated fasting cholesterol in the TAF group, and none with Grade 3 or 4 elevated fasting cholesterol in the TDF group. Thirty-seven subjects (4.4%) in the TAF group and 1 subject (0.2%) in the TDF group had Grade 3 elevated fasting LDL.

Overall, changes in median values of total cholesterol, LDL, HDL, and triglycerides in the TAF group were not clinically relevant, and none of the subjects with Grade 3 elevations in fasting lipids had clinical AEs associated with lipid abnormalities.

1.3. Information about Tenofovir Disoproxil Fumarate (TDF)

For further information on TDF (Viread®), refer to the current investigator’s brochure for TDF (Viread®).

1.4. Rationale for This Study

Given improved treatment options for CHB, more patients are living longer lives while on prolonged treatment. However, as these patients age, comorbidities increase and they are at greater risk for bone and renal disease. Because TAF is more stable in plasma than TDF, and also provides higher intracellular levels of the active phosphorylated metabolite TFV-DP to target cells (eg, HBV-infected hepatocytes) with approximately 90% lower circulating levels of TFV relative to TDF at therapeutically active doses {Agarwal et al 2015, Babusis et al 2013, Murakami et al 2015}, an improved safety profile has been demonstrated with TAF when compared with TDF through 48 Weeks {Buti et al 2016, Chan et al 2016}. In HIV infection, switching virologically suppressed (HIV RNA < 50 copies/mL) patients from TDF-based antiretroviral regimens to a once-a-day, single tablet TAF-based regimen E/C/F/TAF resulted in noninferior efficacy (i.e. maintenance of viral suppression) and improved bone mineral density and renal function at Week 48 compared with those who continued taking their TDF-based regimen {Mills et al 2016}.

Thus, patients with CHB, particularly those with advanced age, who are currently virally suppressed on TDF, may benefit from switching therapy to TAF by maintaining viral suppression while resulting in improved safety of bone and renal parameters compared to TDF treatment.

1.5. Risk/Benefit Assessment for the Study

This concept is supported by recent results of a large dataset of 1733 HIV-infected, treatment naive subjects randomized to receive treatment with the FDC of E/C/F/TAF or E/C/F/TDF [STB; Stribild®]). Renal and bone parameters were significantly less affected in subjects who received E/C/F/TAF compared with E/C/F/TDF {Sax et al 2015}. Moreover, in a large, prospective, randomized (2:1) open-label switch study in 1443 virally suppressed, HIV-infected subjects
(959 subjects randomized to E/C/F/TAF and 477 to continue TDF-based antiretroviral regimens),
results at Week 48 showed that viral suppression was maintained while bone and renal
parameters were significantly improved in the E/C/F/TAF group {Mills et al 2016}. In adult
subjects with CHB, a global Phase 3 program for TAF consisting of 2 prospective, randomized,
active-controlled studies with 1 each in HBeAg-negative (Study GS-US-320-0108) and
HBeAg-positive (Study GS-US-320-0110) subjects is currently ongoing. Primary endpoint data
shows that TAF is as effective as TDF for viral suppression at Week 48. In addition, renal and
bone safety parameters were improved with TAF treatment relative to TDF. In a pooled analysis
of both studies, patients receiving TAF experienced significantly smaller mean percentage
decreases from baseline in hip and spine bone mineral density at week 48 (p < 0.001), and the
median change in estimated glomerular filtration rate (eGFRCG) from baseline to week 48 was
less with TAF compared with TDF (-1.2 mL/min vs. -5.4 mL/min; p < 0.001). In addition,
significantly smaller changes in biomarkers of bone turnover (bone formation markers:
osteocalcin, bone-specific alkaline phosphatase, and procollagen type 1 N-terminal propeptide,
and the bone resorption marker, C-type collagen sequence) and quantitative markers of proximal
tubular function (beta-2 microglobulin to creatinine and retinol binding protein to creatinine
ratios) were seen in TAF subjects compared with TDF subjects at Week 48.

TDF has been used in clinical practice for the treatment of CHB for many years and its use and
safety profile is very well understood by clinicians. Moreover, in ongoing HBV studies
GS-US-320-0108 and GS-US-320-0110, subjects on TAF have similar rates of HBV DNA
suppression as the TDF group, with TAF meeting the primary endpoint of noninferiority to the
TDF group at Week 48. Thus, patients with CHB who are currently virally suppressed on TDF,
should experience no greater risk as pertains to viral suppression by switching therapy to TAF
from TDF. Moreover, throughout the study, subjects will be closely monitored at intervals that
are above those recommended by treatment guidelines for the use of TDF, therefore subjects
who remain on TDF therapy will benefit from additional monitoring.

For subjects receiving TAF, adult data from the Phase 3 studies indicates that TAF is safe and
effective.

The benefit/risk for this study is therefore considered positive.

1.6. Compliance

This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP),
and all applicable regulatory requirements.
2. OBJECTIVES

The primary objectives of this study are as follows:

- To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus continued tenofovir disoproxil fumarate (TDF) 300 mg QD in virologically suppressed subjects with chronic HBV as determined by the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at Week 24.

- To compare the safety and tolerability of switching to TAF 25 mg QD versus continued TDF 300 mg QD in virologically suppressed subjects with chronic HBV at Week 24.

The key secondary objectives of this study are as follows:

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the percent change from baseline in hip and spine BMD at Week 24.

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the change from baseline in estimated creatinine clearance by Cockcroft-Gault method (eGFR\textsubscript{CG}) at Week 24.

Other secondary objectives of this study are as follows:

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the percent change from baseline in hip and spine BMD at Weeks 48 and 96.

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the change from baseline in estimated creatinine clearance by Cockcroft-Gault method (eGFR\textsubscript{CG}) at Weeks 48 and 96.

- To compare the safety and tolerability of switching to TAF 25 mg QD versus continued TDF 300 mg QD for virologically suppressed subjects with chronic hepatitis B at Week 48.

- To evaluate the efficacy of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at Weeks 48 and 96.

- To compare the serological response (loss of HBsAg and seroconversion to anti-HBs, and loss of HBeAg and seroconversion to anti-HBe in HBeAg-positive subjects) of switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96.

- To compare biochemical response (normal ALT and normalized ALT) of switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96.
• To compare the change in fibrosis as assessed by FibroTest® after switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 48 and 96

• To evaluate the comparative open-label efficacy and safety of switching to TAF 25 mg QD from Week 48 through Week 96 in subjects initially randomized to TAF 25 mg QD and in subjects sequentially treated with continued TDF 300 mg QD for 48 weeks and then switched to open-label TAF 25 mg QD

• To evaluate the proportion of subjects with HBV DNA < 20 IU/mL and target detected/not detected (i.e. < LLOD) at Weeks 24, 48, and 96

The exploratory objectives of this study are as follows:
3. **STUDY DESIGN**

3.1. **Study Treatment Plan and Regimen**

This is a randomized, double-blind, multicenter, active-controlled study to evaluate the safety and efficacy of TAF 25 mg QD in virologically suppressed subjects who switch from TDF to TAF compared to continued TDF treatment.

Approximately 300 subjects (with approximately 50% of subjects being ≥ 50 years old) will be randomized in a 1:1 ratio (A:B) to receive either TAF 25 mg QD and matched placebo of TDF 300 mg QD or Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD.

At randomization, subjects will be stratified by screening HBeAg status (HBeAg-negative vs. HBeAg-positive) and age (≥ 50 or < 50 years).

- **Treatment Arm A:** approximately 150 subjects administered TAF 25 mg QD and matched placebo of Tenofovir DF (TDF) 300 mg QD
- **Treatment Arm B:** approximately 150 subjects administered Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD

The duration of double blind treatment is 48 weeks. All subjects who complete 48 weeks of treatment are eligible for participation in the open label TAF 25 mg extension period for an additional 48 weeks (through Week 96). During the double-blind period, subjects with a confirmed creatinine clearance by Cockcroft Gault Method (eGFR\textsubscript{CG}) < 50 ml/min, and > 20% decline in eGFR by CKD-EPI (cystatin C) compared to baseline during the study, will be required to undergo dose modification to every other day dosing of study drug. Subjects with confirmed creatinine clearance < 30 mL/min during the double blind phase of the study will have the study drug permanently discontinued. Subjects with confirmed eGFR\textsubscript{CG} < 50 mL/min will not undergo dose modification to every other day during the open-label TAF 25 mg extension period, nor will treatment be permanently discontinued for confirmed eGFR\textsubscript{CG} < 30 mL/min during the open-label extension period.

Subjects who permanently discontinue study drug (either prematurely or at the end of study [Week 96]) for reasons other than HBsAg loss with confirmed seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or until initiation of appropriate alternative, HBV therapy, whichever occurs first. Use of appropriate, alternative HBV therapy is strongly encouraged.

Subjects with HBsAg loss, and confirmed seroconversion to anti-HBs should discontinue study drug within 3-6 months following confirmation of seroconversion to anti-HBs. Subjects with HBsAg loss with confirmed seroconversion prior to Week 24 are not permitted to discontinue study drug prior to the Week 24 visit. Subjects with HBsAg loss with confirmed seroconversion will be followed off treatment every 4 weeks for 12 weeks and then per the study visit schedule (**Appendix 2**) through Week 96/ED. Discontinuation of study drug for subjects experiencing HBsAg loss with confirmed seroconversion, who have known bridging fibrosis or cirrhosis, should be considered on a case by case basis.
The primary analysis will occur at Week 24 with the primary efficacy endpoint being the proportion of subjects with HBV DNA ≥ 20 IU/mL, as determined by the modified US FDA-defined snapshot algorithm.

An external, independent, multidisciplinary DMC will review the progress and safety of this study. The committee will convene after the last subject enrolled completes Week 24 of the study. However, Gilead will defer to the DMC for any decision to convene earlier or more frequently. At each meeting, the DMC will review routine safety and DXA data and will make recommendations regarding modification of the study treatment.

Subjects with a history of or current diagnosis of compensated cirrhosis (i.e. those with cirrhosis without laboratory or clinical evidence of decompensated liver disease) are eligible for enrollment. Acceptable diagnostic criteria for cirrhosis include a Metavir or Knodell fibrosis score ≥ 4 or Ishak fibrosis score ≥ 5 by liver biopsy, a Fibrotest score ≥ 0.75, or previous Fibroscan result > 12kPa (in countries where locally approved). Available information regarding the presence or absence of cirrhosis by these criteria will be captured in the electronic case report forms at Baseline, and any other time during the trial should an investigator opt to undertake additional studies. The change in fibrosis as assessed by Fibrotest® will be performed in all subjects participating in the trial at Baseline, and Weeks 24, 48, and 96/ED.

3.2. Biomarker Testing

3.2.1. Biomarker Samples to Address the Study Objectives

The following biological specimens will be collected in this study and will be used to evaluate the association of exploratory biomarkers with study drug response, including efficacy and/or adverse events and to increase knowledge and understanding of the biology of chronic hepatitis B and related diseases. The specific analyses will include, but will not be limited to, the biomarkers listed below. Because biomarker science is a rapidly evolving area of investigation, and adverse events in particular are difficult to predict, it is not possible to specify prospectively all tests that will be done on the specimens provided. The testing outlined below is based upon the current state of scientific knowledge. It may be modified during or after the end of the study to remove tests no longer indicated and/or to add new tests based upon the growing state of art knowledge.

- Fasting Urine Biomarkers including, but not limited to, retinol binding protein (RBP) and beta-2 microglobulin

- Fasting Serum Bone Biomarkers including, but not limited to, C-type collagen sequence (CTX) and procollagen type 1 N-terminal propeptide (P1NP)

These specimens will be collected from all subjects in a fasted state at Baseline and Weeks 4, 12, 24, 48, 72, and 96/ED. Samples may be stored by Gilead Sciences for a period of 15 years at the end of the study.
3.2.2. Biomarker Samples for Optional Future Research

3.3. End of Study

End of Study is defined as when the last subject has completed 96 weeks of treatment, or when the last subject has completed 96 weeks of treatment and up to 24 weeks of treatment free follow-up if appropriate, alternative anti-HBV treatment is not initiated after completing 96 weeks of study treatment.

3.4. Post Study Care

Once a subject has completed their study participation, the long-term care of the participant will return to the responsibility of their primary treating physicians.
4. SUBJECT POPULATION

4.1. Number of Subjects and Subject Selection

Approximately 300 subjects (with approximately 50% of subjects being ≥ 50 years old) will be randomized in a 1:1 ratio (A:B) to receive either TAF 25 mg QD and matched placebo of TDF 300 mg QD or Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD.

4.2. Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be eligible to participate in the study:

1) Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures

2) Adult male and non-pregnant, non-lactating female subjects, ≥18 years of age based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (as defined in Appendix 5).

3) Documented evidence of chronic HBV infection previously (e.g., documented HBsAg positive for more than 6 months)

4) Maintained on TDF 300 mg QD for at least 48 weeks, and as monotherapy for CHB for at least 24 weeks prior to screening and with viral suppression (HBV DNA < LLOQ) for a minimum of 12 weeks prior to Screening, and including a Screening HBV DNA value of < 20 IU/mL (by central laboratory)

5) Estimated creatinine clearance ≥ 50 ml/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at the Screening evaluation, as follows:

\[
\text{Estimated Creatinine Clearance (ml/min)} = \frac{(140 - \text{age in years}) \times \text{body weight [kg]}}{(72) \times \text{serum creatinine [mg/dL]}}
\]

(Note: multiply estimated rate by 0.85 for women)

6) Normal ECG (or if abnormal, determined by the Investigator not to be clinically significant)

7) Must be willing and able to comply with all study requirements
4.3. **Exclusion Criteria**

Subjects who meet **any** of the following exclusion criteria are not to be enrolled in this study:

1) Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study

2) Males and females of reproductive potential who are unwilling to use an “effective”, protocol-specified method(s) of contraception during the study. For a list of protocol-specified Contraceptive methods, refer to Appendix 5.

3) Co-infection with HCV, HIV, or HDV

4) Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging)

5) Current evidence of, or recent (≤ 5 years) history of clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage)

6) Abnormal hematological and biochemical parameters, including:
   
   a) Hemoglobin < 10 g/dL
   
   b) Absolute neutrophil count < 750/mm³
   
   c) Platelets ≤ 50,000/mm³
   
   d) AST or ALT > 5 × ULN
   
   e) Albumin < 3.0 mg/dL
   
   f) INR > 1.5 × ULN (unless stable on anticoagulant regimen)
   
   g) Total bilirubin > 2.5 × ULN

7) Received solid organ or bone marrow transplant

8) Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the investigator

9) Malignancy within 5 years prior to Screening, with the exception of specific cancers that are cured by surgical resection (e.g. basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are not eligible.

10) Currently receiving therapy with immunomodulators (e.g. corticosteroids), nephrotoxic agents, or agents capable of modifying renal excretion

11) Known hypersensitivity to study drugs, metabolites, or formulation excipients
12) Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance

13) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.

14) Use of investigational agents within 3 months of screening, unless allowed by the Sponsor

15) Use of any prohibited medications as described in Section 5.4. Subjects on prohibited medications who are otherwise eligible will need a wash out period of at least 30 days prior to the Baseline visit.
5. INVESTIGATIONAL MEDICINAL PRODUCTS

5.1. Randomization, Blinding and Treatment Codes

A centralized randomization procedure via an Interactive Voice/Web Response System (IVRS/IWRS) will be used for this study, whereby study treatment will be assigned to subjects according to the randomization schedule. A unique subject number will be provided during randomization. Eligible subjects (n = 300) will be randomized 1:1 to receive either blinded TAF 25 mg and TDF matched placebo (n = 150) or TDF 300 mg and TAF matched placebo (n = 150) for 48 weeks. Subjects will be stratified by HBeAg status (HBeAg-negative [and anti-HBe positive] vs. HBeAg-positive) and age (> 50 years vs. < 50 years). At Week 48, all subjects will be switched to open-label TAF 25 mg QD for an additional 48 weeks (through Week 96/ED). For the entire duration of the study, subjects and investigators will remain blinded to the initial treatment regimen to which the subjects were randomized.

5.1.1. Procedures for Breaking Treatment Codes

In the event of a medical emergency where breaking the blind is required to provide medical care to the subject, the investigator may obtain treatment assignment directly from the IXRS system for that subject. Gilead recommends but does not require that the investigator contact the Gilead medical monitor before breaking the blind. Treatment assignment should remain blinded unless that knowledge is necessary to determine subject emergency medical care. The rationale for unblinding must be clearly explained in source documentation and on the case report form/ electronic case report form (CRF/eCRF), along with the date on which the treatment assignment was obtained. The investigator is requested to contact the Gilead medical monitor promptly in case of any treatment unblinding.

Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a subject’s treatment assignment is disclosed to the investigator, the subject will have study treatment discontinued. All subjects will be followed until study completion unless consent to do so is specifically withdrawn by the subject.

Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited reporting of suspected unexpected serious adverse reactions (SUSARs).
5.2. Description and Handling of Tenofovir Alafenamide (TAF) and TDF

5.2.1. Formulation

5.2.1.1. Tenofovir Alafenamide (TAF) Tablets

TAF 25 mg tablets contain 28 mg of tenofovir alafenamide fumarate, which is equivalent to 25 mg of tenofovir alafenamide (TAF). The tablets are yellow, round-shaped, and film-coated. The tablets are debossed with “GSI” on one side and “25” on the other side. In addition to the active ingredient, each film-coated tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.

5.2.1.2. Placebo to Match TAF Tablets

Placebo tablets to match TAF 25 mg are yellow, round-shaped, and film-coated. The tablets are debossed with “GSI” on one side and “25” on the other side. Each tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.

5.2.1.3. Tenofovir Disoproxil Fumarate (Viread®, Tenofovir DF, TDF)

TDF 300 mg tablets contain 300 mg of tenofovir disoproxil fumarate (TDF), which is equivalent to 245 mg of tenofovir disoproxil. The tablets are light blue, almond-shaped, plain-faced, and film-coated. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose (hydroxypropyl methylcellulose), glycerol triacetate, titanium dioxide, and indigo carmine aluminum lake.

5.2.1.4. Placebo to Match TDF Tablets

Placebo tablets to match TDF 300 mg are light blue, almond-shaped, plain-faced, film-coated tablets. Each tablet contains the following inactive ingredients: denatonium benzoate, lactose monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The film coating contains the following inactive ingredients: lactose monohydrate, hypromellose (hydroxypropyl methylcellulose), triacetin, titanium dioxide, and indigo carmine aluminum lake.

5.2.2. Packaging and Labeling

TAF, TDF, and their matched placebo tablets are packaged in white, high density polyethylene (HDPE) bottles. Each bottle contains 30 tablets and a silica gel desiccant and polyester packing material. Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an induction-sealed and aluminum-faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be labeled to meet applicable requirements of the United States Food and Drug Administration (FDA), EU Guideline to Good Manufacturing Practice − Annex 13 (Investigational Medicinal Products), and/or other local regulations.

5.2.3. Storage and Handling

TAF, TDF, and their matched placebo tablets should be stored at controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. Until dispensed to the subjects, all bottles of study drugs should be stored in a securely locked area, accessible only to authorized site personnel.

To ensure the stability and proper identification, study drug(s) should not be stored in a container other than the container in which they were supplied.

Consideration should be given to handling, preparation, and disposal through measures that minimize drug contact with the body. Appropriate precautions should be followed to avoid direct eye contact or exposure when handling.

5.3. Dosage and Administration of Tenofovir Alafenamide (TAF) and TDF

Subjects will be randomly assigned (1:1) to receive one of the following treatments in a blinded fashion:

- **Treatment Arm A:** approximately 150 subjects administered TAF 25 mg QD and matched placebo of Tenofovir DF (TDF) 300 mg QD

- **Treatment Arm B:** approximately 150 subjects administered Gilead-provided TDF 300 mg QD and matched placebo of TAF 25 mg QD

It is preferred that subjects take their study drug according to a morning dosing schedule; however, evening dosing is allowable.

All study drugs should be taken at approximately the same time each day with or without food. Subjects taking TDF 300 mg QD with food prior to randomization should continue to take study drug with food; subjects taking TDF 300 mg QD without food prior to randomization should continue to take study drug without food during the study period.

Study drug should be administered after assessing adverse events and concomitant medication(s).
5.4. Prior and Concomitant Medications

Concomitant/previous medications taken within 30 days of screening, up to and including the date of the last study visit, need to be recorded in the source documents and eCRFs.

The following medications are excluded while subjects are participating in the study. These medications are prohibited during the screening period and for a minimum of 30 days prior to the Baseline/Day 1 visit through the end of treatment:

- Investigational agents or devices for any indication
- Nephrotoxic agents (e.g., aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, cyclosporine, tacrolimus)
- Probenecid
- Agents that reduce renal function or compete for active tubular secretion with tenofovir (e.g., cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir)
- Systemic chemotherapeutic agents, systemic corticosteroids (except short-term use of prednisone as a steroid burst [≤ 1 week of use], immunosuppressant, or immunomodulating agents)

Concomitant use of certain medications or herbal/natural supplements (inducers of drug transporters i.e., P-gp) with study drug(s) may result in PK interactions.

Examples of representative medications which are prohibited from 21 days prior to Day 1 through the end of treatment are listed below:

<table>
<thead>
<tr>
<th>Table 5-1. Disallowed Concomitant Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication Class</td>
</tr>
<tr>
<td>Anticonvulsants</td>
</tr>
<tr>
<td>Antimycobacterials</td>
</tr>
<tr>
<td>Herbal/Natural Supplements</td>
</tr>
</tbody>
</table>

Should subjects have a need to initiate treatment with any excluded concomitant medication, including herbal/natural products/therapies, and over the counter medications, the Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In instances where an excluded medication is initiated prior to discussion with the Sponsor, the investigator must notify Gilead Sciences as soon as he/she is aware of the use of the excluded medication.
5.5. Accountability for Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF) and Matched Placebos

The investigator or designee (i.e., pharmacist) is responsible for ensuring adequate accountability of all used and unused investigational medicinal product (IMP) bottles. This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All used and unused IMP bottles dispensed to subjects must be returned to the site.

Investigational product accountability records will be provided to each study site to:

- Record the date received and quantity of IMP bottles
- Record the date, subject number, subject initials, the IMP bottle number dispensed
- Record the date, quantity of used and unused IMP bottles returned, along with the initials of the person recording the information

5.5.1. Investigational Medicinal Product Return or Disposal

At the start of the study, the study monitor will evaluate each study center’s study drug disposal procedures and provide appropriate instruction for return or destruction of unused study drug supplies. If the site has an appropriate Standard Operating Procedure (SOP) for drug destruction, the site may destroy used and unused study drug supplies performed in accordance with the site’s (hospital/pharmacy) SOP. If the site does not have acceptable procedures in place for drug destruction, arrangements will be made between the site and Gilead Sciences (or Gilead Sciences’ representative) for return of unused study drug supplies. A copy of the site’s SOP will be obtained for central files. Where possible, study drug will be destroyed at the site. Upon study completion, a copy of the Investigational Drug Accountability records must be filed at the site. Another copy will be returned to Gilead Sciences. If drug is destroyed on site, the investigator must maintain accurate records for all study drug bottles destroyed. Records must show the identification and quantity of each unit destroyed, the method of destruction, and person who disposed of the drug. All study drug records must be maintained at the site and copies must be submitted to Gilead Sciences at the end of the study.
6. **STUDY PROCEDURES**

The study procedures to be conducted for each subject enrolled in the study are presented in tabular form in Appendix 2 and described in the text that follows.

The investigator must document any deviation from protocol procedures and notify the sponsor or contract research organization (CRO).

6.1. **Subject Enrollment and Treatment Assignment**

It is the responsibility of the investigator to ensure that subjects are eligible to participate in the study prior to enrollment. Once consent has been obtained, all screening tests and procedures have been completed, and study eligibility has been confirmed, subjects will be randomized within 45 days using an IVRS/IWRS. Subjects will receive study drugs within their assigned treatment group as described in Section 3.1.

Candidates who fail to meet eligibility criteria by screening evaluations may be re-screened once after the initial screen if there is a reasonable expectation that the candidate will be eligible after repeat screening.

Retesting of an exclusionary laboratory value during the Screening period is permitted only if in the Principal Investigator’s opinion, the retest value will be within accepted parameters; if the initial value was deemed to be inaccurate, inconsistent with the subject’s previous result(s); in error (e.g. mishandled sample); or due to an extenuating circumstance.

6.2. **Pretreatment Assessments**

6.2.1. **Screening Visit**

Subjects will be screened within 45 days before randomization to determine eligibility for participation in the study. The following will be performed and documented at screening:

- Obtain written informed consent
- Review of inclusion/exclusion criteria
- Obtain medical history (including HBV disease and treatment history)
- Review concomitant medications
- Record any serious adverse events and all adverse events related to protocol mandated procedures occurring after signing of the consent form
- Complete physical examination with vital signs (blood pressure, pulse, respiration rate and temperature), body weight, and height
- ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to the recording)

- DXA scan of hip and spine. The Baseline DXA scan can be performed at any time during the Screening period to ensure the results are received prior to the first dose of the study drug and therefore should be completed at least 14 days prior to the Baseline visit

- Blood sample for:
  - plasma HBV DNA (must be < 20 IU/mL at time of Screening to be eligible)
  - Serum chemistry and liver function tests, hematology, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), ruling out HIV-1, HDV, HCV, serum pregnancy test (for females of child-bearing potential), α-fetoprotein (AFP) and INR. An AFP > 50 ng/mL at Screening must have an appropriate evaluation (i.e., CT scan) in order to rule out HCC prior to being permitted to enter the study.

- Estimated creatinine clearance (using the Cockcroft-Gault method)

- Urine sample for urinalysis and drug screen

Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the clinic within 45 days after screening for randomization into the study.

From the time of obtaining informed consent through the first administration of investigational medicinal product, record all serious adverse events (SAEs), as well as any adverse events related to protocol-mandated procedures on the adverse events case report form (CRF/eCRF). All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical history are to be captured on the medical history CRF/eCRF. See Section 7 Adverse Events and Toxicity Management for additional details.

### 6.2.2. Baseline Assessments

All baseline tests and procedures must be completed prior to the receipt of the first dose of study drug. Subjects screened within 45 days before Baseline will be eligible to participate in the study. Initiation of treatment with study drug should take place on the day of the Baseline visit. The following will be performed at the Baseline visit:

- Review of inclusion/exclusion criteria and confirm medical history (including HBV disease and treatment history)

- Complete physical examination with vital signs (blood pressure, pulse, respiration rate and temperature) and body weight

- Review concomitant medications

- Review adverse events
• Randomization

• Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at least 8 hours prior to blood collection

• Fasting urine sample for renal biomarkers

• Dispense blinded study drugs

• Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), PPD and vitamin D assessment

• Serum Cystatin C testing for estimated glomerular filtration rate (eGFR) by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)

• Estimated creatinine clearance (using the Cockcroft-Gault method)

• Blood sample for Fibrotest®

• Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), PPD

• Health Related Quality of Life (HRQoL) Surveys (CLDQ, SF-36, WPAI)

• Complete the “Fracture Risk Assessment” (FRAX®) eCRF

6.3. Treatment Assessments

6.3.1. Double Blind Visits (Visit Window ± 3 days)

6.3.1.1. Week 4

• Symptom directed physical exam

• Body weight

• Vital signs: blood pressure, pulse, respiration rate, and temperature

• Review concomitant medications
• Review adverse events

• Perform study drug accountability

• Fasting blood sample for bone biomarkers

• Fasting urine sample for renal biomarkers

• Dispense blinded study drugs

• Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, virology (resistance surveillance), **PPD**

• Estimated creatinine clearance (using the Cockcroft-Gault method)

• Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), **PPD**

6.3.1.2. Week 8

• Symptom directed physical exam

• Body weight

• Vital signs: blood pressure, pulse, respiration rate, temperature

• Review concomitant medications

• Review adverse events

• Perform study drug accountability

• Dispense blinded study drugs

• Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, virology (resistance surveillance), **PPD**

• Estimated creatinine clearance (using the Cockcroft-Gault method)

• Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), **PPD**
6.3.1.3.  Week 12

- Symptom directed physical exam
- Body weight
- Vital signs: blood pressure, pulse, respiration rate, and temperature
- Review concomitant medications
- Review adverse events
- Perform study drug accountability
- Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) – no food or drinks, except water, at least 8 hours prior to blood collection
- Fasting urine sample for renal biomarkers
- Dispense blinded study drugs
- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), PPD
- Estimated creatinine clearance (using the Cockcroft-Gault method)
- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), PPD

6.3.1.4.  Week 24 (visit window is – 14 days)

- Complete physical examination with vital signs (blood pressure, pulse, respiration rate and temperature) and body weight
- DXA scan of hip and spine (within 14 days of the expected visit date)
- Review concomitant medications
- Review adverse events
- Perform study drug accountability
- Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) – no food or drinks, except water, at least 8 hours prior to blood collection
- Fasting urine sample for renal biomarkers
- Dispense blinded study drugs
- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), **PPD**
- Estimated creatinine clearance (using the Cockcroft-Gault method)
- Blood sample for Fibrotest®
- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), **PPD**
- Health Related Quality of Life (HRQoL) Surveys (SF-36, WPAI and CLDQ)

6.3.1.5. Week 36

- Symptom directed physical exam
- Body weight
- Vital signs: blood pressure, pulse, respiration rate, and temperature
- Review concomitant medications
- Review adverse events
- Perform study drug accountability
- Dispense blinded study drugs
- Fasting blood sample for metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at least 8 hours prior to blood collection
- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), **PPD**
- Estimated creatinine clearance (using the Cockcroft-Gault method)
- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), **PPD**
6.3.1.6. Week 48 (visit window is −6 weeks)

- Complete physical examination with vital signs (blood pressure, pulse, respiration rate and temperature) and body weight

- ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to the recording)

- DXA scan of hip and spine (within −6 weeks of the expected visit date)

- Review concomitant medications

- Review adverse events

- Perform study drug accountability

- Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) – no food or drinks, except water, at least 8 hours prior to blood collection

- Fasting urine sample for renal biomarkers

- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), \textit{PPD}

- Estimated creatinine clearance (using the Cockcroft-Gault method)

- Blood sample for Fibrotest®

- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), \textit{PPD}

- Health Related Quality of Life (HRQoL) Surveys (CLDQ, SF-36, WPAI)

-Retrieve blinded study drug and dispense open label study drug
6.3.2. Open Label Visits (Visit Window ± 7 days)

6.3.2.1. Week 60

- Symptom directed physical exam
- Body weight
- Vital signs: blood pressure, pulse, respiration rate, and temperature
- Review concomitant medications
- Review adverse events
- Perform study drug accountability
- Dispense open label study drugs
- Fasting blood sample for metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) – no food or drinks, except water, at least 8 hours prior to blood collection
- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg) virology (resistance surveillance), PPD
- Estimated creatinine clearance (using the Cockcroft-Gault method)
- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), PPD

6.3.2.2. Week 72

- Complete physical examination with vital signs (blood pressure, pulse, respiration rate and temperature) and body weight
- DXA scan of hip and spine (within ± 14 days of the expected visit date)
- Review concomitant medications
- Review adverse events
- Perform study drug accountability
- Dispense open label study drugs
- Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) – no food or drinks, except water, at least 8 hours prior to blood collection

- Fasting urine sample for renal biomarkers

- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBeAg and HBsAg), virology (resistance surveillance), FibroTest®

- Estimated creatinine clearance (using the Cockcroft-Gault method)

- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), PPD

6.3.2.3. Week 96

- Complete physical examination with vital signs (blood pressure, pulse, respiration rate and temperature) and body weight

- ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to the recording)

- DXA scan of hip and spine (within ± 14 days of the expected visit date)

- Review concomitant medications

- Review adverse events

- Perform study drug accountability (no study drug will be dispensed at Week 96 visit)

- Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at least 8 hours prior to blood collection

- Fasting urine sample for renal biomarkers

- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), FibroTest®

- Estimated creatinine clearance (using the Cockcroft-Gault method)

- Blood sample for Fibrotest®
• Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), PPD

• Health Related Quality of Life (HRQoL) Surveys (CLDQ, SF-36 and WPAI)

6.4. Post-Treatment Assessments

6.4.1. HBsAg Loss and Seroconversion Subjects

Subjects who discontinue study drug due to HBsAg loss with confirmed seroconversion to anti-HBs on or after the Week 24 visit, will be followed off treatment every 4 weeks for 12 weeks and then per the original study visit schedule through Week 96/ED (excluding drug dispensation and accountability).

6.4.2. All Other Subjects Who Discontinue Study Drug

Subjects who have received at least one dose of study drug and permanently discontinue study drug for reasons other than HBsAg loss with confirmed seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or up to initiation of appropriate, alternative HBV therapy, whichever occurs first.

6.4.3. Treatment-Free Follow Up Visit Assessments (All Subjects)

• Symptom directed physical exam

• Body weight

• Vital signs: blood pressure, pulse, respiration rate, and temperature

• Review concomitant medications

• Review adverse events

• Estimated creatinine clearance (using the Cockcroft-Gault method)

• Urine for urinalysis

6.5. Assessments for Premature Discontinuation from Study

If a subject discontinues study dosing (for example, as a result of an AE), every attempt should be made to keep the subject in the study and continue to perform the required study-related follow-up and procedures (see Section 6.6, Criteria for Discontinuation of Study Treatment). If this is not possible or acceptable to the subject or investigator, the subject may be withdrawn from the study.
The ED Visit should be performed within 72 hours (i.e., visit window is ± 3 days) of the last study drug dose.

- Complete physical exam with vital signs (blood pressure, pulse, respiration rate and temperature) and body weight
- ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to the recording)
- DXA scan of spine and hip to be performed within ±14 days of the expected visit date and is done only if not done within the past 12 weeks of the ED visit
- Review concomitant medications
- Review adverse events
- Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel [total cholesterol, HDL, direct LDL, and triglycerides]) – no food or drinks, except water, at least 8 hours prior to blood collection (only collected if not done in the last 12 weeks)
- Fasting urine sample for renal biomarkers (only collected if not done in the last 12 weeks)
- Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, serum HBsAg (quantitative), HBV serology (qualitative HBsAg and HBeAg), virology (resistance surveillance), Fibrotest®
- Estimated creatinine clearance (using the Cockcroft-Gault method)
- Blood sample for Fibrotest®
- Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of a positive urine test, a serum pregnancy test will be done), PPD
- Health Related Quality of Life (HRQoL) Surveys (SF-36, WPAI and CLDQ) are done only if not done within the past 24 weeks of the ED visit

6.6. Criteria for Discontinuation of Study Treatment

Study medication may be discontinued in the following instances:

- Intercurrent illness that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree. Following resolution of intercurrent illness, the subject may resume study dosing at the discretion of the investigator.
- Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the ability to continue study-specific procedures or is considered to not be in the subject’s best interest
Subjects with confirmed creatinine clearance of < 30 mL/min during the double blind phase of the study will have their study drug permanently discontinued.

HBsAg loss with seroconversion to anti-HBs. These subjects should discontinue study drug within 3-6 months following confirmation of seroconversion to anti-HBs. Subjects with HBsAg loss with confirmed seroconversion before Week 24 are not permitted to discontinue study drug prior to the Week 24 visit.

Discontinuation of study drug for subjects experiencing HBsAg-loss with confirmed seroconversion to anti-HBs, who have known bridging fibrosis or cirrhosis, should be considered on a case by case basis.

Therapeutic failure

Subject request to discontinue for any reason

Subject noncompliance

Pregnancy during the study; refer to Appendix 5

Discontinuation of the study at the request of Gilead, a regulatory agency or an institutional review board or independent ethics committee (IRB/IEC)

6.7. Other Evaluations

6.7.1. Bone and Renal Markers

The following biological specimens will be collected in this study and will be used to evaluate the association of exploratory biomarkers with study drug response, including efficacy and/or adverse events and to increase knowledge and understanding of the biology of chronic hepatitis B and related diseases. The specific analyses will include, but will not be limited to, the biomarkers listed below.

- Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) urine Biomarkers including, but not limited to, retinol binding protein (RBP) and beta-2 microglobulin

- Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) serum Bone Biomarkers including, but not limited to, C-type collagen sequence (CTX) and procollagen type 1 N-terminal propeptide (P1NP)

These specimens will be collected from all subjects at Baseline and Weeks 4, 12, 24, 48, 72, and 96 or ED.
6.8. Resistance Surveillance and Virologic Rebound Management

Sequence analysis of the HBV polymerase/reverse transcriptase (pol/RT) for potential resistance mutations may be attempted for any subject with HBV DNA ≥ 69 IU/mL at Baseline and for subjects who experience viremia (HBV DNA ≥ 69 IU/mL) at Weeks 24, 48, and 96/ED.

As it may not be known at the time of the visit whether a patient is viremic or if it will be their last study visit, a separate serum sample for potential resistance surveillance will be collected at each study visit.

In the event of unconfirmed virologic rebound (HBV DNA ≥ 20 IU/mL), subjects will be asked to return to the clinic for a scheduled or unscheduled blood draw. For virologic rebound occurring within the first 12 weeks of the study, the next scheduled visit will used for follow up. For virologic rebound occurring after Week 12, the subject will return for an unscheduled visit within 2-3 weeks after the date of the original test that resulted with HBV DNA virologic rebound for confirmation of virologic rebound. At this follow up visit, a serum blood sample for resistance testing will be obtained. For unscheduled visits, the subject will be required to bring their supply of study drug with them and be assessed for adherence by pill count, and if necessary, the subject will be re-counseled on adherence to study medication.
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT

7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events

7.1.1. Adverse Events

An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also include pre- or post-treatment complications that occur as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increase in severity or change in nature during or as a consequence of participation in the clinical study will also be considered AEs.

An AE does not include the following:

- Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. The condition that led to the procedure may be an adverse event and must be reported.
- Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the screening visit that do not worsen.
- Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for elective surgery, social and/or convenience admissions).
- Overdose without clinical sequelae (see Section 7.6.1).
- Any medical condition or clinically significant laboratory abnormality with an onset date before the consent form is signed and not related to a protocol-associated procedure is not an AE. It is considered to be pre-existing and should be documented on the medical history CRF.

7.1.2. Serious Adverse Events

A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

- Death
- Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
- In-patient hospitalization or prolongation of existing hospitalization
- Persistent or significant disability/incapacity
• A congenital anomaly/birth defect

• A medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. Medical and scientific judgment must be exercised to determine whether such an event is a reportable under expedited reporting rules. Examples of medically important events include intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; and development of drug dependency or drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal product will be considered a medically important event and subject to expedited reporting requirements.

7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious Adverse Events

Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that require medical or surgical intervention or lead to IMP interruption, modification, or discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory abnormality is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the laboratory result (ie, decreased hemoglobin).

For specific information on handling of clinical laboratory abnormalities in this study, please refer to Section 7.5.

7.2. Assessment of Adverse Events and Serious Adverse Events

The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for causality and severity, and for final review and confirmation of accuracy of event information and assessments.

7.2.1. Assessment of Causality for Study Drugs and Procedures

The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP therapy using clinical judgment and the following considerations:

• No: Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an alternative causality must be provided (eg, pre-existing condition, underlying disease, intercurrent illness, or concomitant medication).

• Yes: There is reasonable possibility that the event may have been caused by the investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causally related in the context of adverse event reporting.

The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) should be assessed using the following considerations:

- **No**: Evidence exists that the adverse event has an etiology other than the study procedure.
- **Yes**: The adverse event occurred as a result of protocol procedures, (eg., venipuncture)

### 7.2.2. Assessment of Severity

Severity of adverse events is to be determined based on GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities (Appendix 4). A distinction should be drawn between seriousness and severity of AEs. An AE that is assessed as Grade 4 (potentially life-threatening) should not be confused with an SAE. Severity is a category utilized for rating the intensity of an event: both AEs and SAEs can be assessed as Grade 4. An event is defined as “serious” when it meets one of the predefined outcomes described above in Section 7.1.2.

### 7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious Adverse Events to Gilead

Requirements for collection prior to study drug initiation:

After informed consent, but prior to initiation of study medication, the following types of events should be reported on the case report form (CRF/eCRF): all SAEs and adverse events related to protocol-mandated procedures.

**Adverse Events**

Following initiation of study medication, collect all AEs, regardless of cause or relationship, until 30-days after last administration of study IMP must be reported to the CRF/eCRF database as instructed.

All AEs should be followed up until resolution or until the adverse event is stable, if possible. Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up period.

**Serious Adverse Events**

All SAEs, regardless of cause or relationship, that occurs after the subject first consents to participate in the study (ie, signing the informed consent) and throughout the duration of the study, including the protocol-required post treatment follow-up period, must be reported to the CRF/eCRF database and Gilead Drug Safety and Public Health (DSPH) as instructed. This also includes any SAEs resulting from protocol-associated procedures performed after informed consent is signed.
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30-days of the last dose of study IMP, regardless of causality, should also be reported.

Investigators are not obligated to actively seek SAEs after the protocol defined follow up period; however, if the investigator learns of any SAEs that occur after study participation has concluded and the event is deemed relevant to the use of IMP, he/she should promptly document and report the event to Gilead DSPH.

- All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined in the CRF/eCRF completion guideline.

**Electronic Serious Adverse Event (eSAE) Reporting Process**

- Site personnel record all SAE data in the eCRF database and from there transmit the SAE information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. Detailed instructions can be found in the eCRF completion guidelines.

- If for any reason it is not possible to record the SAE information electronically, ie, the eCRF database is not functioning, record the SAE on the paper serious adverse event reporting form and submit within 24 hours to:

  **Gilead DSPH:**  
  Fax: PPD  
  Email: PPD

  **Medical Monitor:**  
  Phone: PPD  
  Fax: PPD  
  Email: PPD

- As soon as it is possible to do so, any SAE reported via paper must be transcribed into the eCRF Database according to instructions in the eCRF completion guidelines.

- If an SAE has been reported via a paper form because the eCRF database has been locked, no further action is necessary.

- For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other documents are also to be submitted by e-mail or fax when requested and applicable. Transmission of such documents should occur without personal subject identification, maintaining the traceability of a document to the subject identifiers.

- Additional information may be requested to ensure the timely completion of accurate safety reports.

- Any medications necessary for treatment of the SAE must be recorded onto the concomitant medication section of the subject’s CRF/eCRF and the event description section of the SAE form.
7.4. Gilead Reporting Requirements

Depending on relevant local legislation or regulations, including the applicable US FDA Code of Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and other country-specific legislation or regulations, Gilead may be required to expedite to worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in current regulations.

Assessment of expectedness for SAEs will be determined by Gilead using reference safety information specified in the investigator’s brochure or relevant local label as applicable.

All investigators will receive a safety letter notifying them of relevant SUSAR reports associated with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as is practical, where this is required by local regulatory agencies, and in accordance with the local institutional policy.

7.5. Toxicity Management

- All clinical and clinically significant laboratory toxicities will be managed according to uniform guidelines detailed in Appendix 3.

- Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat testing within 3 calendar days of receipt of results and before investigational medicinal product discontinuation, unless such a delay is not consistent with good medical practice.

- Clinical events and clinically significant laboratory abnormalities will be graded according to the Table for GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities (Appendix 4).

- When restarting investigational medicinal product following resolution of the adverse event, the investigational medicinal product should be restarted at full dose or modified dose that is dependent upon discussion with the Gilead Sciences Medical Monitor.

- Any recurrence of the investigational medicinal product-related Grade 3 or 4 clinical or clinically significant laboratory adverse event following dose interruption mandates permanent discontinuation of investigational medicinal product.

- Administration of study drug may be discontinued due to a clinical or laboratory event. The Gilead Medical Monitor should be consulted prior to dose discontinuation of study drug unless the investigator believes that immediate action is warranted to ensure the continued safety of subject.

- Any questions regarding toxicity management should be directed to the Gilead Sciences Medical Monitor.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event

- Continue investigational medicinal product at the discretion of the investigator.

7.5.2. Grade 3 Laboratory Abnormality or Clinical Event

- For Grade 3 clinically significant laboratory abnormality or clinical event, investigational medicinal product may be continued if the event is considered to be unrelated to investigational medicinal product.

- For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by repeat testing, that is considered to be related to investigational medicinal product, investigational medicinal product should be withheld until the toxicity returns to ≤ Grade 2.

- If a laboratory abnormality recurs to ≥ Grade 3 following rechallenge with investigational medicinal product and is considered related to investigational medicinal product, then investigational medicinal product should be permanently discontinued and the subject managed according to local practice. Recurrence of laboratory abnormalities considered unrelated to investigational medicinal product may not require permanent discontinuation.

7.5.3. Grade 4 Laboratory Abnormality or Clinical Event

- For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality confirmed by repeat testing that is considered related to investigational medicinal product, investigational medicinal product should be permanently discontinued and the subject managed according to local practice. The subject should be followed as clinically indicated until the laboratory abnormality returns to baseline or is otherwise explained, whichever occurs first. A clinically significant Grade 4 laboratory abnormality that is not confirmed by repeat testing should be managed according to the algorithm for the new toxicity grade.

- Investigational medicinal product may be continued without dose interruption for a clinically non-significant Grade 4 laboratory abnormality (e.g., Grade 4 CK after strenuous exercise, or triglyceride elevation that is non-fasting or that can be medically managed) or a clinical event considered unrelated to investigational medicinal product.

7.5.4. Management of Bone Evaluation

As there is uncertainty surrounding the clinical significance and management of decreases in bone mineral density for chronic HBV-infected patients, Gilead recommends that any subject who has a DXA scan that demonstrates a decrease from baseline of > 5% in bone mineral density of the spine region or the hip region be followed per local medical practice at the discretion of the investigator.
7.5.5. **On-Treatment ALT Flare and Post-Treatment Exacerbation of Hepatitis Management**

On-Treatment ALT Flare is defined as:

- Confirmed (within 3 days of receipt of initial laboratory results) serum ALT > 2 × baseline value and > 10 × ULN, with or without associated symptoms

7.5.5.1. **Management of ALT Flare in Subjects Receiving Study Medication**

If laboratory results indicate elevation of ALT > 2 × baseline and > 10 × ULN, the following is recommended:

- Schedule the subject to return to the clinic as soon as possible (ideally within 3 days after initial laboratory results were drawn). During the visit, a clinical assessment of the subject will be performed. The assessment should include a physical examination and evaluation of the subject’s mental status.

- Check the following laboratory parameters: serum ALT and AST, total bilirubin, INR, and serum albumin.

- If the ALT elevation is confirmed, the central clinical laboratory will conduct reflex testing for plasma HBV DNA, serology for HBV (HBsAg and HBsAb), HDV, HAV IgM, HCV, and HEV.

Based on the results of the confirmatory tests, the following treatment modifications are recommended:

**Elevated Liver Enzymes, Normal or Stable relative to baseline Liver Function Tests**

If ALT levels are elevated (i.e., > 2 × baseline and > 10 × ULN) with normal or stable total bilirubin and INR relative to baseline, the subject may remain on study medication and should be monitored weekly as long as ALT levels return to normal or baseline level.

During monitoring, if the ALT values remain persistently elevated, the investigator should discuss with the Gilead Medical Monitor whether the study drug should be discontinued.

For subjects with bridging fibrosis or cirrhosis, study drug discontinuation with treatment-free follow-up is to be avoided due to the potential risk of exacerbation of hepatitis in the setting of low hepatic reserve which could lead to decompensation. Subjects with bridging fibrosis or cirrhosis should be placed on commercially available HBV therapy following study drug discontinuation.

**Elevated Liver Enzymes, Elevated Liver Function Tests**

If ALT values are elevated (i.e., > 2 × baseline and > 10 × ULN), and total bilirubin is confirmed to be 2 × baseline value, and INR is 0.5 above baseline, provided both are > ULN, the investigator should consider discontinuing study medication (upon discussion with the Gilead Medical Monitor, unless the safety of the subject is of immediate concern).
The subject should be monitored weekly as long as ALT, total bilirubin, and INR values remain elevated or above baseline values.

During monitoring, if the ALT values and the liver function tests remain persistently elevated, the investigator should discuss with the Gilead Medical Monitor whether the study drug should be discontinued.

For subjects with bridging fibrosis or cirrhosis, study drug discontinuation with treatment-free follow-up is to be avoided due to the potential risk of exacerbation of hepatitis in the setting of low hepatic reserve which could lead to decompensation. Subjects with bridging fibrosis or cirrhosis should be placed on commercially available HBV therapy following study drug discontinuation.

7.5.5.2. Management of Exacerbation of Hepatitis in Subjects Who Have Discontinued Study Medication

If laboratory results indicate (1) an ALT elevation > 2 × baseline and > 10 × ULN alone OR associated with (2) abnormal laboratory parameters suggestive of worsening hepatic function (total bilirubin 2 × baseline, INR 0.5 above baseline, provided both are > ULN) and the subject is on no post-study therapy for HBV, the following is recommended:

- Schedule the subject to return to the clinic as soon as possible (ideally no later than 3 days after the initial laboratory values were drawn). During the visit, perform a clinical assessment of the subject.

- Check the following laboratory parameters: serum ALT and AST, total bilirubin, INR, and albumin.

- If the ALT elevation is confirmed, the central clinical laboratory will conduct reflex testing for plasma HBV DNA, serology for HBV (HBsAg and HBsAb), HDV, HAV IgM, HCV and HEV. If Plasma HBV DNA is increasing, the investigator should consider immediate initiation of approved therapy.

- The subject should be followed until laboratory parameters (ALT, total bilirubin, INR) return to normal or baseline up to a maximum of 6 months after the initial occurrence of the event.

7.5.6. Management of Ocular Safety

In a nine-month toxicology study conducted in dogs, some animals administered the highest dose of TAF (12-18mg/kg) had minimal mononuclear cell infiltration in the posterior uvea, considered secondary to general debilitation; this finding did not occur in animals given lower doses and it has not occurred in other animal studies. In the TAF HIV program, there is one report of SAEs of Grade 1 visual impairment and Grade 2 autoimmune uveitis in a 13 year-old female subject from Uganda in Study GS-US-292-0106. Onset of both events was Day 14 and both were considered related to study drug (E/C/F/TAF) by the investigator. The SAE of autoimmune uveitis resolved on Day 166, and the visual impairment was ongoing at Day 418 of study drug treatment.
Across the TAF HBV Phase 3 Safety Population, eye disorders were uncommon and balanced between the treatment groups. None were indicative of posterior uveitis, and none resulted in permanent discontinuation of study drug. Nonetheless, if any subject participating in this study develops signs or symptoms of posterior uveitis, investigators should contact the Gilead Medical Monitor to discuss the need for additional ophthalmologic evaluation including dilated fundoscopy and optical coherence tomography (OCT).

7.5.7. Management of Potential Nephrotoxicity

Creatinine clearance (CL_{Cr}), estimated according to the Cockcroft-Gault formula, will be followed post-baseline during the study. All subjects with estimated CL_{Cr} < 50 mL/min must have serum creatinine measured again within 3 calendar days of receipt of results. At the time of this repeat serum creatinine assessment, serum Cystatin C will also be measured and the estimated glomerular filtration rate (eGFR) by CKD-EPI (cystatin C) will be calculated and compared with the baseline measurement of this parameter. During the double-blind period, any subject who has a confirmed CL_{Cr} estimated by the Cockcroft-Gault formula < 50 mL/min and also experiences a > 20% reduction in eGFR by CKD-EPI (cystatin C) from baseline, will be managed as described below:

CKD-EPI (cystatin C) formula adjusted for age and sex:

\[
eGFR \ (\text{mL/min/1.73m}^2) = 133 \times \min(\text{Scys}/0.8, \ 1)^{-0.499} \times \max(\text{Scys}/0.8, \ 1)^{-1.328} \times 0.996^{\text{Age}} \times [0.932 \text{ if female}],
\]

where Scys is serum cystatin C (mg/L), \min(\text{Scys}/0.8, 1) indicates the minimum of Scys/0.8 or 1, and \max(\text{Scys}/0.8, 1) indicates the maximum of Scys/0.8 or 1.

During the double-blind period, subjects meeting the above eGFR criteria (i.e. confirmed CL_{Cr} < 50 mL/min by Cockcroft-Gault equation and > 20% reduction from baseline in eGFR by CKD-EPI equation) will be managed as follows:

- If the CL_{Cr} is confirmed to be ≥ 30 mL/min and < 50 mL/min, the subject will be required to undergo dose modification to every other day dosing of study drug.
- If the CL_{Cr} is confirmed ≥ 30 mL/min to < 50 mL/min and the subject has undergone dose modification to every other day dosing of study drug and subsequently develops a confirmed CL_{Cr} ≥ 50 mL/min, the subject may revert to once daily dosing of study drug after discussion with the Gilead Medical Monitor.
- If the CL_{Cr} is confirmed to be < 30 mL/min, the subject will be required to permanently discontinue study drug.

During the open-label TAF 25 mg extension period, subjects who meet the above eGFR criteria (i.e. confirmed CL_{Cr} ≥ 30 mL/min to < 50 mL/min and > 20% reduction from baseline in eGFR by CKD-EPI equation) are not required to undergo dose modification to every other day dosing of study drug, and subjects with confirmed CL_{Cr} < 30 mL/min are not required to permanently discontinue study drug.
All subjects with negative or trace proteinuria at baseline that develop ≥ 1+ proteinuria on urinalysis are recommended to have a urinalysis repeated, with a concurrent urinalysis and urine chemistry, within two weeks of receipt of results. Upon confirmation of new proteinuria, subjects will be asked to return to the clinic for a scheduled or unscheduled follow-up visit for evaluation. It is recommended that the Investigator contact the Gilead Medical Monitor to discuss if further consultation with a nephrologist is clinically warranted.

7.6. Special Situations Reports

7.6.1. Definitions of Special Situations

Special situation reports include all reports of medication error, abuse, misuse, overdose, reports of adverse events associated with product complaints, occupational exposure with an AE, pregnancy reports regardless of an associated AE and AE in an infant following exposure from breastfeeding.

Medication error is any unintentional error in the prescribing, dispensing, or administration of a medicinal product while in the control of the health care provider, subject, or consumer.

Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a subject.

Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in accordance with the protocol instructions or the local prescribing information.

An overdose is defined as an accidental or intentional administration of a quantity of a medicinal product given per administration or cumulatively which is above the maximum recommended dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in question). In cases of a discrepancy in drug accountability, overdose will be established only when it is clear that the subject has taken the excess dose(s). Overdose cannot be established when the subject cannot account for the discrepancy except in cases in which the investigator has reason to suspect that the subject has taken the additional dose(s).

Product complaint is defined as complaints arising from potential deviations in the manufacture, packaging, or distribution of the medicinal product.

Occupational exposure with an AE is defined as exposure to a medicinal product as a result of one’s professional or non-professional occupation.

7.6.2. Instructions for Reporting Special Situations

7.6.2.1. Instructions for Reporting Pregnancies

The investigator should report pregnancies in female study subjects that are identified after initiation of study medication and throughout the study, including the post study drug follow-up period, to the Gilead DSPH using the pregnancy report form within 24 hours of becoming aware of the pregnancy.

Refer to Section 7.3 and the CRF/eCRF completion guidelines for full instructions on the mechanism of pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a pregnancy without medical reasons.

Any premature termination of pregnancy (eg, a spontaneous abortion, an induced therapeutic abortion due to complications or other medical reasons) must be reported within 24 hours as an SAE. The underlying medical reason for this procedure should be recorded as the AE term.

A spontaneous abortion is always considered to be an SAE and will be reported as described in Sections 7.1.1 and 7.1.2. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must be reported to Gilead DSPH.

The subject should receive appropriate monitoring and care until the conclusion of the pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy outcome report form. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows:

Email: PPD and Fax: PPD

Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs must also be reported and relevant information should be submitted to Gilead DSPH using the pregnancy and pregnancy outcome forms within 24 hours. Monitoring of the subject should continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported directly to Gilead DSPH, fax number PPD or email PPD.

Refer to Appendix 5 for Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements.

7.6.2.2. Reporting Other Special Situations

All other special situation reports must be reported on the special situations report form and forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. These reports must consist of situations that involve study IMP and/or Gilead concomitant medications, but do not apply to non-Gilead concomitant medications.

Special situations involving non-Gilead concomitant medications does not need to be reported on the special situations report form; however, for special situations that result in AEs due to a non-Gilead concomitant medication, the AE should be reported on the AE form.

Any inappropriate use of concomitant medications prohibited by this protocol should not be reported as “misuse,” but may be more appropriately documented as a protocol deviation.

Refer to Section 7.3 and the CRF/eCRF completion guidelines for full instructions on the mechanism of special situations reporting.

All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the symptoms and signs, clinical management, and outcome will be reported, when available.
8. STATISTICAL CONSIDERATIONS

8.1. Analysis Objectives and Endpoints

8.1.1. Analysis Objectives

The primary objectives of this study are as follows:

- To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus continued tenofovir disoproxil fumarate (TDF) 300 mg QD in virologically suppressed subjects with chronic HBV as determined by the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at Week 24

- To compare the safety and tolerability of switching TAF 25 mg QD versus continuing TDF 300 mg QD in virologically suppressed subjects with chronic HBV at Week 24

The key secondary objectives of this study are as follows:

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the percent change from baseline in hip and spine bone mineral density (BMD) at Week 24

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the change from baseline in estimated creatinine clearance by Cockcroft-Gault method (eGFR\textsubscript{CG}) at Week 24

Other secondary objectives of this study are as follows:

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the percent change from baseline in hip and spine bone mineral density (BMD) at Weeks 48 and 96

- To compare the safety of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the change from baseline in estimated creatinine clearance by Cockcroft-Gault method (eGFR\textsubscript{CG}) at Weeks 48 and 96

- To compare the safety and tolerability of switching to TAF 25 mg QD versus continued TDF 300 mg QD in virologically suppressed subjects with chronic hepatitis B at Week 48

- To evaluate the efficacy of switching to TAF 25 mg QD versus continued TDF 300 mg QD as determined by the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at Weeks 48 and 96

- To compare the serological response (loss of HBsAg and seroconversion to anti-HBs, and loss of HBeAg and seroconversion to anti-HBe in HBeAg-positive subjects) of switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96
To compare biochemical response (normal ALT and normalized ALT) of switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96

To compare the change in fibrosis as assessed by FibroTest® for switching to TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 48 and 96

To evaluate the comparative open-label efficacy and safety of switching to TAF 25 mg QD from Week 48 through Week 96 in subjects initially randomized to TAF 25 mg QD and in subjects sequentially treated with continued TDF 300 mg QD for 48 weeks and then switched to open-label TAF 25 mg QD

To evaluate the proportion of patients with HBV DNA < 20 IU/mL and target detected/not detected (i.e. < LLOD) at Weeks 24, 48, and 96

The exploratory objectives of this study are as follows:

8.1.2. Primary Endpoint

The primary efficacy endpoint is the proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at Week 24.

8.1.3. Secondary Endpoint

The secondary efficacy endpoints are:

- The proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined by the modified US FDA-defined snapshot algorithm) at Weeks 48 and 96

- The proportion of subjects with HBV DNA < 20 IU/mL and target detected/not detected (i.e. < LLOD) at Weeks 24, 48 and 96, as determined by the modified US FDA-defined snapshot algorithm

- The proportion of subjects with HBeAg loss and proportion with seroconversion to anti-HBe at Weeks 24, 48, and 96
• The proportion of subjects with HBsAg loss and proportion with seroconversion to anti-HBs at Weeks 24, 48, and 96

• The proportion of subjects with normal ALT and proportion with normalized ALT (by central laboratory and AASLD criteria) at Weeks 24, 48, and 96

• The change from baseline in fibrosis as assessed by FibroTest® at Weeks 48 and 96

The key secondary safety endpoints are:

• The percent change from baseline in hip bone mineral density (BMD) at Week 24

• The percent change from baseline in spine bone mineral density (BMD) at Week 24

• The change from baseline in eGFR_{CG} (measured by Cockcroft-Gault method) at Week 24

The secondary safety endpoints are:

• The percent change from baseline in hip bone mineral density (BMD) at Weeks 48 and 96

• The percent change from baseline in spine bone mineral density (BMD) at Weeks 48 and 96

• The change from baseline in eGFR_{CG} (measured by Cockcroft-Gault method) at Weeks 48 and 96

8.1.4. Other Endpoints of Interest

• The change from baseline in serum markers of bone turnover at Weeks 24, 48, and 96

• The change from baseline in urine markers of renal tubular dysfunction at Weeks 24, 48, and 96

• The effect of treatment on health related to quality of life (via SF-36, CLDQ and WPAI questionnaires) at Weeks 24, 48 and 96

8.2. Analysis Conventions

8.2.1. Analysis Sets

8.2.1.1. Randomized Analysis Set

The randomized Analysis Set includes all subjects who were randomized into the study. This is the primary analysis set for by-subject listings.
8.2.1.2. Efficacy

The primary analysis set for efficacy analysis is the Full Analysis Set (FAS), defined as all randomized subjects who receive at least one dose of study drug. Subjects will be analyzed according to the randomized treatment assignment.

8.2.1.3. Safety

The primary analysis set for safety analyses is the Safety Analysis Set (SAS), defined as all randomized subjects who receive at least one dose of study drug. Subjects will be analyzed according to the treatment actually received. All data collected during treatment will be included in the safety summaries. Data collected during treatment free follow up will be summarized or listed separately.

8.2.1.4. Biomarkers

The Biomarker analysis set will include all subjects who have evaluable biomarkers data.

8.2.1.5. DEXA

8.2.1.5.1. Hip DXA Analysis Set

The Hip DXA Analysis Set includes all subjects who were randomized and had received at least 1 dose of study drug, and had nonmissing baseline hip BMD values. Subjects will be analyzed according to the treatment they actually received.

8.2.1.5.2. Spine DXA Analysis Set

The Spine DXA Analysis Set includes all subjects who were randomized and had received at least 1 dose of study drug, and had nonmissing baseline spine BMD values. Subjects will be analyzed according to the treatment they actually received.

8.3. Data Handling Conventions

For key secondary safety endpoints, an analysis will be performed using the last observation carried forward (LOCF) method to impute missing data.

For other categorical secondary efficacy endpoints, missing data will be handled using a missing = failure approach except for the endpoints of HBV DNA ≥ 20 IU/mL and HBV DNA < 20 IU/mL.

For the remaining endpoints, values for missing data will not be imputed, unless specified otherwise.

8.4. Multiplicity Adjustments

To control type I error for the assessment of the primary efficacy endpoint and key secondary safety endpoints, the hypothesis testing will be performed in a sequential order. The primary hypothesis of non-inferiority of TAF 25 mg QD vs. TDF 300 mg QD with respect to the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined
snapshot algorithm) at Week 24 will be tested first. The non-inferiority test will be performed using a two-sided, 0.05 alpha level. If non-inferiority is established, then multiplicity adjustments will be performed for the following endpoints using a fallback procedure \cite{Wiens et al 2005} in the sequential order given below with a pre-specified two-sided alpha level:

a) Percentage change from baseline in Hip BMD at Week 24 (alpha = 0.02)

b) Percentage change from baseline in Spine BMD at Week 24 (alpha = 0.01)

c) Change from baseline in Creatinine clearance (eGFR\textsubscript{CG}) at Week 24 (alpha = 0.02)

d) Superiority test for proportion of subjects with HBV DNA ≥ 20 IU/mL at Week 24 (alpha = 0.00)
8.5. Demographic Data and Baseline Characteristics

Demographic and baseline measurements will be summarized using standard descriptive methods by treatment group and overall.

Demographic summaries will include sex, race/ethnicity, geographical region, randomization stratification group, and age.

Baseline data will include a summary of body weight, height, body mass index, HBV DNA level, years positive for HBV, ALT level (≤ ULN, > ULN), previous TDF use and other oral nucleoside/nucleotide treatment experience, previous interferon experience, and HBV genotype by history.

8.6. Efficacy Analysis

8.6.1. Primary Analysis

The primary analysis will be performed when the last subject has completed Week 24 assessments or discontinued prematurely. The primary analysis will consist of a non-inferiority evaluation of efficacy of TAF versus TDF, with respect to the proportion of subjects with HBV DNA ≥ 20 IU/mL at Week 24 (as defined by the modified FDA snapshot Algorithm). It will be concluded that TAF is not inferior to the TDF if the upper bound of the two-sided 95% confidence interval of the difference between treatment arms (TAF arm – TDF arm) in the response rate is less than 6% (i.e., a margin of 6% is applied to non-inferiority assessment). The 95% confidence interval will be constructed using the normal approximation method based on stratified Mantel-Haenszel proportions, where stratification factors are HBeAg status (HBeAg positive or negative) and age (≥ 50 or < 50 years).

8.6.1.1. Modified US FDA-Defined Snapshot Algorithm

The US FDA-defined snapshot algorithm, developed for HIV-1 clinical trials, has been modified for use in HBV {U. S. Department of Health and Human Services et al 2015} using on-treatment HBV DNA values of < 20 IU/mL and ≥ 20 IU/mL.

The analysis window at Week 24 is defined as from Study Day 126 to Study Day 209, inclusive. All HBV DNA data collected on-treatment will be used in the snapshot algorithm. Virologic outcome will be defined as the following categories:

- **HBV DNA < 20 IU/mL**: this includes subjects who have the last available on-treatment HBV DNA < 20 IU/mL in the Week 24 analysis window

- **HBV DNA ≥ 20 IU/mL**: this includes subjects who

  1) Have the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 24 analysis window, or

  2) Do not have on-treatment HBV DNA data available in the Week 24 analysis window and
a) Discontinue study drug prior to or in the Week 24 analysis window due to lack of efficacy, or

b) Discontinue study drug prior to or in the Week 24 analysis window due to reason other than lack of efficacy and have the last available on-treatment HBV DNA $\geq 20$ IU/mL

- **No Virologic Data in the Week 24 Analysis Window:** this includes subjects who do not have on-treatment HBV DNA data available in the Week 24 analysis window for any of the following reasons:

  1) Discontinuation of study drug prior to or within the Week 24 analysis window due to reasons other than lack of efficacy and the last available on-treatment HBV DNA value is $< 20$ copies/mL, or

  2) Missing data within the window but who are on study drug treatment

### 8.6.2. Analyses of Secondary Endpoints

Continuous secondary endpoints will be summarized using conventional descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, and maximum) by treatment group and overall. A Wilcoxon rank sum test may be used to compare the treatment groups, in an exploratory manner.

Categorical secondary endpoints will be summarized by number and percentage of subjects that meet the endpoint. A two-sided Mantel-Haenszel test, controlling for the randomization strata, may be used to compare the treatment groups, in an exploratory manner. Missing data will be handled by the missing = failure approach except for the endpoints of HBV DNA $\geq 20$ IU/mL and HBV DNA $< 20$ IU/mL.

### 8.7. Safety Analysis

All safety data collected on or after the date that IMP was first dispensed up to the date of last dose of IMP will be summarized by treatment group (according to the IMP received). Data for the pretreatment and treatment-free follow-up periods will be included in data listings.

#### 8.7.1. Key Secondary Safety Analyses

The percent change from baseline in hip and spine BMD at Weeks 24 and 48 will be analyzed using an ANOVA model. The model will include treatment group as fixed effect. The details are provided in the Statistical Analysis Plan (SAP).

The change from baseline in eGFR$_{CG}$ at Weeks 24 and 48 will be analyzed using a 2-sided Wilcoxon rank sum test to compare the 2 treatment groups. The details are provided in the SAP.
8.7.2. Extent of Exposure

A subject’s extent of exposure to IMP data will be generated from the IMP administration data. Exposure data will be summarized by treatment group.

8.7.3. Adverse Events

Clinical and laboratory adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term (HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be attached to the clinical database.

Events will be summarized on the basis of the date of onset for the event. A treatment-emergent adverse event will be defined as any adverse event that begins on or after the date of first dose of IMP up to the date of last dose of IMP. Continuing adverse events diagnosed prior to the start of treatment and worsening in severity grade, or non-serious adverse events at baseline which become serious, or adverse events resulting in treatment discontinuation after the start of treatment will also be considered treatment-emergent. Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC and PT) will be provided by treatment group:

- Treatment-emergent adverse events
- Treatment-emergent study drug-related adverse events
- Grade 3 or 4 treatment-emergent adverse event
- Grade 3 or 4 treatment-emergent study drug-related adverse event
- Grade 2, 3, or 4 treatment-emergent adverse event
- Grade 2, 3, or 4 treatment-emergent study drug-related adverse event
- AE that caused permanent discontinuation from study drug
- AE that caused change in dose or temporary interruption of study drug
- Treatment-emergent serious adverse event
- Treatment-emergent study drug-related serious adverse event

8.7.4. Laboratory Evaluations

Selected laboratory data (using conventional units) will be summarized using only observed data. Data and change from baseline at all scheduled time points will be summarized.

Graded laboratory abnormalities will be defined using the grading scheme in Appendix 4.
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least one toxicity grade from baseline at any time post baseline up to and including the date of last dose of treatment will be summarized by treatment group. If baseline data are missing, then any graded abnormality (i.e., at least a Grade 1) will be considered treatment emergent.

Laboratory abnormalities that occur before the first dose of IMP or after the subject has been discontinued from treatment will be included in a data listing.

### 8.8. Biomarker Analysis

Selected bone biomarkers, including C-type collagen sequence (CTX) and procollagen type 1 N-terminal propeptide (P1NP), and selected renal biomarkers, including urine retinol binding protein, and urine beta-2-microglobulin, will be summarized by treatment group and visit using descriptive statistics. The difference in change from baseline in these biomarkers between two treatment arms will be tested using Wilcoxon rank sum test.

### 8.9. Sample Size

With respect to the primary efficacy endpoint of proportion of suppressed subjects with HBV DNA ≥ 20 IU/mL (current assay LLOQ), as determined by the modified US FDA-defined snapshot algorithm, at Week 24, when the sample sizes are 150 (TAF 25 mg arm) and 150 (TDF 300 mg arm), a two-group, large-sample normal approximation test of proportions with a one-sided 0.025 significance level will have 97% power to establish non-inferiority of TAF to TDF. It is assumed that both treatment arms will have subjects who have HBV DNA ≥ 20 IU/mL (as defined by the modified US FDA-defined snapshot algorithm) at a rate of 1.8% at Week 24 (based on the rates of suppressed subjects having HBV DNA ≥ 29 IU/mL [the LLOQ of assay during those studies] after 24 weeks of treatment from the combined data of studies GS-US-174-0102 and GS-US-174-0103 with the ratio of HBeAg- to HBeAg+ subjects assumed to be 2:1), with a non-inferiority margin of 6%.

The proposed sample size (n = 150 for the TAF 25 mg arm, n = 150 for the TDF 300 mg arm) also provides > 99% power to detect a 1.21% difference in the percentage change from baseline in hip BMD at Week 24 (assuming a 0.99% [SD 2.09%] change from baseline in TAF 25 mg arm and −0.22% [SD 1.89%] change from baseline in the TDF 300 mg arm, with a two-sided $\alpha = 0.05$); a > 99% power to detect a 1.69% difference in the percentage change from baseline in spine BMD at Week 24 (assuming a 1.50% [SD 2.80%] change from baseline in the TAF 25 mg arm and −0.19% [SD 3.00%] change in the TDF 300 mg arm, with a two-sided $\alpha = 0.05$); a 68% power to detect a 3.6 mL/min difference in the change from baseline in eGFR$_{CG}$ at Week 24 (assuming a +1.6 mL/min [SD 13.0] change from baseline in the TAF 25 mg arm and −2.0 mL/min [SD 12.4] change from baseline in the TDF 300 mg arm, with a two-sided $\alpha = 0.05$). These assumptions were derived from an HIV switch study (GS-US-292-0109) due to the unavailability of switch data from TAF HBV studies.
8.10. Data Monitoring Committee

An external, independent, multidisciplinary DMC will convene and review the progress and safety of this study after the last subject enrolled completes 24 weeks of the study. However, Gilead will defer to the DMC for any decision to convene earlier or more frequently. At each meeting, the DMC will review routine safety and DXA data and will make recommendations regarding modification of the study treatment.

The DMC’s specific activities will be defined by a mutually agreed charter, which will define the DMC’s membership, conduct and meeting schedule.

While the DMC will be asked to advise Gilead regarding future conduct of the study, including possible early study termination, Gilead retains final decision-making authority on all aspects of the study treatment.
9. **RESPONSIBILITIES**

9.1. **Investigator Responsibilities**

9.1.1. **Good Clinical Practice**

The investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki, International Conference on Harmonisation (ICH) guidelines, or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the study subject. These standards are consistent with the European Union Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.


The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, providing documentation of their financial interest or arrangements with Gilead, or proprietary interests in the investigational drug under study. This documentation must be provided prior to the investigator’s (and any subinvestigator’s) participation in the study. The investigator and subinvestigator agree to notify Gilead of any change in reportable interests during the study and for 1 year following completion of the study. Study completion is defined as the date when the last subject completes the protocol-defined activities.

9.1.2. **Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Ethics Committee (EC) Review and Approval**

The investigator (or sponsor as appropriate according to local regulations) will submit this protocol, informed consent form, and any accompanying material to be provided to the subject (such as advertisements, subject information sheets, or descriptions of the study used to obtain informed consent) to an IRB/IEC/EC. The investigator will not begin any study subject activities until approval from the IRB/IEC/EC has been documented and provided as a letter to the investigator.

Before implementation, the investigator will submit to and receive documented approval from the IRB/IEC/EC any modifications made to the protocol or any accompanying material to be provided to the subject after initial approval, with the exception of those necessary to reduce immediate risk to study subjects.

9.1.3. **Informed Consent**

The investigator is responsible for obtaining written informed consent from each individual participating in this study after adequate explanation of the aims, methods, objectives, and potential hazards of the study and before undertaking any study-related procedures. The investigator must use the most current IRB/IEC/EC approved consent form for documenting written informed consent. Each informed consent (or assent as applicable) will be appropriately
signed and dated by the subject or the subject’s legally authorized representative and the person conducting the consent discussion, and also by an impartial witness if required by IRB/IEC/EC.

9.1.4. Confidentiality

The investigator must assure that subjects’ anonymity will be strictly maintained and that their identities are protected from unauthorized parties. Only subject initials, date of birth, another unique identifier (as allowed by local law) and an identification code will be recorded on any form or biological sample submitted to the Sponsor, IRB/IEC/EC, or laboratory. Laboratory specimens must be labeled in such a way as to protect subject identity while allowing the results to be recorded to the proper subject. Refer to specific laboratory instructions for further details. NOTE: The investigator must keep a screening log showing codes, names, and addresses for all subjects screened and for all subjects enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.

The investigator agrees that all information received from Gilead, including but not limited to the investigator brochure, this protocol, CRF/eCRF, the IMP, and any other study information, remain the sole and exclusive property of Gilead during the conduct of the study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior written consent from Gilead. The investigator further agrees to take all reasonable precautions to prevent the disclosure by any employee or agent of the study site to any third party or otherwise into the public domain.

9.1.5. Study Files and Retention of Records

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents should be classified into at least the following two categories: (1) investigator’s study file, and (2) subject clinical source documents.

The investigator’s study file will contain the protocol/amendments, CRF and query forms, and governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and correspondence.

The required source data should include sequential notes containing at least the following information for each subject:

- Subject identification (name, date of birth, gender);
- Documentation that subject meets eligibility criteria, ie, history, physical examination, and confirmation of diagnosis (to support inclusion and exclusion criteria);
- Documentation of the reason(s) a consented subject is not enrolled;
• Participation in study (including study number);
• Study discussed and date of informed consent;
• Dates of all visits;
• Documentation that protocol specific procedures were performed;
• Results of efficacy parameters, as required by the protocol;
• Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
• Record of all adverse events and other safety parameters (start and end date, and including causality and severity);
• Concomitant medication (including start and end date, dose if relevant; dose changes);
• Date of study completion and reason for early discontinuation, if it occurs.

All clinical study documents must be retained by the investigator until at least 2 years or according to local laws, whichever is longer, after the last approval of a marketing application in an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified. Investigators may be required to retain documents longer if specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The investigator must notify Gilead before destroying any clinical study records.

Should the investigator wish to assign the study records to another party or move them to another location, Gilead must be notified in advance.

If the investigator cannot provide for this archiving requirement at the study site for any or all of the documents, special arrangements must be made between the investigator and Gilead to store these records securely away from the site so that they can be returned sealed to the investigator in case of an inspection. When source documents are required for the continued care of the subject, appropriate copies should be made for storage away from the site.

9.1.6. Case Report Forms

For each subject consented, an eCRF will be completed by an authorized study staff member whose training for this function is documented according to study procedures. eCRF should be completed on the day of the subject visit to enable the sponsor to perform central monitoring of safety data. The Eligibility Criteria eCRF should be completed only after all data related to eligibility have been received. Subsequent to data entry, a study monitor will perform source data verification within the EDC system. Original entries as well as any changes to data fields will be stored in the audit trail of the system. Prior to database lock (or any interim time points as described in the clinical data management plan), the investigator will use his/her log in credentials to confirm that the forms have been reviewed, and that the entries accurately reflect
the information in the source documents. The eCRF capture the data required per the protocol schedule of events and procedures. System-generated or manual queries will be issued to the investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, who routinely review the data for completeness, correctness, and consistency. The site coordinator is responsible for responding to the queries in a timely manner, within the system, either by confirming the data as correct or updating the original entry, and providing the reason for the update (e.g. data entry error). At the conclusion of the trial, Gilead will provide the site with a read-only archive copy of the data entered by that site. This archive must be stored in accordance with the records retention requirements outlined in Section 9.1.5.

9.1.7. Investigational Medicinal Product Accountability and Return

At the start of the study, the study monitor will evaluate the study center’s study drug disposal procedures and provide appropriate instruction for return or destruction of unused study drug supplies. If the site has an appropriate Standard Operating Procedure (SOP) for drug destruction, the site may destroy used and unused study drug supplies performed in accordance with the site’s (hospital/pharmacy) SOP. If the site does not have acceptable procedures in place for drug destruction, arrangements will be made between the site and Gilead Sciences (or Gilead Sciences’ representative) for return of unused study drug supplies. A copy of the site’s SOP will be obtained for central files. Where possible, study drug will be destroyed at the site. Upon study completion, a copy of the Investigational Drug Accountability records must be filed at the site. Another copy will be returned to Gilead Sciences. If drug is destroyed on site, the investigator must maintain accurate records for all study drug kits and/or bottles destroyed. Records must show the identification and quantity of each unit destroyed, the method of destruction, and person who disposed of the drug. All study drug records must be maintained at the site and copies must be submitted to Gilead Sciences at the end of the study. The study monitor will review IMP supplies and associated records at periodic intervals.

9.1.8. Inspections

The investigator will make available all source documents and other records for this trial to Gilead’s appointed study monitors, to IRB/IEC/EC, or to regulatory authority or health authority inspectors.

9.1.9. Protocol Compliance

The investigator is responsible for ensuring the study is conducted in accordance with the procedures and evaluations described in this protocol.

9.2. Sponsor Responsibilities

9.2.1. Protocol Modifications

Protocol modifications, except those intended to reduce immediate risk to study subjects, may be made only by Gilead. The investigator must submit all protocol modifications to the IRB/IEC/EC in accordance with local requirements and receive documented approval from all necessary bodies before modifications can be implemented.
9.2.2. **Study Report and Publications**

A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead will ensure that the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in certain cases.

Investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:

- The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form or the study has been completed at all study sites for at least 2 years.

- The investigator will submit to Gilead any proposed publication or presentation along with the respective scientific journal or presentation forum at least 30 days before submission of the publication or presentation.

- No such communication, presentation, or publication will include Gilead’s confidential information (see Section 9.1.4).

- The investigator will comply with Gilead’s request to delete references to its confidential information (other than the study results) in any paper or presentation and agrees to withhold publication or presentation for an additional 60 days in order to obtain patent protection if deemed necessary.

9.3. **Joint Investigator/Sponsor Responsibilities**

9.3.1. **Payment Reporting**

Investigators and their study staff may be asked to provide services performed under this protocol, e.g. attendance at Investigator's Meetings. If required under the applicable statutory and regulatory requirements, Gilead will capture and disclose to Federal and State agencies any expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel expenses or reimbursements, consulting fees, and any other transfer of value.

9.3.2. **Access to Information for Monitoring**

In accordance with regulations and guidelines, the study monitor must have direct access to the investigator’s source documentation in order to verify the accuracy of the data recorded in the CRF/eCRF.

The monitor is responsible for routine review of the CRF/eCRF at regular intervals throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The monitor should have access to any subject records needed to verify the entries on the CRF/eCRF. The investigator agrees to cooperate with the monitor to ensure that any problems detected through any type of monitoring (central, on site) are resolved.
9.3.3. **Access to Information for Auditing or Inspections**

Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the clinical study. If the investigator is notified of an inspection by a regulatory authority the investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to provide to representatives of a regulatory agency or Gilead access to records, facilities, and personnel for the effective conduct of any inspection or audit.

9.3.4. **Study Discontinuation**

Both the sponsor and the investigator reserve the right to terminate the study at any time. Should this be necessary, both parties will arrange discontinuation procedures and notify the appropriate regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead and the investigator will assure that adequate consideration is given to the protection of the subjects’ interests.
10. REFERENCES


Centers for Disease Control (CDC), Division of Viral Hepatitis. Viral Hepatitis Surveillance United States, 2013. 2013.


World Health Organization (WHO). Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015a.


11. APPENDICES

Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements
Appendix 1. Investigator Signature Page

GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404

STUDY ACKNOWLEDGEMENT

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed


This protocol has been approved by Gilead Sciences, Inc. The following signature documents this approval.

PPD

PPD

Medical Monitor

Date

INVESTIGATOR STATEMENT

I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.

I will provide all study personnel under my supervision copies of the protocol and access to all information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure that they are fully informed about the drugs and the study.

Principal Investigator Name (Printed)  Signature

Date  Site Number
## Appendix 2. Study Procedures Table

<table>
<thead>
<tr>
<th>Study Procedures</th>
<th>Screening (45 days)</th>
<th>Baseline (Day 1)</th>
<th>Blinded (± 3 days)</th>
<th>Open Label (± 7 days)</th>
<th>Follow Up&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed Consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History (including HBV disease and treatment history)</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Adverse Events</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Complete Physical Examination with weight and vital signs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Height</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body Weight</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Vital Signs&lt;sup&gt;b&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Symptom driven Physical Examination</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Health Related Quality of Life (CLDQ, SF-36, WPAI)&lt;sup&gt;m&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Serum Chemistry and Liver Tests&lt;sup&gt;b&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Hematology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Fasting metabolic panel&lt;sup&gt;c&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Pregnancy testing (women of child-bearing potential only)</td>
<td>serum</td>
<td>urine (+ve test to be confirmed with serum)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated Creatinine Clearance by Cockcroft-Gault method (eGFR&lt;sub&gt;CG&lt;/sub&gt;)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>HBV serology (qualitative HBsAg and HBeAg) and quantitative HBsAg&lt;sup&gt;ı&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>HCV, HDV, HIV Testing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-fetoprotein (AFP)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Urine drug screen</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DXA scans (Hip &amp; Spine)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG&lt;sup&gt;ı&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma HBV DNA levels</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Randomization</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Accountability</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Study Drug Dispensation</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>FibroTest&lt;sup&gt;ı&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Cystatin C&lt;sup&gt;f&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting Blood for Bone Biomarker&lt;sup&gt;f&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Fasting Urine for Renal Biomarker&lt;sup&gt;f&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
Study Procedures

<table>
<thead>
<tr>
<th>Fracture Risk Assessment (FRAX)</th>
<th>Screening (45 days)</th>
<th>Baseline (Day 1)</th>
<th>Blinded (± 3 days)</th>
<th>Open Label (± 7 days)</th>
<th>Follow Up</th>
<th>Week</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>24*</th>
<th>36</th>
<th>48*</th>
<th>60</th>
<th>72</th>
<th>96</th>
<th>ED*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virology (Sequence analysis of HBV pol/RT for resistance surveillance)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

PPD

a. Vital signs include blood pressure, pulse, respiration rate and temperature.
b. Serum chemistry and Liver Function Tests: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN), and PTH. PTH analyzed at all visits except for Screening. At Baseline, Weeks 24, 48, 72, 96, and ED, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry panel. Liver function tests: PT/INR will be done at Screening and then as a reflex only test for ALT flares.
c. Fasting glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). At Baseline, Weeks 12, 24, 36, 48, 60, 72, and 96/ED analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry panel.
d. The Baseline DXA can be performed at any time during the Screening period, but should be completed at least 14 days prior to the Baseline visit to ensure results are received prior to the first dose of study drug. The Week 24 DXA window is −14 days only and the Week 48 DXA window is −6 weeks only. DXA required for Early Discontinuation (ED) visit if not done within the last 12 weeks and should be done within ±14 days of the expected ED visit date.
e. Subjects must rest quietly in the supine position for a minimum of 5 minutes prior to the recording.
f. Blood for selected bone biomarkers and urine for selected renal biomarkers will be collected in a fasted state. Required for ED visit if the last sample was collected >12 weeks.
g. The Early Discontinuation (ED) visit should be performed within 72 hours of the last study drug dose (+3 days).
h. Subjects who discontinue study drug due to HBsAg loss with confirmed seroconversion to anti-HBs on or after the Week 24 visit, will be followed off treatment every 4 weeks for 12 weeks and then per the original study visit schedule through Week 96/ED. Subjects who have received at least one dose of study drug and permanently discontinue study drug for reasons other than HBsAg loss with confirmed seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or up to initiation of appropriate, alternative HBV therapy, whichever occurs first. Initiation of appropriate, alternative HBV therapy is highly encouraged.
i. HBeAb and HBsAb reflex testing will be performed as needed.
j. Resistance sequence analysis may be performed at BL for subjects with HBV DNA ≥ 69 IU/mL and may be attempted for viremic (HBV DNA ≥ 69 IU/mL) at Wks 24, 48, and 96/ED. As it may not be known at the time of the visit whether a subject is viremic or if it will be their last study visit, a virology sample will be collected as each visit. In the event of unconfirmed virologic rebound (HBV DNA ≥ 20 IU/mL), subjects will be asked to return to the clinic for a scheduled or unscheduled blood draw. For virologic rebound occurring within the first 12 weeks of the study, the next scheduled visit will be used for follow up. For virologic rebound occurring after Week 12, the subject will return for an unscheduled visit 2-3 weeks after the date of the original test that resulted with HBV DNA virologic rebound for confirmation of virologic rebound. At this follow up visit, a serum blood sample for resistance testing will be obtained. For unscheduled visits, the visit will be required to bring their supply of study drug with them and be assessed for adherence by pill count, and if necessary, the subject will be re-counseled on adherence to study medication.
k. The visit window for Week 24 visit is −14 days only. The visit window for Week 48 visit is −6 weeks only.
l. Serum Cystatin C will be done when eGFR < 50 ml/min during blinded period of study.
m. Health Related Quality of Life surveys required for Early Discontinuation (ED) visit if not done within the last 24 weeks of the expected ED visit date.
Appendix 3. Management of Clinical and Laboratory Adverse Events

Grade 1

May continue dosing at the discretion of the investigator

If confirmed and possibly and/or probably related to investigational medicinal products:
1. Withhold investigational medicinal products until ≤ Grade 2
2. Restart all investigational medicinal products at full dose

Grade 2

Repeat lab to confirm toxicity grade

If confirmed and unrelated to investigational medicinal products, dosing may continue at the discretion of the investigator

Grade 3

Repeat lab to confirm toxicity grade

If confirmed and possibly or probably related to investigational medicinal products:
- Discontinue investigational medicinal products dosing permanently and follow at periodic intervals at least weekly until a return to baseline or is otherwise explained

Grade 4

If confirmed and 3 or 4 recurrence that is considered unrelated to investigational medicinal products, continue all investigational medicinal products at the same dose at the discretion of the investigator
### Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities

**Antiviral Toxicity Grading Scale Version: 01 April 2015**

<table>
<thead>
<tr>
<th>HEMATOLOGY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hemoglobin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV POSITIVE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric ≥ 57 Days</strong></td>
<td>8.5 to 10.0 g/dL</td>
<td>7.5 to &lt; 8.5 g/dL</td>
<td>6.5 to &lt; 7.5 g/dL</td>
<td>&lt; 6.5 g/dL</td>
</tr>
<tr>
<td></td>
<td>85 to 100 g/L</td>
<td>75 to &lt; 85 g/L</td>
<td>65 to &lt; 75 g/L</td>
<td>&lt; 65 g/L</td>
</tr>
<tr>
<td></td>
<td>10.0 to 10.9 g/dL</td>
<td>9.0 to &lt; 10.0 g/dL</td>
<td>7.0 to &lt; 9.0 g/dL</td>
<td>&lt; 7.0 g/L</td>
</tr>
<tr>
<td></td>
<td>100 to 109 g/L</td>
<td>90 to &lt; 100 g/L</td>
<td>70 to &lt; 90 g/L</td>
<td>&lt; 70 g/L</td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any decrease from Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5 to &lt; 3.5 g/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25 to &lt; 35 g/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV NEGATIVE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric ≥ 57 Days</strong></td>
<td>8.5 to 9.4 g/dL</td>
<td>7.0 to &lt; 8.5 g/dL</td>
<td>6.0 to &lt; 7.0 g/dL</td>
<td>&lt; 6.0 g/dL</td>
</tr>
<tr>
<td></td>
<td>85 to 94 g/L</td>
<td>70 to &lt; 85 g/L</td>
<td>60 to &lt; 70 g/L</td>
<td>&lt; 60 g/L</td>
</tr>
<tr>
<td><strong>Infant, 36–56 Days</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(HIV POSITIVE OR NEGATIVE)</td>
<td>8.5 to 9.4 g/dL</td>
<td>7.0 to &lt; 8.5 g/dL</td>
<td>6.0 to &lt; 7.0 g/dL</td>
<td>&lt; 6.0 g/dL</td>
</tr>
<tr>
<td></td>
<td>85 to 94 g/L</td>
<td>70 to &lt; 85 g/L</td>
<td>60 to &lt; 70 g/L</td>
<td>&lt; 60 g/L</td>
</tr>
<tr>
<td><strong>Infant, 22–35 Days</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(HIV POSITIVE OR NEGATIVE)</td>
<td>9.5 to 10.5 g/dL</td>
<td>8.0 to &lt; 9.5 g/dL</td>
<td>7.0 to &lt; 8.0 g/dL</td>
<td>&lt; 7.0 g/dL</td>
</tr>
<tr>
<td></td>
<td>95 to 105 g/L</td>
<td>80 to &lt; 95 g/L</td>
<td>70 to &lt; 80 g/L</td>
<td>&lt; 70 g/L</td>
</tr>
<tr>
<td><strong>Infant, 1–21 Days</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(HIV POSITIVE OR NEGATIVE)</td>
<td>12.0 to 13.0 g/dL</td>
<td>10.0 to &lt; 12.0 g/dL</td>
<td>9.0 to &lt; 10.0 g/dL</td>
<td>&lt; 9.0 g/dL</td>
</tr>
<tr>
<td></td>
<td>120 to 130 g/L</td>
<td>100 to &lt; 120 g/L</td>
<td>90 to &lt; 100 g/L</td>
<td>&lt; 90 g/L</td>
</tr>
<tr>
<td><strong>Absolute Neutrophil Count</strong></td>
<td><strong>(ANC)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric, ≥ 7 Months</strong></td>
<td>1000 to 1300/mm$^3$</td>
<td>750 to &lt; 1000/mm$^3$</td>
<td>500 to &lt; 750/mm$^3$</td>
<td>&lt; 500/mm$^3$</td>
</tr>
<tr>
<td></td>
<td>1.00 to 1.30 GI/L</td>
<td>0.75 to &lt; 1.00 GI/L</td>
<td>0.50 to &lt; 0.75 GI/L</td>
<td>&lt; 0.50 GI/L</td>
</tr>
<tr>
<td><strong>Absolute CD4+ Count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV NEGATIVE ONLY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric &gt; 13 Years</strong></td>
<td>300 to 400/mm$^3$</td>
<td>200 to &lt; 300/mm$^3$</td>
<td>100 to &lt; 200/mm$^3$</td>
<td>&lt; 100/mm$^3$</td>
</tr>
<tr>
<td></td>
<td>300 to 400/μL</td>
<td>200 to &lt; 300/μL</td>
<td>100 to &lt; 200/μL</td>
<td>&lt; 100/μL</td>
</tr>
</tbody>
</table>
## HEMATOLOGY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute Lymphocyte Count</td>
<td>HIV NEGATIVE ONLY Adult and Pediatric &gt; 13 Years</td>
<td>HIV NEGATIVE ONLY Adult and Pediatric &gt; 13 Years</td>
<td>HIV NEGATIVE ONLY Adult and Pediatric &gt; 13 Years</td>
<td>HIV NEGATIVE ONLY Adult and Pediatric &gt; 13 Years</td>
</tr>
<tr>
<td></td>
<td>600 to 650/mm³ 0.60 to 0.65 GI/L</td>
<td>500 to &lt; 600/mm³ 0.50 to &lt; 0.60 GI/L</td>
<td>350 to &lt; 500/mm³ 0.35 to &lt; 0.50 GI/L</td>
<td>&lt; 350/mm³ &lt; 0.35 GI/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>100,000 to &lt; 125,000/mm³ 100 to &lt; 125 GI/L</td>
<td>50,000 to &lt; 100,000/mm³ 50 to &lt; 100 GI/L</td>
<td>25,000 to &lt; 50,000/mm³ 25 to &lt; 50 GI/L</td>
<td>&lt; 25,000/mm³ &lt; 25 GI/L</td>
</tr>
<tr>
<td>WBCs</td>
<td>2000/mm³ to 2500/mm³ 2.00 GI/L to 2.50 GI/L</td>
<td>1,500 to &lt; 2,000/mm³ 1.50 to &lt; 2.00 GI/L</td>
<td>1000 to &lt; 1,500/mm³ 1.00 to &lt; 1.50 GI/L</td>
<td>&lt; 1000/mm³ &lt; 1.00 GI/L</td>
</tr>
<tr>
<td>Hypofibrinogenemia</td>
<td>100 to 200 mg/dL 1.00 to 2.00 g/L</td>
<td>75 to &lt; 100 mg/dL 0.75 to &lt; 1.00 g/L</td>
<td>50 to &lt; 75 mg/dL 0.50 to &lt; 0.75 g/L</td>
<td>&lt; 50 mg/dL &lt; 0.50 g/L</td>
</tr>
<tr>
<td>Hyperfibrinogenemia</td>
<td>&gt; ULN to 600 mg/dL &gt; ULN to 6.0 g/L</td>
<td>&gt; 600 mg/dL &gt; 6.0 g/L</td>
<td>— —</td>
<td>— —</td>
</tr>
<tr>
<td>Fibrin Split Product</td>
<td>20 to 40 μg/mL 20 to 40 mg/L</td>
<td>&gt; 40 to 50 μg/mL &gt; 40 to 50 mg/L</td>
<td>&gt; 50 to 60 μg/mL &gt; 50 to 60 mg/L</td>
<td>&gt; 60 μg/mL &gt; 60 mg/L</td>
</tr>
<tr>
<td>Prothrombin Time (PT)</td>
<td>&gt; 1.00 to 1.25 × ULN</td>
<td>&gt; 1.25 to 1.50 × ULN</td>
<td>&gt; 1.50 to 3.00 × ULN</td>
<td>&gt; 3.00 × ULN</td>
</tr>
<tr>
<td>International Normalized Ratio of prothrombin time (INR)</td>
<td>1.1 to 1.5 x ULN</td>
<td>&gt;1.5 to 2.0 x ULN</td>
<td>&gt;2.0 to 3.0 x ULN</td>
<td>&gt;3.0 x ULN</td>
</tr>
<tr>
<td>Activated Partial Thromboplastin Time (APTT)</td>
<td>&gt; 1.00 to 1.66 × ULN</td>
<td>&gt; 1.66 to 2.33 × ULN</td>
<td>&gt; 2.33 to 3.00 × ULN</td>
<td>&gt; 3.00 × ULN</td>
</tr>
<tr>
<td>Methemoglobin</td>
<td>5.0 to 10.0%</td>
<td>&gt; 10.0 to 15.0%</td>
<td>&gt; 15.0 to 20.0%</td>
<td>&gt; 20.0%</td>
</tr>
</tbody>
</table>

* An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. Please follow the Gilead convention of grading any result within the LLN and ULN a 0.
<table>
<thead>
<tr>
<th>CHEMISTRY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyponatremia</td>
<td>130 to &lt;LLN mEq/L</td>
<td>125 to &lt; 130 mEq/L</td>
<td>121 to &lt; 125 mEq/L</td>
<td>&lt; 121 mEq/L</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>130 to &lt;LLN mmol/L</td>
<td>125 to &lt; 130 mmol/L</td>
<td>121 to &lt; 125 mmol/L</td>
<td>&lt; 121 mmol/L</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>&gt;ULN to 150 mEq/L</td>
<td>&gt; 150 to 154 mEq/L</td>
<td>&gt; 154 to 159 mEq/L</td>
<td>&gt; 159 mEq/L</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>&gt;ULN to 150 mmol/L</td>
<td>&gt; 150 to 154 mmol/L</td>
<td>&gt; 154 to 159 mmol/L</td>
<td>&gt; 159 mmol/L</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Adult and Pediatric</td>
<td>3.0 to &lt;LLN mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Infant &lt;1 Year</td>
<td>3.0 to 3.4 mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Adult and Pediatric</td>
<td>5.6 to 6.0 mEq/L</td>
<td>&gt; 6.0 to 6.5 mEq/L</td>
<td>&gt; 6.5 to 7.0 mEq/L</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Infant &lt;1 Year</td>
<td>&gt;ULN to 6.0 mEq/L</td>
<td>&gt; 6.0 to 6.5 mEq/L</td>
<td>&gt; 6.5 to 7.0 mEq/L</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>Adult and Pediatric</td>
<td>55 to 64 mg/dL</td>
<td>40 to &lt; 55 mg/dL</td>
<td>30 to &lt; 40 mg/dL</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>Infant &lt;1 Month</td>
<td>50 to 54 mg/dL</td>
<td>40 to &lt; 50 mg/dL</td>
<td>30 to &lt; 40 mg/dL</td>
</tr>
<tr>
<td>Hyperglycemia, Nonfasting</td>
<td>116 to 160 mg/dL</td>
<td>&gt; 160 to 250 mg/dL</td>
<td>&gt; 250 to 500 mg/dL</td>
<td>&gt; 500 mg/dL</td>
</tr>
<tr>
<td>Hyperglycemia, Fasting</td>
<td>110 to 125 mg/dL</td>
<td>&gt;125 to 250 mg/dL</td>
<td>&gt;250 to 500 mg/dL</td>
<td>&gt;500 mg/dL</td>
</tr>
</tbody>
</table>

---

Tenofovir Alafenamide (TAF), GS-7340
Protocol GS-US-320-4018 Final
Gilead Sciences, Inc.
CONFIDENTIAL Page 110 30 September 2016
<table>
<thead>
<tr>
<th>CHEMISTRY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypocalcemia</strong> (corrected for albumin if appropriate*)</td>
<td>7.8 &lt; LLN mg/dL</td>
<td>7.0 to &lt; 7.8 mg/dL</td>
<td>6.1 to &lt; 7.0 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
</tr>
<tr>
<td><strong>Pediatric ≥2 Years</strong></td>
<td>7.0 to &lt; 1.94 mmol/L</td>
<td>&lt; 6.1 mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pediatric ≥7 days -2 Years</strong></td>
<td>7.8 to 8.4 mg/dL</td>
<td>7.0 to &lt; 7.8 mg/dL</td>
<td>6.1 to &lt; 7.0 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
</tr>
<tr>
<td><strong>Pediatric ≥7 days -2 Years</strong></td>
<td>1.94 to 2.10 mmol/L</td>
<td>1.74 to &lt; 1.94 mmol/L</td>
<td>1.51 to &lt; 1.74 mmol/L</td>
<td>&lt; 1.51 mmol/L</td>
</tr>
<tr>
<td><strong>Infant, &lt; 7 Days</strong></td>
<td>6.0 to &lt; 6.5 mg/dL</td>
<td>5.5 to &lt; 6.0 mg/dL</td>
<td>&lt; 5.5 mg/dL</td>
<td></td>
</tr>
<tr>
<td><strong>Infant, &lt; 7 Days</strong></td>
<td>1.49 to &lt; 1.61 mmol/L</td>
<td>1.36 to &lt; 1.49 mmol/L</td>
<td>&lt; 1.36 mmol/L</td>
<td></td>
</tr>
<tr>
<td><strong>Hypercalcemia</strong> (corrected for albumin if appropriate*)</td>
<td>&gt; ULN to 11.5 mg/dL</td>
<td>&gt; 11.5 to 12.5 mg/dL</td>
<td>&gt; 12.5 to 13.5 mg/dL</td>
<td>&gt; 13.5 mg/dL</td>
</tr>
<tr>
<td><strong>Adult and Pediatric ≥ 7 Days</strong></td>
<td>&gt; ULN to 2.88 mmol/L</td>
<td>&gt; 2.88 to 3.13 mmol/L</td>
<td>&gt; 3.13 to 3.38 mmol/L</td>
<td>&gt; 3.38 mmol/L</td>
</tr>
<tr>
<td><strong>Infant, &lt; 7 Days</strong></td>
<td>11.5 to 12.4 mg/dL</td>
<td>≥ 11.5 mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infant, &lt; 7 Days</strong></td>
<td>2.86 to 3.10 mmol/L</td>
<td>&gt; 12.4 to 12.9 mg/dL</td>
<td>≥ 12.9 mg/dL</td>
<td></td>
</tr>
<tr>
<td><strong>Hypocalcemia (ionized)</strong></td>
<td>3.0 mg/dL to &lt; LLN</td>
<td>2.5 to &lt; 3.0 mg/dL</td>
<td>2.0 to &lt; 2.5 mg/dL</td>
<td>&lt; 2.0 mg/dL</td>
</tr>
<tr>
<td><strong>Hypocalcemia (ionized)</strong></td>
<td>0.74 mmol/L to &lt; LLN</td>
<td>0.62 to &lt; 0.74 mmol/L</td>
<td>0.49 to &lt; 0.62 mmol/L</td>
<td>&lt; 0.49 mg/dL</td>
</tr>
<tr>
<td><strong>Hypercalcemia (ionized)</strong></td>
<td>&gt; ULN to 6.0 mg/dL</td>
<td>&gt; 6.0 to 6.5 mg/dL</td>
<td>&gt; 6.5 to 7.0 mg/dL</td>
<td>&gt; 7.0 mg/dL</td>
</tr>
<tr>
<td><strong>Hypercalcemia (ionized)</strong></td>
<td>&gt; ULN to 1.50 mmol/L</td>
<td>&gt; 6.0 mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypomagnesemia</strong></td>
<td>1.40 to &lt; LLN mg/dL</td>
<td>1.04 to &lt; 1.40 mg/dL</td>
<td>0.67 to &lt; 1.04 mg/dL</td>
<td>&lt; 0.67 mg/dL</td>
</tr>
<tr>
<td><strong>Hypomagnesemia</strong></td>
<td>1.2 to &lt; LLN mEq/L</td>
<td>0.9 to &lt; 1.2 mEq/L</td>
<td>0.6 to &lt; 0.9 mEq/L</td>
<td>&lt; 0.6 mEq/L</td>
</tr>
<tr>
<td><strong>Hypomagnesemia</strong></td>
<td>0.58 to &lt; LLN mmol/L</td>
<td>0.43 to &lt; 0.58 mmol/L</td>
<td>0.28 to &lt; 0.43 mmol/L</td>
<td>&lt; 0.28 mmol/L</td>
</tr>
</tbody>
</table>
## CHEMISTRY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypophosphatemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric</strong></td>
<td>2.0 to &lt; LLN mg/dL</td>
<td>1.5 to &lt; 2.0 mg/dL</td>
<td>1.0 to &lt; 1.5 mg/dL</td>
<td>&lt; 1.0 mg/dL</td>
</tr>
<tr>
<td>&gt; 14 Years</td>
<td>0.63 to &lt; LLN mmol/L</td>
<td>0.47 to &lt; 0.63 mmol/L</td>
<td>0.31 to &lt; 0.47 mmol/L</td>
<td>&lt; 0.31 mmol/L</td>
</tr>
<tr>
<td><strong>Pediatric 1 Year–14 Years</strong></td>
<td>3.0 to &lt;LLN mg/dL</td>
<td>2.5 to &lt; 3.0 mg/dL</td>
<td>1.5 to &lt; 2.5 mg/dL</td>
<td>&lt; 1.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>0.96 to &lt;LLN mmol/L</td>
<td>0.80 to &lt; 0.96 mmol/L</td>
<td>0.47 to &lt; 0.80 mmol/L</td>
<td>&lt; 0.47 mmol/L</td>
</tr>
<tr>
<td><strong>Pediatric &lt; 1 Year</strong></td>
<td>3.5 to &lt;LLN mg/dL</td>
<td>2.5 to &lt; 3.5 mg/dL</td>
<td>1.5 to &lt; 2.5 mg/dL</td>
<td>&lt; 1.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.12 to &lt;LLN mmol/L</td>
<td>0.80 to &lt; 1.12 mmol/L</td>
<td>0.47 to &lt; 0.80 mmol/L</td>
<td>&lt; 0.47 mmol/L</td>
</tr>
<tr>
<td><strong>Hyperbilirubinemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric</strong></td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.5 × ULN</td>
<td>&gt; 2.5 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>&gt; 14 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infant, ≤ 14 Days</strong></td>
<td>NA</td>
<td>20.0 to 25.0 mg/dL</td>
<td>&gt; 25.0 to 30.0 mg/dL</td>
<td>&gt; 30.0 mg/dL</td>
</tr>
<tr>
<td>(non-hemolytic)</td>
<td>342 to 428 μmol/L</td>
<td>&gt; 428 to 513 μmol/L</td>
<td>&gt; 513 μmol/L</td>
<td></td>
</tr>
<tr>
<td><strong>Infant, ≤ 14 Days</strong></td>
<td>NA</td>
<td>NA</td>
<td>20.0 to 25.0 mg/dL</td>
<td>&gt; 25.0 mg/dL</td>
</tr>
<tr>
<td>(hemolytic)</td>
<td>342 to 428 μmol/L</td>
<td>342 to 428 μmol/L</td>
<td>&gt; 513 μmol/L</td>
<td></td>
</tr>
<tr>
<td><strong>Blood Urea Nitrogen</strong></td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td><strong>Hyperuricemia</strong></td>
<td>&gt;ULN to 10.0 mg/dL</td>
<td>&gt; 10.0 to 12.0 mg/dL</td>
<td>&gt; 12.0 to 15.0 mg/dL</td>
<td>&gt; 15.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN to 597 μmol/L</td>
<td>&gt; 597 to 716 μmol/L</td>
<td>&gt; 716 to 895 μmol/L</td>
<td>&gt; 895 μmol/L</td>
</tr>
<tr>
<td><strong>Hypouricemia</strong></td>
<td>1.5 mg/dL to &lt; LLN</td>
<td>1.0 to &lt; 1.5 mg/dL</td>
<td>0.5 to &lt; 1.0 mg/dL</td>
<td>&lt; 0.5 mg/dL</td>
</tr>
<tr>
<td><strong>Adult and Pediatric</strong></td>
<td>87 μmol/L to &lt; LLN</td>
<td>57 to &lt; 87 μmol/L</td>
<td>27 to &lt; 57 μmol/L</td>
<td>&lt; 27 μmol/L</td>
</tr>
<tr>
<td>≥ 1 year</td>
<td>N/A</td>
<td>1.0 mg/dl to &lt;LLN-</td>
<td>0.5 to &lt; 1.0 mg/dL</td>
<td>&lt; 0.5 mg/dL</td>
</tr>
<tr>
<td><strong>Infant &lt; 1 Year</strong></td>
<td></td>
<td>57 μmol to &lt;LLN</td>
<td>27 to &lt; 57 μmol/L</td>
<td>&lt; 27 μmol/L</td>
</tr>
</tbody>
</table>
### CHEMISTRY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine**</td>
<td>&gt; 1.50 to 2.00 mg/dL</td>
<td>&gt; 2.00 to 3.00 mg/dL</td>
<td>&gt; 3.00 to 6.00 mg/dL</td>
<td>&gt; 6.00 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; 133 to 177 μmol/L</td>
<td>&gt; 177 to 265 μmol/L</td>
<td>&gt; 265 to 530 μmol/L</td>
<td>&gt; 530 μmol/L</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>16.0 mEq/L to &lt; LLN</td>
<td>11.0 to &lt; 16.0 mEq/L</td>
<td>8.0 to &lt; 11.0 mEq/L</td>
<td>&lt; 8.0 mEq/L</td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 4 Years</td>
<td>16.0 mmol/L to &lt; LLN</td>
<td>11.0 to &lt; 16.0 mmol/L</td>
<td>8.0 to &lt; 11.0 mmol/L</td>
<td>&lt; 8.0 mmol/L</td>
</tr>
<tr>
<td>Pediatric &lt; 4 Years</td>
<td>NA</td>
<td>11.0 mEq/L to &lt; LLN</td>
<td>8.0 to &lt; 11.0 mEq/L</td>
<td>&lt; 8.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>11.0 mmol/L to &lt; LLN</td>
<td>8.0 to &lt; 11.0 mmol/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides (Fasting)</td>
<td>NA</td>
<td>500 to 750 mg/dL</td>
<td>&gt; 750 to 1200 mg/dL</td>
<td>&gt; 1200 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.64–8.47 mmol/L</td>
<td>&gt; 8.47–13.55 mmol/L</td>
<td></td>
</tr>
<tr>
<td>LDL (Fasting) Adult</td>
<td>130 to 160 mg/dL</td>
<td>&gt;160 to 190 mg/dL</td>
<td>&gt; 190 mg/dL</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>3.35 to 4.15 mmol/L</td>
<td>&gt;4.15 to 4.92 mmol/L</td>
<td>&gt;4.92 mmol/L</td>
<td></td>
</tr>
<tr>
<td>LDL (Fasting) Pediatric &gt;2 to &lt;18 years</td>
<td>110 to 130 mg/dL</td>
<td>&gt;130 to 190 mg/dL</td>
<td>&gt; 190 mg/dL</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>2.84 to 3.37 mmol/L</td>
<td>&gt;3.37 to 4.92 mmol/L</td>
<td>&gt;4.92 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia (Fasting)</td>
<td>200 to 239 mg/dL</td>
<td>&gt; 239 to 300 mg/dL</td>
<td>&gt; 300 mg/dL</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>5.16 to 6.19 mmol/L</td>
<td>&gt; 6.19 to 7.77 mmol/L</td>
<td>&gt; 7.77 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Pediatric &lt; 18 Years</td>
<td>170 to 199 mg/dL</td>
<td>&gt; 199 to 300 mg/dL</td>
<td>&gt; 300 mg/dL</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>4.39 to 5.15 mmol/L</td>
<td>&gt; 5.15 to 7.77 mmol/L</td>
<td>&gt; 7.77 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Creatine Kinase</td>
<td>3.0 to &lt; 6.0 × ULN</td>
<td>6.0 to &lt; 10.0 × ULN</td>
<td>10.0 to &lt; 20.0 × ULN</td>
<td>≥ 20.0 × ULN</td>
</tr>
</tbody>
</table>

* Calcium should be corrected for albumin if albumin is < 4.0 g/dL

** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects > 70 yrs. Please follow the Gilead convention of grading any result within the LLN and ULN a 0.
<table>
<thead>
<tr>
<th>ENZYMES</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (SGOT)</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>ALT (SGPT)</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>GGT</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>Total Amylase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.0 × ULN</td>
<td>&gt; 2.0 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Pancreatic Amylase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.0 × ULN</td>
<td>&gt; 2.0 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Lipase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 3.0 × ULN</td>
<td>&gt; 3.0 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Albumin</td>
<td>-</td>
<td>2.0 to &lt; LLN g/dL</td>
<td>&lt; 2.0 g/dL</td>
<td>NA</td>
</tr>
<tr>
<td>Pediatrics &lt;16 years</td>
<td></td>
<td>20 to &lt; LLN g/L</td>
<td>&lt; 20 g/L</td>
<td></td>
</tr>
<tr>
<td>≥ 16 years</td>
<td>3.0 g/dL to &lt; LLN</td>
<td>2.0 to &lt; 3.0 g/dL</td>
<td>&lt; 2.0 g/dL</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>30 g/L to &lt; LLN</td>
<td>20 to 30 g/L</td>
<td>&lt; 20 g/L</td>
<td></td>
</tr>
<tr>
<td>URINALYSIS</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>Hematuria (Dipstick)</td>
<td>1+</td>
<td>2+</td>
<td>3-4+</td>
<td>NA</td>
</tr>
<tr>
<td>Hematuria (Quantitative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>See Note below</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>&gt;ULN - 10 RBC/HPF</td>
<td>&gt; 10-75 RBC/HPF</td>
<td>&gt; 75 RBC/HPF</td>
<td>NA</td>
</tr>
<tr>
<td>Males</td>
<td>6-10 RBC/HPF</td>
<td>&gt; 10-75 RBC/HPF</td>
<td>&gt; 75 RBC/HPF</td>
<td>NA</td>
</tr>
<tr>
<td>Proteinuria (Dipstick)</td>
<td>1+</td>
<td>2–3+</td>
<td>4+</td>
<td>NA</td>
</tr>
<tr>
<td>Proteinuria, 24 Hour Collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric ≥ 10 Years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200 to 999 mg/24 h</td>
<td>&gt;999 to 1999 mg/24 h</td>
<td>&gt;1999 to 3500 mg/24 h</td>
<td>&gt;3500 mg/24 h</td>
<td></td>
</tr>
<tr>
<td><strong>Pediatric &gt; 3 Mo to &lt; 10 Years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>201 to 499 mg/m²/24 h</td>
<td>&gt;499 to 799 mg/m²/24 h</td>
<td>&gt;799 to 1000 mg/m²/24 h</td>
<td>&gt;1000 mg/ m²/24 h</td>
<td></td>
</tr>
<tr>
<td>Glycosuria (Dipstick)</td>
<td>1+</td>
<td>2-3+</td>
<td>4+</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Notes:**
- Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to Dipstick Hematuria.
- With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
- If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for the AE.
### CARDIOVASCULAR

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac Arrhythmia (general) (By ECG or physical exam)</td>
<td>Asymptomatic AND No intervention indicated</td>
<td>Asymptomatic AND Non-urgent medical intervention indicated</td>
<td>Symptomatic, non-life-threatening AND Non-urgent medical intervention indicated</td>
<td>Life-threatening arrhythmia OR Urgent intervention indicated</td>
</tr>
<tr>
<td>Cardiac-ischemia/Infarction</td>
<td>NA</td>
<td>NA</td>
<td>Symptomatic ischemia (stable angina) OR Testing consistent with ischemia</td>
<td>Unstable angina OR Acute myocardial infarction</td>
</tr>
<tr>
<td>Hemorrhage (significant acute blood loss)</td>
<td>NA</td>
<td>Symptomatic AND No transfusion indicated</td>
<td>Symptomatic AND Transfusion of ≤ 2 units packed RBCs (for children ≤ 10 cc/kg) indicated</td>
<td>Life-threatening hypotension OR Transfusion of &gt; 2 units packed RBCs indicated (for children ≤ 10 cc/kg) indicated</td>
</tr>
<tr>
<td>Hypertension (with repeat testing at same visit)</td>
<td>140–159 mmHg systolic OR 90–99 mmHg diastolic</td>
<td>&gt; 159–179 mmHg systolic OR &gt; 99–109 mmHg diastolic</td>
<td>&gt; 179 mmHg systolic OR &gt; 109 mmHg diastolic</td>
<td>Life-threatening consequences (eg, malignant hypertension) OR Hospitalization (other than ER visit) indicated</td>
</tr>
<tr>
<td><strong>Pediatric ≤ 17 Years</strong> (with repeat testing at same visit)</td>
<td>NA</td>
<td>91st–94th percentile adjusted for age, height, and gender (systolic and/or diastolic)</td>
<td>≥ 95th percentile adjusted for age, height, and gender (systolic and/or diastolic)</td>
<td>Life-threatening consequences (eg, malignant hypertension) OR Hospitalization indicated (other than emergency room visit)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>NA</td>
<td>Symptomatic, corrected with oral fluid replacement</td>
<td>Symptomatic, IV fluids indicated</td>
<td>Shock requiring use of vasopressors or mechanical assistance to maintain blood pressure</td>
</tr>
<tr>
<td>Pericardial Effusion</td>
<td>Asymptomatic, small effusion requiring no intervention</td>
<td>Asymptomatic, moderate or larger effusion requiring no intervention</td>
<td>Effusion with non-life-threatening physiologic consequences OR Effusion with nonurgent intervention indicated</td>
<td>Life-threatening consequences (eg, tamponade) OR Urgent intervention indicated</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td><strong>Prolonged PR Interval</strong></td>
<td>PR interval 0.21 to 0.25 sec</td>
<td>PR interval &gt; 0.25 sec</td>
<td>Type II 2nd degree AV block OR Ventricular pause &gt; 3.0 sec</td>
<td>Complete AV block</td>
</tr>
<tr>
<td><strong>Pediatric ≤ 16 Years</strong></td>
<td>1st degree AV block (PR &gt; normal for age and rate)</td>
<td>Type I 2nd degree AV block</td>
<td>Type II 2nd degree AV block</td>
<td>Complete AV block</td>
</tr>
<tr>
<td><strong>Prolonged QTc</strong></td>
<td>Asymptomatic, QTc interval 0.45 to 0.47 sec OR Increase interval &lt; 0.03 sec above baseline</td>
<td>Asymptomatic, QTc interval 0.48 to 0.49 sec OR Increase in interval 0.03 to 0.05 sec above baseline</td>
<td>Asymptomatic, QTc interval ≥ 0.50 sec OR Increase in interval ≥ 0.06 sec above baseline</td>
<td>Life-threatening consequences, eg, Torsade de pointes or other associated serious ventricular dysrhythmia</td>
</tr>
<tr>
<td><strong>Pediatric ≤ 16 Years</strong></td>
<td>Asymptomatic, QTc interval 0.450 to 0.464 sec</td>
<td>Asymptomatic, QTc interval 0.465 to 0.479 sec</td>
<td>Asymptomatic, QTc interval ≥ 0.480 sec</td>
<td>Life-threatening consequences, eg, Torsade de pointes or other associated serious ventricular dysrhythmia</td>
</tr>
<tr>
<td><strong>Thrombosis/Embolism</strong></td>
<td>NA</td>
<td>Deep vein thrombosis AND No intervention indicated (eg, anticoagulation, lysis filter, invasive procedure)</td>
<td>Deep vein thrombosis AND Intervention indicated (eg, anticoagulation, lysis filter, invasive procedure)</td>
<td>Embolic event (eg, pulmonary embolism, life-threatening thrombus)</td>
</tr>
<tr>
<td><strong>Vasovagal Episode</strong></td>
<td>Present without loss of consciousness</td>
<td>Present with transient loss of consciousness</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>(associated with a procedure of any kind)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ventricular Dysfunction</strong></td>
<td>NA</td>
<td>Asymptomatic diagnostic finding AND intervention indicated</td>
<td>New onset with symptoms OR Worsening symptomatic CHF</td>
<td>Life-threatening CHF</td>
</tr>
</tbody>
</table>
### RESPIRATORY

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchospasm (acute)</td>
<td>FEV1 or peak flow reduced to 70% to 80%</td>
<td>FEV1 or peak flow 50% to 69%</td>
<td>FEV1 or peak flow 25% to 49%</td>
</tr>
<tr>
<td>Dyspnea or Respiratory Distress</td>
<td>Dyspnea on exertion with no or minimal interference with usual social &amp; functional activities</td>
<td>Dyspnea on exertion causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Dyspnea at rest causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Pediatric &lt; 14 Years</td>
<td>Wheezing OR minimal increase in respiratory rate for age</td>
<td>Nasal flaring OR Intercostal retractions OR Pulse oximetry 90% to 95%</td>
<td>Dyspnea at rest causing inability to perform usual social &amp; functional activities OR Pulse oximetry &lt; 90%</td>
</tr>
</tbody>
</table>

### OCULAR/VISUAL

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>Asymptomatic but detectable on exam</td>
<td>Symptomatic anterior uveitis OR Medical intervention indicated</td>
<td>Posterior or pan-uveitis OR Operative intervention indicated</td>
</tr>
<tr>
<td>Visual Changes (from baseline)</td>
<td>Visual changes causing no or minimal interference with usual social &amp; functional activities</td>
<td>Visual changes causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Visual changes causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Condition</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alopecia</td>
<td>Thinning detectable by study participant or caregiver (for disabled adults)</td>
<td>Thinning or patchy hair loss detectable by health care provider</td>
<td>Complete hair loss</td>
</tr>
<tr>
<td>Cutaneous Reaction – Rash</td>
<td>Localized macular rash</td>
<td>Diffuse macular, maculopapular, or morbilliform rash OR Target lesions</td>
<td>Diffuse macular, maculopapular, or morbilliform rash with vesicles or limited number of bullae OR Superficial ulcerations of mucous membrane limited to one site</td>
</tr>
<tr>
<td>Hyperpigmentation</td>
<td>Slight or localized</td>
<td>Marked or generalized</td>
<td>NA</td>
</tr>
<tr>
<td>Hypopigmentation</td>
<td>Slight or localized</td>
<td>Marked or generalized</td>
<td>NA</td>
</tr>
<tr>
<td>Pruritis (itching – no skin lesions) (See also Injection Site Reactions: Pruritis associated with injection)</td>
<td>Itching causing no or minimal interference with usual social &amp; functional activities</td>
<td>Itching causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Itching causing inability to perform usual social &amp; functional activities</td>
</tr>
</tbody>
</table>
### GASTROINTESTINAL

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anorexia</td>
<td>Loss of appetite without decreased oral intake</td>
<td>Loss of appetite associated with decreased oral intake without significant weight loss</td>
<td>Loss of appetite associated with significant weight loss</td>
<td>Life-threatening consequences OR Aggressive intervention indicated [eg, tube feeding or total parenteral nutrition]</td>
</tr>
<tr>
<td>Ascites</td>
<td>Asymptomatic</td>
<td>Symptomatic AND Intervention indicated (eg, diuretics or therapeutic paracentesis)</td>
<td>Symptomatic despite intervention</td>
<td>Life-threatening consequences</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>NA</td>
<td>Symptomatic AND Medical intervention indicated</td>
<td>Radiologic, endoscopic, or operative intervention indicated</td>
<td>Life-threatening consequences (eg, sepsis or perforation)</td>
</tr>
<tr>
<td>Constipation</td>
<td>NA</td>
<td>Persistent constipation requiring regular use of dietary modifications, laxatives, or enemas</td>
<td>Obstipation with manual evacuation indicated</td>
<td>Life-threatening consequences (eg, obstruction)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline/24 hr</td>
<td>Persistent episodes of unformed to wetary stools OR Increase of 4–6 stools over baseline per 24 hrs.</td>
<td>Bloody diarrhea OR Increase of ≥ 7 stools per 24-hour period OR IV fluid replacement indicated</td>
<td>Life-threatening consequences (eg, hypotensive shock)</td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 1 Year</td>
<td>Liquid stools (more unformed than usual) but usual number of stools</td>
<td>Liquid stools with increased number of stools OR Mild dehydration</td>
<td>Liquid stools with moderate dehydration</td>
<td>Liquid stools resulting in severe dehydration with aggressive rehydration indicated OR Hypotensive shock</td>
</tr>
<tr>
<td>Pediatric &lt; 1 Year</td>
<td>Symptomatic but able to eat usual diet</td>
<td>Symptoms causing altered dietary intake without medical intervention indicated</td>
<td>Symptoms causing severely altered dietary intake with medical intervention indicated</td>
<td>Life-threatening reduction in oral intake</td>
</tr>
<tr>
<td>Dysphagia-Odynophagia</td>
<td>Symptomatic but able to eat usual diet</td>
<td>Symptoms causing altered dietary intake without medical intervention indicated</td>
<td>Symptoms causing severely altered dietary intake with medical intervention indicated</td>
<td>Life-threatening reduction in oral intake</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td><strong>Mucositis/Stomatitis</strong> (clinical exam)</td>
<td>Erythema of the mucosa</td>
<td>Patchy pseudomembranes or ulcerations</td>
<td>Confluent pseudomembranes or ulcerations OR Mucosal bleeding with minor trauma</td>
<td>Tissue necrosis OR Diffuse spontaneous mucosal bleeding OR Life-threatening consequences (eg, aspiration, choking)</td>
</tr>
<tr>
<td>See also Proctitis, Dysphagia-Odynophagia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nausea</strong></td>
<td>Transient (&lt; 24 hours) or intermittent nausea with no or minimal interference with oral intake</td>
<td>Persistent nausea resulting in decreased oral intake for 24-48 hours</td>
<td>Persistent nausea resulting in minimal oral intake for &gt; 48 hours OR Aggressive rehydration indicated (eg, IV fluids)</td>
<td>Life-threatening consequences (eg, hypotensive shock)</td>
</tr>
<tr>
<td><strong>Pancreatitis</strong></td>
<td>NA</td>
<td>Symptomatic AND Hospitalization not indicated (other than ER visit)</td>
<td>Symptomatic AND Hospitalization indicated (other than ER visit)</td>
<td>Life-threatening consequences (eg, sepsis, circulatory failure, hemorrhage)</td>
</tr>
<tr>
<td><strong>Proctitis</strong> (functional- symptomatic)</td>
<td>Rectal discomfort AND No intervention indicated</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities OR Medical intervention indicated</td>
<td>Symptoms causing inability to perform usual social/functional activities OR Operative intervention indicated</td>
<td>Life-threatening consequences (eg, perforation)</td>
</tr>
<tr>
<td>Also see Mucositis/Stomatitis for Clinical Exam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vomiting</strong></td>
<td>Transient or intermittent vomiting with no or minimal interference with oral intake</td>
<td>Frequent episodes of vomiting with no or mild dehydration</td>
<td>Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated</td>
<td>Life-threatening consequences (eg, hypotensive shock)</td>
</tr>
<tr>
<td>NEUROLOGICAL</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alteration in Personality-Behavior or in Mood</td>
<td>Alteration causing no or minimal interference with usual social &amp; functional activities</td>
<td>Alteration causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Alteration causing inability to perform usual social &amp; functional activities</td>
<td>Behavior potentially harmful to self or others (eg, suicidal/homicidal ideation or attempt, acute psychosis) OR Causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>(eg, agitation, anxiety, depression, mania, psychosis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altered Mental Status</td>
<td>Changes causing no or minimal interference with usual social &amp; functional activities</td>
<td>Mild lethargy or somnolence causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Confusion, memory impairment, lethargy, or somnolence causing inability to perform usual social &amp; functional activities</td>
<td>Delirium OR obtundation, OR coma</td>
</tr>
<tr>
<td>For Dementia, see Cognitive and Behavioral/Attentional Disturbance (including dementia and ADD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ataxia</td>
<td>Asymptomatic ataxia detectable on exam OR Minimal ataxia causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptomatic ataxia causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptomatic ataxia causing inability to perform usual social &amp; functional activities</td>
<td>Disabling ataxia causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Cognitive and Behavioral/Attentional Disturbance (including dementia and Attention Deficit Disorder)</td>
<td>Disability causing no or minimal interference with usual social &amp; functional activities OR Specialized resources not indicated</td>
<td>Disability causing greater than minimal interference with usual social &amp; functional activities OR Specialized resources on part-time basis indicated</td>
<td>Disability causing inability to perform usual social &amp; functional activities OR Specialized resources on a full-time basis indicated</td>
<td>Disability causing inability to perform basic self-care functions OR Institutionalization indicated</td>
</tr>
<tr>
<td>CNS Ischemia (acute)</td>
<td>NA</td>
<td>NA</td>
<td>Transient ischemic attack</td>
<td>Cerebral vascular accident (CVA, stroke) with neurological deficit</td>
</tr>
<tr>
<td>Developmental delay – Pediatric ≤ 16 Years</td>
<td>Mild developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Moderate developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Severe developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Developmental regression, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Headache</strong></td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform basic self-care functions OR Hospitalization indicated (other than ER visit) OR Headache with significant impairment of alertness or other neurologic function</td>
</tr>
<tr>
<td><strong>Insomnia</strong></td>
<td>NA</td>
<td>Difficulty sleeping causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Difficulty sleeping causing inability to perform usual social &amp; functional activities</td>
<td>Disabling insomnia causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td><strong>Neuromuscular Weakness (including myopathy &amp; neuropathy)</strong></td>
<td>Asymptomatic with decreased strength on exam OR Minimal muscle weakness causing no or minimal interference with usual social &amp; functional activities</td>
<td>Muscle weakness causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Muscle weakness causing inability to perform usual social &amp; functional activities</td>
<td>Disabling muscle weakness causing inability to perform basic self-care functions OR Respiratory muscle weakness impairing ventilation</td>
</tr>
<tr>
<td><strong>Neurosensory Alteration (including paresthesia and painful neuropathy)</strong></td>
<td>Asymptomatic with sensory alteration on exam or minimal paresthesia causing no or minimal interference with usual social &amp; functional activities</td>
<td>Sensory alteration or paresthesia causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Sensory alteration or paresthesia causing inability to perform usual social &amp; functional activities</td>
<td>Disabling sensory alteration or paresthesia causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td><strong>Seizure: (new onset)</strong></td>
<td>NA</td>
<td>1 seizure</td>
<td>2–4 seizures</td>
<td>Seizures of any kind that are prolonged, repetitive (eg, status epilepticus), or difficult to control (eg, refractory epilepsy)</td>
</tr>
<tr>
<td>NEUROLOGICAL</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------</td>
<td>--------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Seizure: (pre-existing)</td>
<td>NA</td>
<td>Increased frequency of pre-existing seizures (non-repetitive) without change in seizure character OR infrequent breakthrough seizures while on stable meds in a previously controlled seizure disorder</td>
<td>Change in seizure character from baseline either in duration or quality (eg, severity or focality)</td>
<td>Seizures of any kind that are prolonged, repetitive (eg, status epilepticus), or difficult to control (eg, refractory epilepsy)</td>
</tr>
<tr>
<td>For Worsening of Existing Epilepsy the Grades Should Be Based on an Increase from Previous Level of Control to Any of These Levels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizure – Pediatric &lt; 18 Years</td>
<td></td>
<td>Seizure, generalized onset with or without secondary generalization, lasting &lt; 5 minutes with &lt; 24 hours post ictal state</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting 5-20 minutes with &lt; 24 hours post ictal state</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting &gt; 20 minutes</td>
</tr>
<tr>
<td>Syncope (not associated with a procedure)</td>
<td>NA</td>
<td>Present</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vertigo</td>
<td></td>
<td>Vertigo causing no or minimal interference with usual social &amp; functional activities</td>
<td>Vertigo causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Vertigo causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Disabling vertigo causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>MUSCULOSKELETAL</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>Joint pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Joint pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Joint pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling joint pain causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>See also Arthritis</td>
<td>Arthritis</td>
<td>Stiffness or joint swelling causing no or minimal interference with usual social &amp; functional activities</td>
<td>Stiffness or joint swelling causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Stiffness or joint swelling causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>See also Arthralgia</td>
<td>Bone Mineral Loss</td>
<td>BMD t-score or z-score −2.5 to −1.0</td>
<td>BMD t-score or z-score &lt; −2.5</td>
<td>Pathological fracture (including loss of vertebral height)</td>
</tr>
<tr>
<td>Pediatric &lt; 21 Years</td>
<td>BMD z-score −2.5 to −1.0</td>
<td>BMD z-score &lt; −2.5</td>
<td>Pathological fracture (including loss of vertebral height)</td>
<td>Pathologic fracture causing life-threatening consequences</td>
</tr>
<tr>
<td>Myalgia (non-injection site)</td>
<td>Muscle pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Muscle pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Muscle pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling muscle pain causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>NA</td>
<td>Asymptomatic with radiographic findings AND No operative intervention indicated</td>
<td>Symptomatic bone pain with radiographic findings OR Operative intervention indicated</td>
<td>Disabling bone pain with radiographic findings causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>SYSTEMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute Systemic Allergic Reaction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localized urticaria (wheals) with no medical intervention indicated</td>
<td>Localized urticaria with medical intervention indicated OR Mild angioedema with no medical intervention indicated</td>
<td>Generalized urticaria OR Angioedema with medical intervention indicated OR Symptomatic mild bronchospasm</td>
<td>Acute anaphylaxis OR Life-threatening bronchospasm OR laryngeal edema</td>
<td></td>
</tr>
<tr>
<td><strong>Chills</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td><strong>Fatigue Malaise</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>Incapacitating fatigue/malaise symptoms causing inability to perform basic self-care functions</td>
<td></td>
</tr>
<tr>
<td><strong>Fever (nonaxillary)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37.7°C to 38.6°C 99.8°F to 101.5°F</td>
<td>38.7°C to 39.3°C 101.6°F to 102.8°F</td>
<td>39.4°C to 40.5°C 102.9°F to 104.9°F</td>
<td>&gt; 40.5°C &gt; 104.9°F</td>
<td></td>
</tr>
<tr>
<td><strong>Pain- Indicate Body Site</strong> See also Injection Site Pain, Headache, Arthralgia, and Myalgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling pain causing inability to perform basic self-care functions OR Hospitalization (other than ER visit) indicated</td>
<td></td>
</tr>
<tr>
<td><strong>Unintentional Weight Loss</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA</td>
<td>5% to 9% loss in body weight from baseline</td>
<td>10% to 19% loss in body weight from baseline</td>
<td>≥ 20% loss in body weight from baseline OR Aggressive intervention indicated [eg, tube feeding or total parenteral nutrition]</td>
<td></td>
</tr>
</tbody>
</table>
## INJECTION SITE REACTION

<table>
<thead>
<tr>
<th>Injection Site Pain (pain without touching) Or Tenderness (pain when area is touched)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain/tenderness causing no or minimal limitation of use of limb</td>
<td>Pain/tenderness limiting use of limb OR Pain/tenderness causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Pain/tenderness causing inability to perform usual social &amp; functional activities</td>
<td>Pain/tenderness causing inability to perform basic self-care function OR Hospitalization (other than ER visit) indicated for management of pain/tenderness</td>
<td></td>
</tr>
</tbody>
</table>

### Injection Site Reaction (Localized), > 15 Years

<table>
<thead>
<tr>
<th>Pediatric ≤ 15 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythema OR Induration of $5 \times 5$ cm to $9 \times 9$ cm (or $25–81 \times cm^2$)</td>
</tr>
<tr>
<td>Erythema OR Induration OR Edema present but ≤ 2.5 cm diameter</td>
</tr>
</tbody>
</table>

### Pruritis Associated with Injection

<table>
<thead>
<tr>
<th>See also Skin: Pruritis (itching—no skin lesions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itching localized to injection site AND Relieved spontaneously or with &lt; 48 h treatment</td>
</tr>
<tr>
<td>NA</td>
</tr>
<tr>
<td>ENDOCRINE/METABOLIC</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>Lipodystrophy (eg, back of neck, breasts, abdomen)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>Gynecomastia</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Lipoatrophy (eg, fat loss from the face, extremities, buttocks)</td>
</tr>
</tbody>
</table>
### GENITOURINARY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermenstrual Bleeding (IMB)</td>
<td>Spotted observed by participant OR Minimal blood observed during clinical or colposcopic exam</td>
<td>Intermenstrual bleeding not greater in duration or amount than usual menstrual cycle</td>
<td>Intermenstrual bleeding greater in duration or amount than usual menstrual cycle</td>
<td>Hemorrhage with life-threatening hypotension OR Operative intervention indicated</td>
</tr>
<tr>
<td>Urinary Tract obstruction (eg, stone)</td>
<td>NA</td>
<td>Signs or symptoms of urinary tract obstruction without hydronephrosis or renal dysfunction</td>
<td>Signs or symptoms of urinary tract obstruction with hydronephrosis or renal dysfunction</td>
<td>Obstruction causing life-threatening consequences</td>
</tr>
</tbody>
</table>

### INFECTION

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection (any other than HIV infection)</td>
<td>Localized, no systemic antiμbial treatment indicated AND Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Systemic antiμbial treatment indicated OR Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Systemic antiμbial treatment indicated AND Symptoms causing inability to perform usual social &amp; functional activities OR Operative intervention (other than simple incision and drainage) indicated</td>
<td>Life-threatening consequences (eg, septic shock)</td>
</tr>
</tbody>
</table>

**Basic Self-care Functions:** Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.

**Usual Social & Functional Activities:** Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements

1) Definitions

a. Definition of Childbearing Potential

For the purposes of this study, a female born subject is considered of childbearing potential following the initiation of puberty (Tanner stage 2) until becoming post-menopausal, unless permanently sterile or with medically documented ovarian failure.

Women are considered to be in a postmenopausal state when they are ≥ 54 years of age with cessation of previously occurring menses for ≥ 12 months without an alternative cause.

Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a female subject of any age.

b. Definition of Male Fertility

For the purposes of this study, a male born subject is considered of fertile after the initiation of puberty unless permanently sterile by bilateral orchidectomy or medical documentation.

2) Contraception Requirements for Female Subjects

a. Study Drug Effects on Pregnancy and Hormonal Contraception

Data from clinical pharmacokinetic interaction studies of TAF have demonstrated that there is no reduction in the clinical efficacy of hormonal contraception. Non-clinical toxicity studies in animals (rats and rabbits) of TAF have demonstrated no adverse effect on fertility or embryo-fetal development. However, there are no clinical studies of TAF in pregnant women. Please refer to the latest version of the investigator’s brochure for additional information.

b. Contraception Requirements for Female Subjects of Childbearing Potential

The inclusion of female subjects of childbearing potential requires using at least an acceptable effective contraceptive measure. They must have a negative serum pregnancy test at Screening and a negative pregnancy test on the Baseline/Day 1 visit prior to randomization. At minimum, a pregnancy test will be performed at the end of relevant systemic exposure. In the event of a delayed menstrual period (over one month between menstruations), a pregnancy test must be performed to rule out pregnancy. This is even true for women of childbearing potential with infrequent or irregular periods. They must also agree to one of the following from Screening until the end of relevant systemic exposure.
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable method of contraception only when it is in line with the subject’s preferred and usual lifestyle.

Or

Consistent and correct use of 1 of the following methods of birth control listed below.

- Intrauterine device (IUD) with a failure rate of < 1% per year
- Intrauterine hormone-releasing system (IUS) with a failure rate of < 1% per year
- Tubal sterilization
- Essure micro-insert system (provided confirmation of success 3 months after procedure)
- Vasectomy in the male partner (provided that the partner is the sole sexual partner and had confirmation of surgical success 3 months after procedure)
- Barrier methods (one female barrier and one male barrier must be used in combination)
  - Female barriers: Diaphragm with spermicide or Cervical cap with spermicide
  - Male barriers: Male condom (with or without spermicide)
- Hormonal methods
  - Oral contraceptives (either combined or progesterone only)
  - Injectable progesterone
  - Implants of levonorgestrel
  - Transdermal contraceptive patch
  - Contraceptive vaginal ring

Female subjects must also refrain from egg donation and in vitro fertilization during treatment and until at least 30 days after the end of relevant systemic exposure.

3) Contraception Requirements for Male Subjects

During the study, male subjects with female partners of childbearing potential should use condoms when engaging in intercourse of reproductive potential.
4) Unacceptable Birth Control Methods

Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM). Female condom and male condom should not be used together.

5) Procedures to be Followed in the Event of Pregnancy

Subjects will be instructed to notify the investigator if they become pregnant at any time during the study, or if they become pregnant within 30 days of last study drug dose. Subjects who become pregnant or who suspect that they are pregnant during the study must report the information to the investigator and discontinue study drug immediately. Subjects whose partner has become pregnant or suspects she is pregnant during the study must report the information to the investigator. Instructions for reporting pregnancy, partner pregnancy, and pregnancy outcome are outlined in Section 7.6.2.1.